1 | ( L ) ASCORBATO DI CALCIO | 1件: Calcium Calcium | - | - | - | 2件: 96 96, 97 💬 |
2 | (-)-3-(4-Aminophenyl)-2-methoxypropionic acid | - | - | - | - | 1件: 97 97 💬 |
3 | (1-13C) Sodium Acetate | 2件: Acetate Acetate, Sodium acetate | 1件: Sodium acetate
Sodium acetate
💬 | - | - | 1件: 251 251 💬 |
4 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
5 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 💬 |
6 | (11C)PE2I | - | - | - | - | 1件: 6 6 💬 |
7 | (18)F-FDG | - | - | - | - | 1件: 85 85 💬 |
8 | (18F)FPGLU | - | - | - | - | 1件: 86 86 💬 |
9 | (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide | - | - | - | - | 1件: 11 11 💬 |
10 | (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide) | - | - | - | - | 1件: 6 6 💬 |
11 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-y1] butanamide | - | - | - | - | 1件: 309 309 💬 |
12 | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide | - | - | - | - | 1件: 309 309 💬 |
13 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
14 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
15 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
16 | (3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile, | - | - | - | - | 1件: 46 46 💬 |
17 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
18 | (3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1- | - | - | - | - | 1件: 46 46 💬 |
19 | (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile | - | - | - | - | 1件: 231 231 💬 |
20 | (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-{[4’- | - | - | - | - | 1件: 79 79 💬 |
21 | (6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate | - | - | - | - | 1件: 2 2 💬 |
22 | (6S)-6-{propyl-[2-[2-thienyl]ethyl]amino}-5,6,7,8-tetrahydro-1-naphtalenol | - | - | - | - | 1件: 6 6 💬 |
23 | (7R,8R,9R)-2.3-Dimethyl-8-hydroxy-7(2-methoxyethoxy)- 9-phenyl-7.8.9.10-tetrahydro-imidazo-[1.2-h].[1.7].- naphthyridine | - | - | - | - | 1件: 301 301 💬 |
24 | (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime | - | - | - | - | 1件: 161 161 💬 |
25 | (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate | - | - | - | - | 1件: 6 6 💬 |
26 | (Pyr1)apelin-13 | - | - | - | - | 1件: 86 86 💬 |
27 | (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide | - | - | - | - | 1件: 13 13 💬 |
28 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4- | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
29 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
30 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
31 | (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4YL)SULFONYL)4,4A,5,6,7,8HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN4AYL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 75 75 💬 |
32 | (R)-3-(1-oxo-propoxy)-4-(N,N,N-trimethyl amonium chloride)-butanoic acid | 2件: Butyric Acid Butyric Acid, Chloride ion | - | - | - | 1件: 97 97 💬 |
33 | (R)-[N-metil-11C1-PK11195(PK) | - | - | - | - | 1件: 127 127 💬 |
34 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
35 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1H-PYRAZOLE-4-CARBOXAMIDE | 1件: Pyrazole Pyrazole | - | - | - | 1件: 58 58 💬 |
36 | (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1METHYL-1HPYRAZOLE-4-CARBOXAMIDE | - | - | - | - | 1件: 58 58 💬 |
37 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
38 | (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 272 272 💬 |
39 | (S)- 2- Amino- 4,5,6,7- tetrahydro- 6- (propylamino)benzothiazol | - | - | - | - | 1件: 6 6 💬 |
40 | (S)-(+)-2-(4-(3-fluorobenzyl)oxybenzyl)aminopropanamide methanesulfonate | - | - | - | - | 1件: 6 6 💬 |
41 | (S)-(-)-3-(4-Aminophenyl)-2-methoxypropionic Acid | - | - | - | - | 1件: 97 97 💬 |
42 | (S)-2-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid | - | - | - | - | 1件: 86 86 💬 |
43 | (S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one | - | - | - | - | 1件: 240 240 💬 |
44 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2- YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
45 | (S)-3-((3-(1-((6-(3,4-DIMETHOXYPHENYL)PRYAZIN-2-YL)AMINO)ETHYL)PHENYL)CARBAMOYL)-5-METHYLPRIDIN-1-IUM | - | - | - | - | 1件: 86 86 💬 |
46 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazo | - | - | - | - | 1件: 284 284 💬 |
47 | (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
48 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-m | - | - | - | - | 1件: 284 284 💬 |
49 | (S)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide | 3件: Hydroxide ion Hydroxide ion, Magnesium, Magnesium hydroxide | 1件: Magnesium hydroxide
Magnesium hydroxide
💬 | - | - | 1件: 284 284 💬 |
50 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5- yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
51 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxyben | - | - | - | - | 1件: 97 97 💬 |
52 | (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride | - | - | - | - | 1件: 97 97 💬 |
53 | * D.3.4 Solution for infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
54 | * D.3.4 Solution for injection in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
55 | * D.3.4 Solution for injection/infusion in pre-filled syringe | - | - | - | - | 1件: 97 97 💬 |
56 | * D.3.6.2.1 - valore : Every 4 weeks dosing of 200 mg | - | - | - | - | 1件: 41 41 💬 |
57 | * D.3.6.2.1 - valore :Every 4 weeks dosing of 400 mg | - | - | - | - | 1件: 41 41 💬 |
58 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
59 | 0.005% Lacripep | - | - | - | - | 1件: 53 53 💬 |
60 | 0.01% Lacripep | - | - | - | - | 1件: 53 53 💬 |
61 | 0.02% Fm, SH | - | - | - | - | 1件: 53 53 💬 |
62 | 0.02% Fm, SH, 0.05% CsA | - | - | - | - | 1件: 53 53 💬 |
63 | 0.02% Fm, SH, AS | - | - | - | - | 1件: 53 53 💬 |
64 | 0.04 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
65 | 0.05%cyclosporin eye drop | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 38 38 💬 |
66 | 0.08 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
67 | 0.12% saline | - | - | - | - | 1件: 299 299 💬 |
68 | 0.15mg KPG-818 dose | - | - | - | - | 1件: 49 49 💬 |
69 | 0.2 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
70 | 0.4 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
71 | 0.4mL prefilled syringes | - | - | - | - | 1件: 107 107 💬 |
72 | 0.6 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
73 | 0.8 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
74 | 0.9% Isotonic Saline (IS), 4mL | - | - | - | - | 1件: 299 299 💬 |
75 | 009-0 | - | - | - | - | 1件: 6 6 💬 |
76 | 009-1 | - | - | - | - | 1件: 6 6 💬 |
77 | 009-4 | - | - | - | - | 1件: 6 6 💬 |
78 | 0109-0012A 100 mg/ml | - | - | - | - | 1件: 46 46 💬 |
79 | 0109-0012A 25 mg/ml | - | - | - | - | 1件: 46 46 💬 |
80 | 0109-0012A 50 mg/ml | - | - | - | - | 1件: 46 46 💬 |
81 | 0114-0006B | - | - | - | - | 2件: 46 46, 96 💬 |
82 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
83 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
84 | 1 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
85 | 1 ml 0.9 % NaCl | - | - | - | - | 1件: 46 46 💬 |
86 | 1% lignocaine | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 84 84 💬 |
87 | 1,2-Dihexadecanoyl-sn-Glycero-3-Phospho-(1-raac-glycerol) | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 79 79 💬 |
88 | 1,5 (Butylimino)-1,5-dideoxy-D-glucitol | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 299 299 💬 |
89 | 1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c | - | - | - | - | 1件: 46 46 💬 |
90 | 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride | 1件: Piperazine Piperazine | 1件: Piperazine
Piperazine
💬 | - | - | 1件: 58 58 💬 |
91 | 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
92 | 1-(6-BENZOTHIAZOLYLSULFONYL)-5-CHLORO-1H-INDOLE-2-BUTANOIC ACID | 2件: Butyric Acid Butyric Acid, Indole | - | - | - | 1件: 51 51 💬 |
93 | 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-3-quinoline carboxylic acid | - | - | - | - | 1件: 299 299 💬 |
94 | 1-{6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone | - | - | - | - | 1件: 13 13 💬 |
95 | 1.0 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
96 | 1.0 mg rasagiline mesylate | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
97 | 1.0 mg RPC103 | - | - | - | - | 1件: 97 97 💬 |
98 | 1.0 mg RPC1063 | - | - | - | - | 1件: 97 97 💬 |
99 | 1.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
100 | 1.0mg RPC1063 | - | - | - | - | 1件: 13 13 💬 |
101 | 1.2 mg Lu AE04621 | - | - | - | - | 1件: 6 6 💬 |
102 | 1.2 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
103 | 1.8 mg ZGN-440 for injectable suspension | - | - | - | - | 1件: 193 193 💬 |
104 | 10 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
105 | 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
106 | 10% liquid formulation of human immunoglobulin | - | - | - | - | 1件: 14 14 💬 |
107 | 10-mg dose of E5501 lipid-based oral | - | - | - | - | 1件: 63 63 💬 |
108 | 100 mg ELX (VX-445) / 50 mg TEZ / 75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
109 | 100 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
110 | 100 mg TEZ/150 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
111 | 100 mg VX-445 /50 mg TEZ/75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
112 | 100 mg VX-445/50 mg TEZ /75 mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
113 | 100-mg ELX (VX-445) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
114 | 100-mg ELX (VX-455) / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
115 | 100-mg VX-445 / 50-mg TEZ / 75- mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
116 | 100-mg VX-445 / 50-mg TEZ / 75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
117 | 100-mg VX-445 /50-mg TEZ/75-mg | - | - | - | - | 1件: 299 299 💬 |
118 | 100-mg VX-445/50-mg TEZ/75-mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
119 | 100mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
120 | 100mg VX-445/50mg TEZ /75mg IVA FDC | - | - | - | - | 1件: 299 299 💬 |
121 | 11-beta-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
122 | 11-ß-hydroxysteroid dehydrogenase type 1 | - | - | - | - | 1件: 75 75 💬 |
123 | 118-42-3 | - | - | - | - | 1件: 46 46 💬 |
124 | 11C]-PK-11195 | - | - | - | - | 1件: 13 13 💬 |
125 | 124I-labeled monoclonal antibody Mu 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
126 | 124I-p5+14 Injection | - | - | - | - | 1件: 28 28 💬 |
127 | 13-15mg/kg/d Ursodeoxycholic | - | - | - | - | 1件: 93 93 💬 |
128 | 13-valent pneumococcal conjugate vaccine (13-PCV) | - | - | - | - | 1件: 13 13 💬 |
129 | 14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration | - | - | - | - | 3件: 13 13, 96, 97 💬 |
130 | 15 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
131 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
132 | 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
133 | 15 or 45 mg | - | - | - | - | 1件: 67 67 💬 |
134 | 15-0 H20 | - | - | - | - | 2件: 6 6, 19 💬 |
135 | 15-O labeled water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 46 46 💬 |
136 | 150 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
137 | 150 mg open-label secukinumab | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
138 | 150mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 💬 |
139 | 15N ammonium chloride (15NH4Cl) | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 251 251 💬 |
140 | 1639325-43-1 | - | - | - | - | 1件: 254 254 💬 |
141 | 1643368-58-4 | - | - | - | - | 2件: 53 53, 160 💬 |
142 | 17,21-Dihydroxypregna-1,4-diene-3,11,20-trione | - | - | - | - | 1件: 41 41 💬 |
143 | 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
144 | 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one | - | - | - | - | 1件: 75 75 💬 |
145 | 18F-AV-133 | 1件: Florbenazine F-18 Florbenazine F-18 | - | - | - | 1件: 6 6 💬 |
146 | 18F-AV-1451 | - | - | - | - | 3件: 5 5, 7, 127 💬 |
147 | 18F-AV-45 | - | - | - | - | 2件: 6 6, 127 💬 |
148 | 18F-DPA-714 and 18F-FDG | 1件: Fludeoxyglucose (18F) Fludeoxyglucose (18F) | - | - | - | 1件: 13 13 💬 |
149 | 18F-DTBZ AV-133 | - | - | - | - | 1件: 6 6 💬 |
150 | 18F-Fluoro-L-dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
151 | 18F-FTC-146 | - | - | - | - | 1件: 206 206 💬 |
152 | 18F] LBT-999 | - | - | - | - | 1件: 6 6 💬 |
153 | 18F]-(E)-N-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane | - | - | - | - | 1件: 6 6 💬 |
154 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
155 | 1[(6- Allyl- 8beta- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
156 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- | - | - | - | - | 1件: 6 6 💬 |
157 | 1[(6- Allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea | - | - | - | - | 1件: 6 6 💬 |
158 | 1mg/kg/hr TXA intravenous infusion till the last suture | - | - | - | - | 1件: 70 70 💬 |
159 | 2 x 10 mg Natura-alpha capsules | - | - | - | - | 1件: 97 97 💬 |
160 | 2% lignocaine | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 84 84 💬 |
161 | 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | 1件: Diflunisal Diflunisal | 1件: Diflunisal
Diflunisal
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 28 28 💬 |
162 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 💬 |
163 | 2,5-Dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide | - | - | - | - | 1件: 6 6 💬 |
164 | 2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: Benzoic acid
Benzoic acid
💬 | - | - | 1件: 51 51 💬 |
165 | 2-(2-(2-Amino-9H-purin-9-yl)ethyl)-1,3-propanediol diacetate ester | 1件: Famciclovir Famciclovir | 1件: Famciclovir
Famciclovir
💬 | - | - | 1件: 13 13 💬 |
166 | 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide | - | - | - | - | 1件: 86 86 💬 |
167 | 2-[[[(2R)-1-[1-[(4-CHLORO-3-METHYLPHENYL)METHYL]-4- PIPERIDINYL]-5-OXO-2-PYRROLIDINYL]CARBONYL]AMINO]- N,N,6-TRIMETHYL-4-PYRIDINECARBOXAMIDE,DIHYDROCHLORIDE | - | - | - | - | 2件: 6 6, 162 💬 |
168 | 2-amino-4-(methyl[11C]sulfanyl)butanoic acid | 1件: Butyric Acid Butyric Acid | - | - | - | 1件: 34 34 💬 |
169 | 2-deoxy-2 [F-18] fluoro-2-d-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 1件: 49 49 💬 |
170 | 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl) acetamide | 1件: Acetamide Acetamide | - | - | - | 1件: 86 86 💬 |
171 | 2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt | 1件: Hydroxide ion Hydroxide ion | - | - | - | 1件: 46 46 💬 |
172 | 2.0 MIU IL-2 per day | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 2 2 💬 |
173 | 20 mg BID of PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
174 | 20 mg fampridine-SR (4-aminopyridine, 4-AP) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
175 | 200 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
176 | 20mg/0.5ml GA | - | - | - | - | 1件: 13 13 💬 |
177 | 20mg/0.5ml glatiramer acetate | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
178 | 225mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
179 | 25 mg BIA9 1067 | - | - | - | - | 1件: 6 6 💬 |
180 | 250 mg LX3305 BID | - | - | - | - | 1件: 46 46 💬 |
181 | 250 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
182 | 25mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
183 | 29180.00.00, 34681.00.00, 34681.01.00, 34681.02.00 | - | - | - | - | 1件: 113 113 💬 |
184 | 2S,4R-(-)-ketoconazole | 1件: Ketoconazole Ketoconazole | 1件: Ketoconazole
Ketoconazole
💬 | 1件: CYP17A1 CYP17A1 💬 | 6件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
185 | 2S,4R-(-)-ketoconazole, levoketoconazole | 2件: Ketoconazole Ketoconazole, Levoketoconazole | 2件: Ketoconazole
Ketoconazole
,
Levoketoconazole
💬 | 3件: CYP11A1 CYP11A1, CYP11B1, CYP17A1 💬 | 7件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
186 | 3 mg [14C]-A4250 capsule | - | - | - | - | 3件: 93 93, 297, 338 💬 |
187 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
188 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
189 | 3,4-DIAMINOPYRIDINE | - | - | - | - | 2件: 12 12, 13 💬 |
190 | 3,4-Diaminopyridine Phosphate | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
191 | 3- (9,10- Didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate | - | - | - | - | 1件: 6 6 💬 |
192 | 3-(3,4-Dihydroxyphenyl)-L-alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
193 | 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID | 1件: Pyrazole Pyrazole | - | - | - | 1件: 28 28 💬 |
194 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- | - | - | - | - | 1件: 93 93 💬 |
195 | 3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic acid | - | - | - | - | 1件: 93 93 💬 |
196 | 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | - | - | - | - | 2件: 51 51, 85 💬 |
197 | 3-hydroxy-2-methyl-4H-pyrane-4-one iron (III) complex (3:1), Ferric (3-hydroxy-2-methyl-4-pyrone), Tris-maltol-iron (III), Tri=maltol-iron (III) | 1件: Tromethamine Tromethamine | 1件: Tromethamine
Tromethamine
💬 | - | - | 2件: 96 96, 97 💬 |
198 | 3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one. | 1件: Pyrazole Pyrazole | - | - | - | 1件: 2 2 💬 |
199 | 300 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
200 | 331731-18-1 | - | - | - | - | 4件: 46 46, 96, 97, 271 💬 |
201 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
202 | 4 mg/kg CNTO 136 | - | - | - | - | 1件: 49 49 💬 |
203 | 4% chlorhexidine gluconate liquid skin cleanser | 1件: Chlorhexidine Chlorhexidine | 1件: Chlorhexidine
Chlorhexidine
💬 | - | - | 1件: 299 299 💬 |
204 | 4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulphonamide | - | - | - | - | 1件: 46 46 💬 |
205 | 4'-iodo-4'-deoxydoxorubicin | 1件: Iodine Iodine | 1件: Iodine
Iodine
💬 | - | - | 1件: 28 28 💬 |
206 | 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base | 1件: Methane Methane | - | - | - | 1件: 2 2 💬 |
207 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
208 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide | 1件: Pyrazole Pyrazole | - | - | - | 1件: 46 46 💬 |
209 | 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 5 5 💬 |
210 | 4-Benzyl-2-naphthalen-1-yl-1,2,4- thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
211 | 4-benzyl-2-naphthalen-1-yl-1,2,4-thiadiazolidine-3,5-dione | - | - | - | - | 1件: 113 113 💬 |
212 | 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
213 | 40 MG- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL | - | - | - | - | 1件: 107 107 💬 |
214 | 400 mg BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
215 | 400 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
216 | 44/154/85-C | - | - | - | - | 1件: 50 50 💬 |
217 | 44/196/81-C | - | - | - | - | 1件: 50 50 💬 |
218 | 4cc of lidocaïne® | - | - | - | - | 1件: 149 149 💬 |
219 | 4D-125 IVT Injection | - | - | - | - | 1件: 90 90 💬 |
220 | 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | 2件: Estradiol Estradiol, Lidocaine | 3件: Estradiol
Estradiol
,
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 7件: ESR1 ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 13件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Breast cancer, Chemical carcinogenesis - receptor activation, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway 💬 | 1件: 226 226 💬 |
221 | 5-[4-[2-(5-(1-hydroxyethyl)-2- pyridinyl)ethoxy]benzyl]-2,4- thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
222 | 5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
223 | 5-[[4-[2-[5-(1-HYDROXYETHYL)-2-PYRIDINYL]ETHOXY]PHENYL]METHYL]-2,4-THIAZOLIDINEDIONE HYDROCHLORIDE | 1件: 2,4-thiazolidinedione 2,4-thiazolidinedione | - | - | - | 1件: 20 20 💬 |
224 | 5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin | 1件: Chlorine Chlorine | - | - | - | 2件: 46 46, 271 💬 |
225 | 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium | - | - | - | - | 1件: 8 8 💬 |
226 | 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | - | - | - | - | 1件: 228 228 💬 |
227 | 50 mg BIA 9 1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
228 | 50 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
229 | 500 0500 0 | - | - | - | - | 1件: 19 19 💬 |
230 | 500 mg LX3305 QD | - | - | - | - | 1件: 46 46 💬 |
231 | 50mcg rhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
232 | 52069.00.01 | - | - | - | - | 1件: 13 13 💬 |
233 | 534-1508 | - | - | - | - | 1件: 85 85 💬 |
234 | 549-0261/F02-01 | - | - | - | - | 2件: 96 96, 97 💬 |
235 | 552-02 | - | - | - | - | 2件: 53 53, 299 💬 |
236 | 56/104/75-C | - | - | - | - | 1件: 50 50 💬 |
237 | 6% Hypertonic Saline (HS), 4mL | - | - | - | - | 1件: 299 299 💬 |
238 | 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine | - | - | - | - | 1件: 38 38 💬 |
239 | 6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate | - | - | - | - | 1件: 46 46 💬 |
240 | 6-[(methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine | - | - | - | - | 1件: 96 96 💬 |
241 | 6-[18F]Fluorodopa | - | - | - | - | 1件: 6 6 💬 |
242 | 6-[18F]Fluorodopamine | - | - | - | - | 1件: 6 6 💬 |
243 | 6-[2-(3,4-diethoxyphenyl)thiazol-4-yl] pyridine-2-carboxylic acid | - | - | - | - | 1件: 97 97 💬 |
244 | 6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one | - | - | - | - | 1件: 2 2 💬 |
245 | 6036937.00.01 | - | - | - | - | 1件: 6 6 💬 |
246 | 66215-101 | - | - | - | - | 1件: 86 86 💬 |
247 | 6abeta - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
248 | 6aß - apomorphine-10,11-diol hydrochloride hemihydrate | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
249 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
250 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
251 | 70930.00.00 | - | - | - | - | 1件: 46 46 💬 |
252 | 750 mg metformin and 7.5 g L-citrulline daily p.o. | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
253 | 75mg CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 1件: 86 86 💬 |
254 | 75mg SHP647 (PF-00547659) | - | - | - | - | 1件: 97 97 💬 |
255 | 80mg ELX / 40mg TEZ / 60mg IVA | - | - | - | - | 1件: 299 299 💬 |
256 | 89Zr-SBC-103 | - | - | - | - | 1件: 19 19 💬 |
257 | 9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER | 1件: Linoleic acid Linoleic acid | - | - | - | 2件: 2 2, 5 💬 |
258 | 98-92-0 | - | - | - | - | 1件: 107 107 💬 |
259 | 99mTc-rhAnnexin V-128 | - | - | - | - | 2件: 46 46, 271 💬 |
260 | : 2-{4-[(5,6-difenilpirazin-2-yl)(isopropil)amino]butoxi}-N- | - | - | - | - | 1件: 86 86 💬 |
261 | : immunoglobulina umana normale 10% per somministrazione endovenosa | - | - | - | - | 1件: 14 14 💬 |
262 | [11C]-GSK2256098 500 MBq | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 💬 |
263 | [11C]-PIB | - | - | - | - | 1件: 6 6 💬 |
264 | [11C]MPC6827 | - | - | - | - | 1件: 2 2 💬 |
265 | [11C]PXT012253 | - | - | - | - | 1件: 6 6 💬 |
266 | [123I] 5-IA | - | - | - | - | 1件: 6 6 💬 |
267 | [123I] IBVM and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
268 | [123I] mZINT injection and serial dynamic SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
269 | [123I]-IBVM | - | - | - | - | 1件: 6 6 💬 |
270 | [123I]B-CIT | - | - | - | - | 1件: 6 6 💬 |
271 | [123I]B-CIT SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
272 | [123I]beta CIT | - | - | - | - | 1件: 6 6 💬 |
273 | [123I]beta CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
274 | [123I]beta-CIT | - | - | - | - | 1件: 6 6 💬 |
275 | [123I]beta-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
276 | [123I]CLINDE | - | - | - | - | 2件: 6 6, 13 💬 |
277 | [123I]MNI-420 | - | - | - | - | 2件: 6 6, 8 💬 |
278 | [123I]ß CIT | - | - | - | - | 1件: 6 6 💬 |
279 | [123I]ß CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
280 | [123I]ß-CIT | - | - | - | - | 1件: 6 6 💬 |
281 | [123I]ß-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 💬 |
282 | [124I]IB PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
283 | [14C] AT1001 | - | - | - | - | 1件: 19 19 💬 |
284 | [14C]-BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
285 | [15-O]water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 206 206 💬 |
286 | [18F] CFPyPB | - | - | - | - | 1件: 6 6 💬 |
287 | [18F] FES | - | - | - | - | 1件: 86 86 💬 |
288 | [18F] GE-180 | - | - | - | - | 1件: 2 2 💬 |
289 | [18F] LBT-999 PET | - | - | - | - | 1件: 6 6 💬 |
290 | [18F] PBR06 | - | - | - | - | 2件: 6 6, 13 💬 |
291 | [18F] PI-2620 | - | - | - | - | 1件: 6 6 💬 |
292 | [18F]-FBA-A20FMDV2 | - | - | - | - | 1件: 85 85 💬 |
293 | [18F]-FEPPA | - | - | - | - | 2件: 6 6, 13 💬 |
294 | [18F]-FLT-PET/CT scans | - | - | - | - | 1件: 34 34 💬 |
295 | [18F]-PI2620 | - | - | - | - | 1件: 5 5 💬 |
296 | [18F]DPA-714 PET | - | - | - | - | 1件: 2 2 💬 |
297 | [18F]DPA-714 PET scan | - | - | - | - | 1件: 6 6 💬 |
298 | [18F]FDOPA | - | - | - | - | 2件: 6 6, 17 💬 |
299 | [18F]FDOPA PET/CT | - | - | - | - | 1件: 6 6 💬 |
300 | [18F]Florbetaben | - | - | - | - | 1件: 28 28 💬 |
301 | [18F]Florbetapir | - | - | - | - | 1件: 5 5 💬 |
302 | [18F]Florbetapir PET imaging | - | - | - | - | 1件: 13 13 💬 |
303 | [18F]flumazenil | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
304 | [18F]Fluoro-2-deoxy-2-D-glucose | 2件: D-glucose D-glucose, Dextrose, unspecified form | 1件: Glucose
Glucose
💬 | - | - | 2件: 86 86, 88 💬 |
305 | [18F]FP-R01-MG-F2 | - | - | - | - | 2件: 85 85, 94 💬 |
306 | [18F]FPEB | - | - | - | - | 3件: 6 6, 8, 206 💬 |
307 | [18F]FPEB PET imaging | - | - | - | - | 1件: 206 206 💬 |
308 | [18F]FSPG | - | - | - | - | 2件: 96 96, 97 💬 |
309 | [18F]MK-9470 | - | - | - | - | 1件: 6 6 💬 |
310 | [18F]MNI-1126 | - | - | - | - | 1件: 6 6 💬 |
311 | [18F]MNI-815 (MNI-815) | - | - | - | - | 1件: 5 5 💬 |
312 | [18F]MNI-952 | - | - | - | - | 1件: 5 5 💬 |
313 | [18F]MNI-958 | - | - | - | - | 1件: 5 5 💬 |
314 | [18F]MPPF | - | - | - | - | 1件: 6 6 💬 |
315 | [18F]P17-059 | - | - | - | - | 1件: 6 6 💬 |
316 | [18F]PBR06 | - | - | - | - | 1件: 2 2 💬 |
317 | [18F]PI-2620 | - | - | - | - | 2件: 6 6, 127 💬 |
318 | [18F]T807 ([18F]MNI-777) | - | - | - | - | 2件: 5 5, 6 💬 |
319 | [18F]UCB-2897 | - | - | - | - | 1件: 6 6 💬 |
320 | [21CFR640.30] Plasma from 18 - 25 year old volunteer donors | - | - | - | - | 1件: 6 6 💬 |
321 | [C-11]Methylreboxetine | - | - | - | - | 1件: 13 13 💬 |
322 | [C-11]PBR28 | - | - | - | - | 1件: 13 13 💬 |
323 | [C11]PK-1195 PET scan | - | - | - | - | 1件: 13 13 💬 |
324 | [F-18]PBR06 | - | - | - | - | 1件: 13 13 💬 |
325 | [F-18]SDM-8 | - | - | - | - | 1件: 13 13 💬 |
326 | [Zr-89]Oxine-labeled leukocytes PET/MRI | 1件: Oxyquinoline Oxyquinoline | 1件: Oxyquinoline
Oxyquinoline
💬 | - | - | 1件: 13 13 💬 |
327 | A fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine | 3件: Clarithromycin Clarithromycin, Clofazimine, Rifabutin | 3件: Clarithromycin
Clarithromycin
,
Clofazimine
,
Rifabutin
💬 | - | - | 1件: 96 96 💬 |
328 | A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R) | - | - | - | - | 1件: 51 51 💬 |
329 | A-1293543.74 | - | - | - | - | 1件: 96 96 💬 |
330 | A4250 (1200 µg) | - | - | - | - | 1件: 338 338 💬 |
331 | A4250 (400 µg) | - | - | - | - | 1件: 338 338 💬 |
332 | A4250-015 | - | - | - | - | 1件: 297 297 💬 |
333 | A: 1 dosis | - | - | - | - | 1件: 97 97 💬 |
334 | A: PTH (1-84) | - | - | - | - | 1件: 235 235 💬 |
335 | AAV-GAD Dose 1 | - | - | - | - | 1件: 6 6 💬 |
336 | AAV2CUhCLN2 (3x10^12 particle units) | - | - | - | - | 1件: 19 19 💬 |
337 | AAV5-RPGR 4e11 | - | - | - | - | 1件: 90 90 💬 |
338 | AAVrh.10-hMPSIIIA | - | - | - | - | 1件: 19 19 💬 |
339 | AAVrh.10cuARSA | - | - | - | - | 1件: 19 19 💬 |
340 | AAVrh.10CUCLN2 | - | - | - | - | 1件: 19 19 💬 |
341 | AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
342 | AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies | - | - | - | - | 1件: 19 19 💬 |
343 | AB 1003 | - | - | - | - | 1件: 2 2 💬 |
344 | AB-1001 Gene Therapy | - | - | - | - | 1件: 8 8 💬 |
345 | ABA, open-label (OL) | - | - | - | - | 1件: 46 46 💬 |
346 | Abacavir sulfate, Lamivudine and Zidovudine | 4件: Abacavir Abacavir, Lamivudine, Sulfate ion, Zidovudine | 3件: Lamivudine
Lamivudine
,
Zidovudine
,
Abacavir
💬 | - | - | 1件: 265 265 💬 |
347 | Abatacept (BMS-188667) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
348 | ABBV-006 | - | - | - | - | 1件: 97 97 💬 |
349 | ABBV-066 | - | - | - | - | 2件: 96 96, 97 💬 |
350 | ABBV-0805 | - | - | - | - | 1件: 6 6 💬 |
351 | ABBV-105 | - | - | - | - | 2件: 46 46, 49 💬 |
352 | ABBV-105, A-1519938.0 | - | - | - | - | 1件: 46 46 💬 |
353 | ABBV-119 | - | - | - | - | 1件: 299 299 💬 |
354 | ABBV-154 | - | - | - | - | 2件: 46 46, 96 💬 |
355 | Abetimus sodium (LJP 394) | 1件: Abetimus Abetimus | - | - | - | 1件: 49 49 💬 |
356 | AbGn-168H | - | - | - | - | 1件: 97 97 💬 |
357 | Abituzumab 1500 mg | 1件: Abituzumab Abituzumab | - | - | - | 1件: 51 51 💬 |
358 | ABO-101 | - | - | - | - | 1件: 19 19 💬 |
359 | ABO-102 | - | - | - | - | 1件: 19 19 💬 |
360 | ABT 494 | - | - | - | - | 1件: 46 46 💬 |
361 | ABT 494 12mg | - | - | - | - | 2件: 46 46, 96 💬 |
362 | ABT 494 3mg | - | - | - | - | 2件: 46 46, 96 💬 |
363 | ABT-122 | - | - | - | - | 1件: 46 46 💬 |
364 | ABT-199 | - | - | - | - | 1件: 49 49 💬 |
365 | ABT-494 | - | - | - | - | 7件: 41 41, 46, 49, 96, 97, 107, 271 💬 |
366 | ABT-494 15mg | - | - | - | - | 1件: 46 46 💬 |
367 | ABT-494 30mg | - | - | - | - | 1件: 46 46 💬 |
368 | ABT-874/Human monoclonal antibody against IL-12 | - | - | - | - | 1件: 13 13 💬 |
369 | ABX-1431 | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 💬 |
370 | ABX-1431 HCl | 1件: ABX-1431 ABX-1431 | - | - | - | 1件: 13 13 💬 |
371 | ABX464 100mg | - | - | - | - | 2件: 46 46, 97 💬 |
372 | ABY-035 | - | - | - | - | 1件: 271 271 💬 |
373 | AC-203 1% Topical Ointment | - | - | - | - | 1件: 162 162 💬 |
374 | Accelerated 1 hour-infusion | - | - | - | - | 2件: 96 96, 97 💬 |
375 | Accordion Pill Carbidopa/Levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
376 | Accordion Pill ¿ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
377 | Accordion Pill ¿ Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
378 | Accordion Pill? Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
379 | Accordion Pill? Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
380 | Accordion Pill¿ Carbidopa/levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
381 | Accordion Pill™ Carbidopa/Levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
382 | Accordion Pill™ Carbidopa/Levodopa 50/400 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
383 | Accordion Pill™ Carbidopa/Levodopa 50/500 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
384 | ACE-011 | - | - | - | - | 1件: 86 86 💬 |
385 | ACE-011 / MK - 7962 | - | - | - | - | 1件: 86 86 💬 |
386 | ACE-011 / MK-7962 | - | - | - | - | 1件: 86 86 💬 |
387 | ACE-011/ MK-7962 | - | - | - | - | 1件: 86 86 💬 |
388 | ACE-031 (Extension of cohort 1 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
389 | ACE-031 (Extension of cohort 2 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
390 | ACE-031 (Extension of cohort 3 from core study, A031-03) | - | - | - | - | 1件: 113 113 💬 |
391 | ACE-031 0.5 mg/kg q4wk | - | - | - | - | 1件: 113 113 💬 |
392 | ACE-031 1.0 mg/kg q2wk | - | - | - | - | 1件: 113 113 💬 |
393 | ACE-083 | - | - | - | - | 2件: 10 10, 113 💬 |
394 | ACER-002 (celiprolol) 200 mg BID | 1件: Celiprolol Celiprolol | 1件: Celiprolol
Celiprolol
💬 | 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 168 168 💬 |
395 | Acetohydroxamic Acid Oral Tablet [Lithostat] | 1件: Acetohydroxamic acid Acetohydroxamic acid | 1件: Acetohydroxamic acid
Acetohydroxamic acid
💬 | - | - | 1件: 251 251 💬 |
396 | ACETYL- L- CARNITINE | 1件: Levocarnitine Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 265 265 💬 |
397 | Acetyl-L-carnitine | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
398 | Acetyl-L-carnitine 1000mg 2X per day for 3 months | 2件: Acetylcarnitine Acetylcarnitine, Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 298 298 💬 |
399 | Acetyl-l-leucine | 2件: L-Acetylleucine L-Acetylleucine, Leucine | 1件: Leucine
Leucine
💬 | - | - | 2件: 19 19, 65 💬 |
400 | Acetylsalicylic acid at 1st visit, | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
401 | ACH-0144471 | - | - | - | - | 2件: 62 62, 222 💬 |
402 | ACH-0144471 compresse | - | - | - | - | 1件: 222 222 💬 |
403 | ACH-0145228 | - | - | - | - | 1件: 62 62 💬 |
404 | ACHIM as solute (10^9 intestinal microbes/ml) | - | - | - | - | 1件: 51 51 💬 |
405 | ACIDE TRANEXAMIQUE MYLAN 0,5 g/ 5 mL, solution injectable | - | - | - | - | 1件: 299 299 💬 |
406 | ACP-001 | - | - | - | - | 1件: 78 78 💬 |
407 | ACP-001 (TransCon hGH) | - | - | - | - | 1件: 78 78 💬 |
408 | ACP-011 | - | - | - | - | 1件: 78 78 💬 |
409 | ACP-103 | - | - | - | - | 1件: 6 6 💬 |
410 | ACR16 10 mg | - | - | - | - | 1件: 8 8 💬 |
411 | ACR16 45 mg | - | - | - | - | 1件: 8 8 💬 |
412 | ACT - 064992 | - | - | - | - | 1件: 86 86 💬 |
413 | ACT-050089 | - | - | - | - | 1件: 86 86 💬 |
414 | ACT-050089 (Ro 61-0612) | - | - | - | - | 1件: 86 86 💬 |
415 | ACT-064992 | - | - | - | - | 5件: 51 51, 85, 86, 88, 210 💬 |
416 | ACT-064992 (macitentan) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
417 | ACT-064992 / JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
418 | ACT-064992/ JNJ-67896062 | - | - | - | - | 1件: 86 86 💬 |
419 | ACT-064992D | - | - | - | - | 1件: 86 86 💬 |
420 | ACT-1 | - | - | - | - | 1件: 13 13 💬 |
421 | ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
422 | ACT-128800 Dose 1 | - | - | - | - | 1件: 13 13 💬 |
423 | ACT-128800 Dose 2 | - | - | - | - | 1件: 13 13 💬 |
424 | ACT-128800 Dose 3 | - | - | - | - | 1件: 13 13 💬 |
425 | ACT-178418 | - | - | - | - | 1件: 86 86 💬 |
426 | ACT-434964 | - | - | - | - | 1件: 19 19 💬 |
427 | ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 61 61, 62 💬 |
428 | Actemra(EU-licensed) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
429 | ACTHAR Gel 40 units twice weekly | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
430 | Acthar low dose (40 U) | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 49 49 💬 |
431 | ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML | 1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 2件: 62 62, 66 💬 |
432 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily. | - | - | - | - | 1件: 276 276 💬 |
433 | Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. | - | - | - | - | 1件: 6 6 💬 |
434 | Active drug: pimavanserin 17mg (2 strength tablets) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
435 | Active Investigational Treatment ENT-01 | - | - | - | - | 1件: 6 6 💬 |
436 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
437 | Actos 15 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
438 | Actos 45 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 2 2 💬 |
439 | Actrapid 100 IU/ml, Solution for injection in a vial | - | - | - | - | 1件: 299 299 💬 |
440 | Actrapid Penfill 100UI/ml | - | - | - | - | 1件: 299 299 💬 |
441 | ACTUS-101 | - | - | - | - | 1件: 256 256 💬 |
442 | ACU-4429 | - | - | - | - | 1件: 301 301 💬 |
443 | ACZ885 150 mg (Canakinumab) | 1件: Canakinumab Canakinumab | 1件: Canakinumab
Canakinumab
💬 | 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 107 107 💬 |
444 | ACZ885, 150mg/1.0ml | - | - | - | - | 2件: 266 266, 267 💬 |
445 | AD 452 | - | - | - | - | 1件: 46 46 💬 |
446 | AD 452 18 mg tablet | - | - | - | - | 1件: 46 46 💬 |
447 | AD 452 4.5 mg Tablet | - | - | - | - | 1件: 46 46 💬 |
448 | AD 452 9 mg tablet | - | - | - | - | 1件: 46 46 💬 |
449 | Ad26.COV2-S.02 | - | - | - | - | 1件: 299 299 💬 |
450 | Adalimumab (40mg) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
451 | Adalimumab - US licensed Humira | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
452 | Adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
453 | Adalimumab 40 mg eow or ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
454 | Adalimumab 40 mg sc every other week | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
455 | Adalimumab 40 mg subcutaneous (SC) every other week (EOW) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
456 | Adalimumab 40mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
457 | Adalimumab 40mg q2w | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
458 | Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
459 | Adderall XR | - | - | - | - | 1件: 13 13 💬 |
460 | Adderall XR 10 mg | - | - | - | - | 1件: 13 13 💬 |
461 | Adderall XR 5mg | - | - | - | - | 1件: 13 13 💬 |
462 | ADEMPAS - 0,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
463 | ADEMPAS - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
464 | ADEMPAS - 1,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
465 | ADEMPAS - 2 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
466 | ADEMPAS - 2,5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PP/ALU) - 42 COMPRESSE | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
467 | Adempas 0.125 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
468 | Adempas 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
469 | Adempas 0.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
470 | Adempas 1 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
471 | Adempas 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
472 | Adempas 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
473 | Adempas 1.5 mg Film Coated Tablet | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
474 | Adempas 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 299 💬 |
475 | Adempas® 0.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
476 | Adempas® 1.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
477 | Adempas® 1.5 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
478 | Adempas® 2.0 mg film-coated tablets | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
479 | Adempas¿ 0.5 mg compressa rivestita con film | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
480 | Adempas¿ 1.0 | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
481 | Adempas¿ 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
482 | Adempas¿ 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
483 | ADENO-ASSOCIATED VIRAL (AAV) SEROTYPE 8 (AAV2/8) VECTOR WITH LIVER-SPECIFIC THYROXINE-BINDING GLOBULIN (TBG) PROMOTER, DRIVING THE EXPRESSION OF THE HUMAN ARSB GENE | 1件: Levothyroxine Levothyroxine | 1件: Levothyroxine
Levothyroxine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 1件: 19 19 💬 |
484 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-betagal) | - | - | - | - | 1件: 19 19 💬 |
485 | Adeno-associated virus (AAV) serotype rh.10 expressing human betagalactosidase (AAVrh.10-CAG-ßgal) | - | - | - | - | 1件: 19 19 💬 |
486 | Adeno-associated virus serotype 2/6 encoding Left side-zinc finger nuclease (ZFN1), SB-A6P-ZLEFT Vector | - | - | - | - | 1件: 19 19 💬 |
487 | Adeno-associated virus serotype rh.10 expressing beta-galactosidase | 1件: Tilactase Tilactase | 1件: Lactase
Lactase
💬 | - | - | 1件: 19 19 💬 |
488 | Adeno-associated virus type 2 vector encoding Rab escort protein 1 | - | - | - | - | 1件: 90 90 💬 |
489 | Administration of a low dose of desipramine | 1件: Desipramine Desipramine | 1件: Desipramine
Desipramine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 156 156 💬 |
490 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | 1件: 65 65 💬 |
491 | Administration of stable isotope-labelled leucine- | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 6 6 💬 |
492 | ADS-001 | - | - | - | - | 1件: 231 231 💬 |
493 | ADS-5102, 137 mg | - | - | - | - | 1件: 13 13 💬 |
494 | Advagraf 0,5mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
495 | Advagraf 1mg | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
496 | ADVATE 1000 IU powder and solvent for solution for injection | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 💬 |
497 | ADVATE 1000IU powder and solvent for solution for injection | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 💬 |
498 | Adverse Reactions of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
499 | Adverse Reactions of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
500 | ADVM-043 | - | - | - | - | 1件: 231 231 💬 |
501 | ADX-102 1% Topical Dermal Cream (reproxalap) | 1件: Reproxalap Reproxalap | 1件: Reproxalap
Reproxalap
💬 | - | - | 1件: 160 160 💬 |
502 | Aerolised Liposomal Ciclosporin A | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
503 | Aerolised Liposomal Ciclosporin A 10mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
504 | Aerolised Liposomal Ciclosporin A 5mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
505 | Aerosolized human Alpha-1 Antitrypsin | - | - | - | - | 1件: 231 231 💬 |
506 | Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | - | - | - | - | 1件: 299 299 💬 |
507 | AEZS-130 | - | - | - | - | 1件: 78 78 💬 |
508 | AEZS-130 (formerly ARD-07) | - | - | - | - | 1件: 78 78 💬 |
509 | Afamelanotide (16 mg implant) | 1件: Afamelanotide Afamelanotide | 1件: Afamelanotide
Afamelanotide
💬 | 1件: MC1R MC1R 💬 | 2件: Melanogenesis Melanogenesis, Neuroactive ligand-receptor interaction 💬 | 1件: 159 159 💬 |
510 | Afimetoran (10mg) | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
511 | AFQ056 with L-dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
512 | Agalsidase beta from Biosidus 1 mg/kg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
513 | AGLE 102 | - | - | - | - | 1件: 36 36 💬 |
514 | AGS-009 | - | - | - | - | 1件: 49 49 💬 |
515 | AGT-181 | - | - | - | - | 1件: 19 19 💬 |
516 | AGT-181 (HIRMAb-IDUA) | - | - | - | - | 1件: 19 19 💬 |
517 | AGT-182 | - | - | - | - | 1件: 19 19 💬 |
518 | AIN457, 150 mg | - | - | - | - | 1件: 271 271 💬 |
519 | AIN457, 150mg | - | - | - | - | 1件: 37 37 💬 |
520 | AK106-001616 | 1件: AK106-001616 AK106-001616 | - | - | - | 1件: 46 46 💬 |
521 | AKCEA-ANGPTL3-LRX | - | - | - | - | 2件: 79 79, 265 💬 |
522 | AKR-501, YM-477 | - | - | - | - | 1件: 63 63 💬 |
523 | AL-108 | - | - | - | - | 1件: 5 5 💬 |
524 | Aldurazyme (laronidase) | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 2件: 19 19, 256 💬 |
525 | Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
526 | ALDURAZYME*INFUS 1FL 5ML 500U | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
527 | Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994 | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 46 46 💬 |
528 | Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994) | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 46 46 💬 |
529 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
530 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
531 | Alemtuzumab 12 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
532 | Alemtuzumab Injection [Lemtrada] | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
533 | Alendronate versus alfacalcidol (1-alpha OH vitamin D) | 3件: Alendronic acid Alendronic acid, Alfacalcidol, Vitamin D | 2件: Alfacalcidol
Alfacalcidol
,
Alendronic acid
💬 | 2件: FDPS FDPS, VDR 💬 | 9件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Terpenoid backbone biosynthesis, Tuberculosis 💬 | 3件: 41 41, 46, 50 💬 |
534 | Alicalm (polymeric liquid formula) | - | - | - | - | 1件: 96 96 💬 |
535 | ALK-001 | - | - | - | - | 1件: 301 301 💬 |
536 | ALK-001 (No generic name) | - | - | - | - | 1件: 301 301 💬 |
537 | Alkalinized Lidocaine-Heparin | 2件: Heparin Heparin, Lidocaine | 3件: Lidocaine
Lidocaine
,
Adomiparin
,
Lidocaine hydrochloride monohydrate
💬 | 6件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | 4件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬 | 1件: 226 226 💬 |
538 | AlloGen-LI | - | - | - | - | 1件: 70 70 💬 |
539 | Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
540 | Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
541 | Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
542 | Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) | - | - | - | - | 1件: 6 6 💬 |
543 | Allogeneic Cardiosphere-Derived Cells (CAP-1002) | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 💬 |
544 | Allogeneic donor derived B-lymphocytes | - | - | - | - | 1件: 60 60 💬 |
545 | ALLOGENIC HUMAN HETEROLOGOUS LIVER CELLS | - | - | - | - | 1件: 251 251 💬 |
546 | Allopurinol Sandoz 100 mg, tabletten | 1件: Allopurinol Allopurinol | 1件: Allopurinol
Allopurinol
💬 | 1件: XDH XDH 💬 | 6件: Caffeine metabolism Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Peroxisome, Purine metabolism 💬 | 1件: 96 96 💬 |
547 | Alpha 1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
548 | Alpha 1-proteinase inhibitor (human) | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
549 | Alpha Lipoic Acid | 1件: Lipoic acid Lipoic acid | - | - | - | 1件: 13 13 💬 |
550 | Alpha-1 Antitrypsin (AAT) | - | - | - | - | 1件: 231 231 💬 |
551 | Alpha-1 Antitrypsin (human) | - | - | - | - | 1件: 231 231 💬 |
552 | Alpha-1 HC 100 mg | - | - | - | - | 1件: 299 299 💬 |
553 | Alpha-1 HC 200 mg | - | - | - | - | 1件: 299 299 💬 |
554 | Alpha-1 MP | - | - | - | - | 1件: 231 231 💬 |
555 | Alpha-1 proteinase inhibitor (human) | - | - | - | - | 1件: 231 231 💬 |
556 | ALPHA-1-ANTITRYPSIN | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
557 | ALPHA-LIPOIC ACID | 1件: Lipoic acid Lipoic acid | - | - | - | 2件: 2 2, 13 💬 |
558 | Alpha-lipoic acid and L-acetyl carnitine | 2件: Levocarnitine Levocarnitine, Lipoic acid | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 5 5 💬 |
559 | Alphanate 1000 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
560 | Alphanate 1500 I.U. | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
561 | ALPHANATE*INF 1F 1000UI+F 10ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
562 | ALPHANATE*INF 1F 1500UI+F 10ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
563 | ALPHANATE*INF 1F 250UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
564 | ALPHANATE*INF 1F 500UI+F 5ML | 2件: Beroctocog alfa Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
565 | ALPN-101 | - | - | - | - | 1件: 49 49 💬 |
566 | ALRN-5281 0.015 mg/kg | - | - | - | - | 1件: 78 78 💬 |
567 | ALRN-5281 0.05 mg/kg | - | - | - | - | 1件: 78 78 💬 |
568 | ALRN-5281 0.15 mg/kg | - | - | - | - | 1件: 78 78 💬 |
569 | ALTH12-1:4 | - | - | - | - | 1件: 97 97 💬 |
570 | ALTH12-2:4 | - | - | - | - | 1件: 97 97 💬 |
571 | Altropane (123I) Injection | 1件: Altropane Altropane | - | - | - | 1件: 6 6 💬 |
572 | ALTU-135 | 1件: ALTU-135 ALTU-135 | - | - | - | 1件: 299 299 💬 |
573 | ALTUS-135 | - | - | - | - | 1件: 299 299 💬 |
574 | Alvelestat oral tablet - dose 1 | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 💬 |
575 | ALX-0061 | - | - | - | - | 2件: 46 46, 49 💬 |
576 | ALX-0061 150 mg/mL | - | - | - | - | 1件: 49 49 💬 |
577 | ALX-0061 Nanobody | - | - | - | - | 1件: 46 46 💬 |
578 | ALX-0081 | - | - | - | - | 1件: 64 64 💬 |
579 | ALX-009 | - | - | - | - | 1件: 299 299 💬 |
580 | ALX-0600 | - | - | - | - | 1件: 96 96 💬 |
581 | ALXN2040 (ACH-0144471) | - | - | - | - | 1件: 62 62 💬 |
582 | AM-01 | - | - | - | - | 1件: 51 51 💬 |
583 | Amantadin-ratiopharm 100mg | - | - | - | - | 1件: 6 6 💬 |
584 | Amantadine Level | 1件: Amantadine Amantadine | 1件: Amantadine
Amantadine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
585 | AMB-05X | - | - | - | - | 1件: 85 85 💬 |
586 | Ambrisentan - low dose | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
587 | American ginseng extract HT-1001 | 2件: Ginseng Ginseng, Panax quinquefolius whole | 1件: Ginseng
Ginseng
💬 | - | - | 1件: 13 13 💬 |
588 | AMG 108 | 1件: AMG 108 AMG 108 | - | - | - | 1件: 46 46 💬 |
589 | AMG 139 | - | - | - | - | 1件: 96 96 💬 |
590 | AMG 145 | - | - | - | - | 1件: 79 79 💬 |
591 | AMG 157 | 1件: Tezepelumab Tezepelumab | 1件: Tezepelumab
Tezepelumab
💬 | 1件: TSLP TSLP 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 98 98 💬 |
592 | AMG 162 | - | - | - | - | 2件: 46 46, 274 💬 |
593 | AMG 181 | - | - | - | - | 2件: 96 96, 97 💬 |
594 | AMG 407 | - | - | - | - | 2件: 56 56, 107 💬 |
595 | AMG 827 140 mg | - | - | - | - | 1件: 46 46 💬 |
596 | AMG-407 | - | - | - | - | 2件: 56 56, 107 💬 |
597 | Amgevita 40 mg Injektionslösung im Fertigpen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
598 | Amgevita 40 mg Injektionslösung in einer Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
599 | Amgevita 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
600 | Amifampridine Phosphate 10 MG Oral Tablet | 2件: Amifampridine Amifampridine, Phosphate ion | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 3 3 💬 |
601 | Amikacina liposomal (Arikace?) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
602 | Ammonium (15N) chloride | 1件: Chloride ion Chloride ion | - | - | - | 1件: 251 251 💬 |
603 | AMP-110 | - | - | - | - | 1件: 46 46 💬 |
604 | AMPHOTERICINE B, LIPOSOME | - | - | - | - | 1件: 60 60 💬 |
605 | AMT-101 | - | - | - | - | 2件: 46 46, 97 💬 |
606 | AMT-101 (oral) | - | - | - | - | 1件: 97 97 💬 |
607 | AMT-130 | 1件: AMT-130 AMT-130 | - | - | - | 1件: 8 8 💬 |
608 | ANA001XHCl (Syntagon) or VEXA-04 (Patheon) | - | - | - | - | 1件: 156 156 💬 |
609 | Anakinra (r-metHuIL-1ra) | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
610 | Anatomical Landmark-guided Suprascapular Nerve Block | - | - | - | - | 1件: 149 149 💬 |
611 | ANAVEX2-73 oral liquid | - | - | - | - | 1件: 156 156 💬 |
612 | AndroGel 1 % Topical Gel | - | - | - | - | 1件: 13 13 💬 |
613 | Androgel 10 grams of gel containing 100 mg of testosterone | 1件: Testosterone Testosterone | 1件: Testosterone
Testosterone
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
614 | Angiotensin-(1-7) | 1件: Angiotensin II Angiotensin II | 2件: Angiotensin II
Angiotensin II
,
Angiotensin II
💬 | 2件: AGTR1 AGTR1, AGTR2 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
615 | Anifrolumab 1000 mg | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬 |
616 | Anti IL-1beta antibody | - | - | - | - | 1件: 46 46 💬 |
617 | Anti IL-1beta antibody, subclass IgG4 | - | - | - | - | 1件: 46 46 💬 |
618 | Anti IL-1ß antibody | - | - | - | - | 1件: 46 46 💬 |
619 | Anti IL-1ß antibody, subclass IgG4 | - | - | - | - | 1件: 46 46 💬 |
620 | Anti LP40 antibody, subclass IgG4 | - | - | - | - | 1件: 49 49 💬 |
621 | Anti LP40 antibody, subclass IgG4 LA294 | - | - | - | - | 2件: 13 13, 46 💬 |
622 | Anti LP40 anticuerpo, subclase IgG4 | - | - | - | - | 1件: 49 49 💬 |
623 | Anti Lymphotoxin Alpha | - | - | - | - | 1件: 46 46 💬 |
624 | Anti-(misfolded human superoxide dismutase 1) human IgG1m3 monoclonal antibody | - | - | - | - | 1件: 2 2 💬 |
625 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 💬 |
626 | Anti-CD20 small modular immunopharmaceutical, WYE-400087 | - | - | - | - | 1件: 46 46 💬 |
627 | Anti-human T-lymphocyte immunoglobulin from horse | - | - | - | - | 1件: 60 60 💬 |
628 | ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS | - | - | - | - | 1件: 51 51 💬 |
629 | Anti-IL-12 | - | - | - | - | 2件: 13 13, 96 💬 |
630 | Anti-IL-20 (109-0012) | 1件: Fletikumab Fletikumab | 1件: Fletikumab
Fletikumab
💬 | 1件: IL20 IL20 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
631 | Anti-interleukin-1B monoclonal antibody | - | - | - | - | 1件: 106 106 💬 |
632 | Anti-IP-10 Antibody | - | - | - | - | 1件: 97 97 💬 |
633 | Anti-Mullerian hormone (AMH) level | - | - | - | - | 1件: 13 13 💬 |
634 | Anticuerpo monoclonal anti-LINGO-1 humano | - | - | - | - | 1件: 13 13 💬 |
635 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
636 | ANTOX (vers) 1.2 | - | - | - | - | 1件: 298 298 💬 |
637 | ANTOX (vers.)1.2 | - | - | - | - | 1件: 298 298 💬 |
638 | Antox version 1.2 | - | - | - | - | 1件: 298 298 💬 |
639 | AOC 1001 | - | - | - | - | 1件: 113 113 💬 |
640 | AOC 1020 | - | - | - | - | 1件: 113 113 💬 |
641 | AOC 1044 | - | - | - | - | 1件: 113 113 💬 |
642 | AP-101 | - | - | - | - | 1件: 2 2 💬 |
643 | AP-CD/LD | - | - | - | - | 1件: 6 6 💬 |
644 | AP1189, 100 mg | - | - | - | - | 1件: 46 46 💬 |
645 | APD334 L-arginine | 2件: Arginine Arginine, L-arginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 97 97 💬 |
646 | APL-130277 | - | - | - | - | 1件: 6 6 💬 |
647 | APL-1401 | - | - | - | - | 1件: 97 97 💬 |
648 | Apomorphine 0.25% (2.5mg/ml) | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
649 | Apomorphine hydrochloride 1.8mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
650 | Apomorphine hydrochloride 4.0 mg inhalation powder, pre-dispensed | 1件: Apomorphine Apomorphine | 1件: Apomorphine
Apomorphine
💬 | 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
651 | ApoTamox 10mg | - | - | - | - | 1件: 111 111 💬 |
652 | Apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side | 1件: Sinecatechins Sinecatechins | 1件: Sinecatechins
Sinecatechins
💬 | - | - | 1件: 160 160 💬 |
653 | Apraclonidine Hcl 0.5% Oph Soln | 1件: Apraclonidine Apraclonidine | 1件: Apraclonidine
Apraclonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
654 | Apremilast (CC-10004) | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 56 56 💬 |
655 | Apremilast 10 mg | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
656 | Apriso 0.375G ER CAP | - | - | - | - | 1件: 97 97 💬 |
657 | Aprovel (150 mg) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
658 | Aprovel 150 mg Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
659 | APT-1011 | - | - | - | - | 1件: 98 98 💬 |
660 | APT-1011 - 3 mg | - | - | - | - | 1件: 98 98 💬 |
661 | APT-1011 3 mg HS | - | - | - | - | 1件: 98 98 💬 |
662 | AQX-1125 | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
663 | AQX-1125 100 mg | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
664 | AQX-1125 200 mg | 1件: AQX-1125 AQX-1125 | - | - | - | 1件: 226 226 💬 |
665 | AR-42 | 1件: AR-42 AR-42 | - | - | - | 1件: 34 34 💬 |
666 | AR401959 L-arginine | 2件: Arginine Arginine, L-arginine | 1件: Arginine
Arginine
💬 | - | - | 3件: 96 96, 97, 98 💬 |
667 | Arbaclofen placarbil 15 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
668 | Arbaclofen placarbil 45 mg BID | 2件: Arbaclofen Arbaclofen, Arbaclofen Placarbil | 2件: Arbaclofen placarbil
Arbaclofen placarbil
,
Arbaclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
669 | ARC 1779 | - | - | - | - | 2件: 64 64, 288 💬 |
670 | ARCT-032 | - | - | - | - | 1件: 299 299 💬 |
671 | ARGX-113 | - | - | - | - | 5件: 11 11, 14, 35, 53, 63 💬 |
672 | ARGX-117 | - | - | - | - | 1件: 14 14 💬 |
673 | ARGX-117 IV | - | - | - | - | 1件: 14 14 💬 |
674 | Aricept 10 mg | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
675 | Aricept 10 mg filmdragerade tabletter | 1件: Donepezil Donepezil | 1件: Donepezil
Donepezil
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 13 13 💬 |
676 | Arikayce™ 140 mg | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
677 | ARINA-1 | - | - | - | - | 2件: 228 228, 299 💬 |
678 | Arm 1 - GEH120714 (18F) Injection | - | - | - | - | 1件: 13 13 💬 |
679 | ARRY-438162 | - | - | - | - | 1件: 46 46 💬 |
680 | ARRY-438162, MEK inhibitor | - | - | - | - | 1件: 46 46 💬 |
681 | ART-123 | - | - | - | - | 1件: 85 85 💬 |
682 | Artamin 150 mg | - | - | - | - | 1件: 171 171 💬 |
683 | ARZERRA - 100 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONE(VETRO) - 5 ML(20MG/ML) 3 FLACONI | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
684 | ARZERRA - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 50 ML (20 MG/ML) 1 FLACONCINO + 2 KIT DI PROLUNGA | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
685 | Asacol 400 mg | - | - | - | - | 1件: 97 97 💬 |
686 | Asacol 400 mg (mesalamine) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
687 | Asacol 400 mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
688 | Asacol 400mg tablet | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
689 | Asacol® 400 mg | - | - | - | - | 1件: 97 97 💬 |
690 | ASC42 10 mg | - | - | - | - | 1件: 93 93 💬 |
691 | ASC42 15 mg | - | - | - | - | 1件: 93 93 💬 |
692 | ASF-1096 Cream 0.25% | - | - | - | - | 1件: 49 49 💬 |
693 | ASF-1096 Cream 0.5% | - | - | - | - | 1件: 49 49 💬 |
694 | ASF-1096 Cream 1.0% | - | - | - | - | 1件: 49 49 💬 |
695 | ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide | - | - | - | - | 1件: 46 46 💬 |
696 | AST-120 | - | - | - | - | 2件: 96 96, 97 💬 |
697 | AT 10 | - | - | - | - | 2件: 6 6, 85 💬 |
698 | AT-1501 | - | - | - | - | 1件: 66 66 💬 |
699 | AT1001 150 mg | - | - | - | - | 1件: 19 19 💬 |
700 | Atacicept 150 mg | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 13 13, 49 💬 |
701 | Atacicept: with loading dose | 1件: Atacicept Atacicept | 1件: Atacicept
Atacicept
💬 | 2件: TNFSF13 TNFSF13, TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 💬 |
702 | Ataluren 1000 mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
703 | Ataluren 1000mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 246 246 💬 |
704 | Ataluren 125 mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
705 | Ataluren 125mg | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 246 246 💬 |
706 | ATH-1017 | - | - | - | - | 1件: 6 6 💬 |
707 | ATH434 dose level 1 | - | - | - | - | 1件: 17 17 💬 |
708 | ATH434 dose level 2 | - | - | - | - | 1件: 17 17 💬 |
709 | ATI-450 | - | - | - | - | 2件: 46 46, 106 💬 |
710 | ATI-450 20mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
711 | ATI-450 50mg oral tablet BID | - | - | - | - | 1件: 46 46 💬 |
712 | ATN-103 | - | - | - | - | 1件: 46 46 💬 |
713 | ATN-103 10 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
714 | ATN-103 10 mg q8wks | - | - | - | - | 1件: 46 46 💬 |
715 | ATN-103 30 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
716 | ATN-103 80 mg q4wks | - | - | - | - | 1件: 46 46 💬 |
717 | ATN-103 80 mg q8wks | - | - | - | - | 1件: 46 46 💬 |
718 | Atorvastatin 10mg | 1件: Atorvastatin Atorvastatin | 1件: Atorvastatin
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
719 | Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet | 2件: Acetylcysteine Acetylcysteine, Atorvastatin | 2件: Acetylcysteine
Acetylcysteine
,
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 63 63 💬 |
720 | ATR-101 | - | - | - | - | 2件: 75 75, 81 💬 |
721 | ATX-MS-1467 | - | - | - | - | 1件: 13 13 💬 |
722 | ATYR1923 1.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
723 | ATYR1923 3.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
724 | ATYR1923 5.0 mg/kg | 1件: ATYR1923 ATYR1923 | - | - | - | 1件: 84 84 💬 |
725 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BISTER (ALU/ALU) PERFORATO MONODOSE - 10 X 1 COMPRESSA | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
726 | AUBAGIO - 14 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 28 COMPRESSE | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
727 | Aubagio 14 mg film-coated tablets | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
728 | Autologous cardiac stem cells (JRM-001) | - | - | - | - | 2件: 210 210, 211 💬 |
729 | Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene | - | - | - | - | 1件: 65 65 💬 |
730 | AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
731 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING THE HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 💬 |
732 | Autologous CD34+ cells transduced with a lentiviral vector encoding the ARSA cDNA | - | - | - | - | 1件: 19 19 💬 |
733 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTI-D VECTOR ENCODING ABCD1 CDNA | - | - | - | - | 1件: 20 20 💬 |
734 | Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy | - | - | - | - | 1件: 65 65 💬 |
735 | Autologous CD34+ cells transduced with WASP lentiviral vector | - | - | - | - | 1件: 65 65 💬 |
736 | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence | - | - | - | - | 1件: 65 65 💬 |
737 | Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII | - | - | - | - | 1件: 19 19 💬 |
738 | Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | - | - | - | - | 1件: 65 65 💬 |
739 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
740 | Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
741 | Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA | - | - | - | - | 1件: 20 20 💬 |
742 | Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 | - | - | - | - | 1件: 46 46 💬 |
743 | Autologous ovalbumin-specific type 1 regulatory T lymphocytes expanded population | - | - | - | - | 1件: 96 96 💬 |
744 | AUTOLOGOUS T-LYMPHOCYTES | - | - | - | - | 1件: 13 13 💬 |
745 | Autologous T-regulatory lymphocytes | - | - | - | - | 1件: 2 2 💬 |
746 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
747 | AV-101 | 1件: AV-101 AV-101 | - | - | - | 2件: 6 6, 86 💬 |
748 | AVALOX - 400 | - | - | - | - | 1件: 6 6 💬 |
749 | Avandia administration for 6-12 weeks | - | - | - | - | 1件: 265 265 💬 |
750 | AVB-114 | - | - | - | - | 1件: 96 96 💬 |
751 | AVI-4658 | - | - | - | - | 1件: 113 113 💬 |
752 | AVI-4658 (Eteplirsen) | 1件: Eteplirsen Eteplirsen | 1件: Eteplirsen
Eteplirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
753 | AVI-4658 (PMO) | - | - | - | - | 1件: 113 113 💬 |
754 | AVI-4658 for Injection | - | - | - | - | 1件: 113 113 💬 |
755 | Avonex (Interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
756 | Avonex (interferon beta-1a), Biogen Idec Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
757 | AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
758 | Avonex 30 microgram/0.5 ml Solution for Injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
759 | AVONEX 30 microgramos/0,5 ml (Interferón Beta - 1a) Solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
760 | Avonex 30 microgramos/0.5 ml Solución para inyección | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
761 | AVONEX 30 µg/0,5 ml solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
762 | AVONEX IM 4SIR 30MCG/0,5ML 4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
763 | AVONEX*IM 4SIR 30MCG/0,5ML+4AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
764 | Avonex® monotherapy (6.0 MIU administered i.m. each week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
765 | AVP-923-45 | - | - | - | - | 1件: 6 6 💬 |
766 | AVR-RD-01 | - | - | - | - | 1件: 19 19 💬 |
767 | AVR-RD-02 | - | - | - | - | 1件: 19 19 💬 |
768 | AVTX-803 (L-Fucose) | 1件: Fucose Fucose | - | - | - | 1件: 65 65 💬 |
769 | AVX 470 | - | - | - | - | 1件: 97 97 💬 |
770 | AVXS-101 | - | - | - | - | 1件: 3 3 💬 |
771 | AVXS-101 (previously known as scAAV9.CB.SMN) | - | - | - | - | 1件: 3 3 💬 |
772 | AXO-AAV-GM2 Low Dose | - | - | - | - | 1件: 19 19 💬 |
773 | AZD3241 100mg | - | - | - | - | 1件: 17 17 💬 |
774 | AZD3241 Alternative titration scheme with formulation 1 or 2 | - | - | - | - | 1件: 6 6 💬 |
775 | AZD3241 ER formulation 1 | - | - | - | - | 1件: 6 6 💬 |
776 | AZD3241 Extended release tablets 100 mg | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 💬 |
777 | AZD7325 (Low-Dose) | - | - | - | - | 1件: 206 206 💬 |
778 | AZD9567 10 mg | - | - | - | - | 1件: 46 46 💬 |
779 | AZD9567 125 mg | - | - | - | - | 1件: 46 46 💬 |
780 | AZD9567 155 mg | - | - | - | - | 1件: 46 46 💬 |
781 | AZD9567 40 mg | - | - | - | - | 1件: 46 46 💬 |
782 | AZILECT 1 mg comprimidos | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
783 | Azilect 1mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
784 | AZILECT® 1 mg Tabletten | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 2 2 💬 |
785 | AZTREONAM LYSINE | 2件: Aztreonam Aztreonam, Lysine | 2件: Aztreonam
Aztreonam
,
Lysine
💬 | - | - | 1件: 299 299 💬 |
786 | Aztreonam Lysine for Inhalation | 2件: Aztreonam Aztreonam, Lysine | 2件: Aztreonam
Aztreonam
,
Lysine
💬 | - | - | 1件: 299 299 💬 |
787 | Aztreonam Lysine for Inhalation (AZLI) | 2件: Aztreonam Aztreonam, Lysine | 2件: Aztreonam
Aztreonam
,
Lysine
💬 | - | - | 1件: 228 228 💬 |
788 | Aztreonan lysine | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
789 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 💬 |
790 | B-Lymphocyte Stimulator (BLyS) | - | - | - | - | 1件: 65 65 💬 |
791 | B. lactis B94 | - | - | - | - | 1件: 193 193 💬 |
792 | B6, B12, L-methylfolate | 1件: Levomefolic acid Levomefolic acid | 1件: Levomefolic acid
Levomefolic acid
💬 | - | - | 1件: 6 6 💬 |
793 | Baclofen (baclofen Tab. 10mg) treatment | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 70 70 💬 |
794 | Baclofen ER Capsules (GRS) 10 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
795 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
796 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
797 | BAF312 0,25 mg tablet | - | - | - | - | 1件: 13 13 💬 |
798 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 💬 |
799 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 💬 |
800 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 💬 |
801 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 💬 |
802 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 💬 |
803 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 💬 |
804 | BAF312 1 mg | - | - | - | - | 1件: 50 50 💬 |
805 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 💬 |
806 | BAF312 1mg | - | - | - | - | 1件: 50 50 💬 |
807 | BAF312 1mg tablet | - | - | - | - | 1件: 50 50 💬 |
808 | BAF312 4 mg tablet | - | - | - | - | 1件: 13 13 💬 |
809 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 💬 |
810 | Bardoxolone methyl 10 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 67 67 💬 |
811 | Bardoxolone methyl 15 mg | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 67 67 💬 |
812 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
813 | Baricitinib 4 MG | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
814 | BASSADO 10CPS 100MG | - | - | - | - | 1件: 23 23 💬 |
815 | BAX 111 | - | - | - | - | 1件: 288 288 💬 |
816 | BAY 63-2521 0.06 % | - | - | - | - | 1件: 86 86 💬 |
817 | BAY 63-2521 0.3 % | - | - | - | - | 1件: 86 86 💬 |
818 | BAY 63-2521 coated tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
819 | BAY 63-2521 coated tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
820 | BAY 63-2521 coated tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
821 | BAY 63-2521 IR coated tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
822 | BAY 63-2521 IR coated tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
823 | BAY 63-2521 IR coated tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
824 | BAY 63-2521 IR tablet 0.5 mg | - | - | - | - | 1件: 88 88 💬 |
825 | BAY 63-2521 IR tablet 1.0 mg | - | - | - | - | 1件: 88 88 💬 |
826 | BAY 63-2521 IR tablet 1.5 mg | - | - | - | - | 1件: 88 88 💬 |
827 | BAY 63-2521 IR tablet 2.0 mg | - | - | - | - | 1件: 88 88 💬 |
828 | BAY 63-2521 IR tablets 0.5 mg | - | - | - | - | 1件: 86 86 💬 |
829 | BAY 63-2521 IR tablets 1 mg | - | - | - | - | 1件: 86 86 💬 |
830 | BAY 63-2521 IR tablets 1.0 mg | - | - | - | - | 1件: 86 86 💬 |
831 | BAY 63-2521 IR tablets 1.5 mg | - | - | - | - | 1件: 86 86 💬 |
832 | BAY 63-2521 IR tablets 2.0 mg | - | - | - | - | 1件: 86 86 💬 |
833 | BAY 63-2521 tablets 0.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
834 | BAY 63-2521 tablets 1 mg | - | - | - | - | 2件: 86 86, 88 💬 |
835 | BAY 63-2521 tablets 1.5 mg | - | - | - | - | 2件: 86 86, 88 💬 |
836 | BAY 79-4998 | - | - | - | - | 1件: 13 13 💬 |
837 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 💬 |
838 | BBP-418 | - | - | - | - | 1件: 113 113 💬 |
839 | BBT-401-1S | - | - | - | - | 1件: 97 97 💬 |
840 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 💬 |
841 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 💬 |
842 | BCD-033 (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
843 | BCD-054 180 mcg | - | - | - | - | 1件: 13 13 💬 |
844 | BCD-054 240 mcg | - | - | - | - | 1件: 13 13 💬 |
845 | BCD-055 | - | - | - | - | 2件: 46 46, 271 💬 |
846 | BCD-063 | - | - | - | - | 1件: 13 13 💬 |
847 | BCD-085 | - | - | - | - | 2件: 93 93, 271 💬 |
848 | BCD-089 | - | - | - | - | 1件: 46 46 💬 |
849 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 💬 |
850 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 💬 |
851 | BCD-132 | - | - | - | - | 1件: 13 13 💬 |
852 | BCD-132, 125 mg | - | - | - | - | 1件: 13 13 💬 |
853 | BCD-132, 500 mg | - | - | - | - | 1件: 13 13 💬 |
854 | BCD-148 | - | - | - | - | 1件: 62 62 💬 |
855 | BCG20-0134 | - | - | - | - | 1件: 13 13 💬 |
856 | Beetainterferoni -1a | - | - | - | - | 1件: 13 13 💬 |
857 | BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée | - | - | - | - | 1件: 94 94 💬 |
858 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
859 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
860 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: Belantamab mafodotin
Belantamab mafodotin
💬 | 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 💬 |
861 | Belimumab 1 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 💬 |
862 | Belimumab 10 mg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 222 222 💬 |
863 | Belimumab 10 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 43 43, 46, 49 💬 |
864 | Belimumab 10 mg/kg plus standard therapy | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
865 | Belimumab 100 mg SC | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
866 | Belimumab 10mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
867 | Belimumab 4 mg/kg | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 💬 |
868 | Belimumab plus Late Vaccination | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
869 | Benazepril hydrochloride 10 milligram (mg) Tab | 1件: Benazepril Benazepril | 1件: Benazepril
Benazepril
💬 | 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 218 218 💬 |
870 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 53 53 💬 |
871 | Benlysta 400 mg powder for concentrate for solution for infusion | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 43 43, 49 💬 |
872 | Benlysta 400 mg powder for concentrate for solution for infusions | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
873 | Benlysta 400mg polvere per concentrato per soluzione per infusione | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 43 43 💬 |
874 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
875 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Benzimidazole Benzimidazole | - | - | - | 1件: 46 46 💬 |
876 | Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 298 298 💬 |
877 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 💬 |
878 | Beta-1b interferoni | - | - | - | - | 1件: 13 13 💬 |
879 | Beta-lactam antibiotic | - | - | - | - | 1件: 299 299 💬 |
880 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
881 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
882 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
883 | BETAFERON® (interferon beta-1b) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
884 | Betaloc ZOK 100, 95 mg | - | - | - | - | 1件: 113 113 💬 |
885 | Betamethasone Oral Solution Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
886 | Betamethasone solution as intramuscular injection Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
887 | Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
888 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
889 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 4件: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle, Neisseria meningitidis serogroup b fhbp fusion protein antigen, Neisseria meningitidis serogroup b nada protein antigen, Neisseria meningitidis serogroup b nhba fusion protein antigen | - | - | - | 1件: 66 66 💬 |
890 | Bezafibrat Genericon retard 400 mg | - | - | - | - | 1件: 93 93 💬 |
891 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
892 | Bezafibrate 400 MG | 1件: Bezafibrate Bezafibrate | 1件: Bezafibrate
Bezafibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 💬 |
893 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 💬 |
894 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 💬 |
895 | BG-12 120 | - | - | - | - | 1件: 13 13 💬 |
896 | BG9418 (interferon beta 1-a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
897 | BG9418 (interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 💬 |
898 | BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
899 | BGP-014 | - | - | - | - | 1件: 97 97 💬 |
900 | BGP-014 Capsules | - | - | - | - | 1件: 97 97 💬 |
901 | BGX-0214 | - | - | - | - | 1件: 46 46 💬 |
902 | BHT-3009 0.5 mg | - | - | - | - | 1件: 13 13 💬 |
903 | BHT-3009 1.5 mg | - | - | - | - | 1件: 13 13 💬 |
904 | BHT-3009-01 | - | - | - | - | 1件: 13 13 💬 |
905 | BHV-0223 | - | - | - | - | 1件: 2 2 💬 |
906 | BHV-4157 | - | - | - | - | 1件: 17 17 💬 |
907 | BI 1015550 | - | - | - | - | 1件: 85 85 💬 |
908 | BI 1015550 18 mg Film Coated Tablet | - | - | - | - | 1件: 85 85 💬 |
909 | BI 1015550 9 mg Film Coated Tablet | - | - | - | - | 1件: 85 85 💬 |
910 | BI 1265162 | - | - | - | - | 1件: 299 299 💬 |
911 | BI 1265162 10 µg | - | - | - | - | 1件: 299 299 💬 |
912 | BI 1265162 100 µg | - | - | - | - | 1件: 299 299 💬 |
913 | BI 1265162 25 µg | - | - | - | - | 1件: 299 299 💬 |
914 | BI 1265162 50 µg | - | - | - | - | 1件: 299 299 💬 |
915 | BI 443651 | - | - | - | - | 1件: 299 299 💬 |
916 | BI 655064 low dose | - | - | - | - | 1件: 46 46 💬 |
917 | BI 655066 10 mg/ml | - | - | - | - | 1件: 96 96 💬 |
918 | BIA 5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
919 | BIA 6-512 100 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
920 | BIA 6-512 100 mg dose | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
921 | BIA 6-512 400 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
922 | BIA 9-1067 | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
923 | BIA 9-1067 (test) | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
924 | BIA 9-1067 15 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
925 | BIA 9-1067 25 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
926 | BIA 9-1067 30 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
927 | BIA 9-1067 5 mg | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
928 | BIA 9-1067 micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
929 | BIA 9-1067 non-micronized | 1件: BIA BIA | - | - | - | 1件: 6 6 💬 |
930 | BIA-5-1058 | 1件: BIA BIA | - | - | - | 1件: 86 86 💬 |
931 | BIBF 1120 | - | - | - | - | 2件: 51 51, 85 💬 |
932 | BIBF 1120 ES | - | - | - | - | 1件: 85 85 💬 |
933 | BIIB 017 | - | - | - | - | 1件: 13 13 💬 |
934 | BIIB017 (Peginterferon beta-1a) | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
935 | BIIB033 (ANTI-LINGO) | - | - | - | - | 1件: 13 13 💬 |
936 | BIIB033 (ANTI-LINGO) - EV Substance Code SUB118957 | - | - | - | - | 1件: 13 13 💬 |
937 | BIIB059 (litifilimab) | - | - | - | - | 1件: 49 49 💬 |
938 | BIIL 284 BS low dose | - | - | - | - | 1件: 46 46 💬 |
939 | BIIL 284 BS, low dose | - | - | - | - | 1件: 299 299 💬 |
940 | BIIL 284 BS, low dose, adult patients | - | - | - | - | 1件: 299 299 💬 |
941 | BIIL 284 BS, low dose, pediatric patients | - | - | - | - | 1件: 299 299 💬 |
942 | BINOCRIT*1SIR 40000UI/1ML | 1件: Erythropoietin Erythropoietin | - | - | - | 1件: 18 18 💬 |
943 | Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
944 | BION-1301 Multiple Doses | - | - | - | - | 1件: 66 66 💬 |
945 | BION-1301 Single Dose | - | - | - | - | 1件: 66 66 💬 |
946 | Biopsy of the labial salivary gland | - | - | - | - | 1件: 53 53 💬 |
947 | BIRB 796 BS, low dose | - | - | - | - | 1件: 46 46 💬 |
948 | BIRT 2584 XX | - | - | - | - | 1件: 13 13 💬 |
949 | Bitterschleifenblume-ganzpflanze 1,5ml/10ml | - | - | - | - | 1件: 97 97 💬 |
950 | BIVV001 (rFVIIIFc-VWF-XTEN) | - | - | - | - | 1件: 288 288 💬 |
951 | Bladder instillation with heparin/ lidocaine | 2件: Heparin Heparin, Lidocaine | 3件: Lidocaine
Lidocaine
,
Adomiparin
,
Lidocaine hydrochloride monohydrate
💬 | 6件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | 4件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬 | 1件: 226 226 💬 |
952 | BLI-1300 high dose | - | - | - | - | 1件: 96 96 💬 |
953 | BLI-1300 low dose | - | - | - | - | 1件: 96 96 💬 |
954 | Blood coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
955 | Blood draw for the laboratory assessment | - | - | - | - | 1件: 303 303 💬 |
956 | BMN 044 | - | - | - | - | 1件: 113 113 💬 |
957 | BMN 044 IV 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
958 | BMN 044 IV 9 mg/kg | - | - | - | - | 1件: 113 113 💬 |
959 | BMN 044 SC 6 mg/kg | - | - | - | - | 1件: 113 113 💬 |
960 | BMN 045 | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
961 | BMN 053 | - | - | - | - | 1件: 113 113 💬 |
962 | BMN 110 | - | - | - | - | 1件: 19 19 💬 |
963 | BMN 110 - Every Other Week | - | - | - | - | 1件: 19 19 💬 |
964 | BMN 110 - Weekly | - | - | - | - | 1件: 19 19 💬 |
965 | BMN 110 Every Other Week | - | - | - | - | 1件: 19 19 💬 |
966 | BMN 110 Weekly | - | - | - | - | 1件: 19 19 💬 |
967 | BMN 111 | - | - | - | - | 1件: 276 276 💬 |
968 | BMN 165 | - | - | - | - | 1件: 240 240 💬 |
969 | BMN 165 (rAvPAL-PEG) | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
970 | BMN 190 | - | - | - | - | 1件: 19 19 💬 |
971 | BMN165 40mg/day | - | - | - | - | 1件: 240 240 💬 |
972 | BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1) | - | - | - | - | 1件: 19 19 💬 |
973 | BMS 188667 (Abatacept) | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 13 13 💬 |
974 | BMS-188667 | - | - | - | - | 9件: 46 46, 49, 53, 65, 96, 97, 107, 222, 271 💬 |
975 | BMS-936557 (Anti-IP-10 Antibody) | - | - | - | - | 1件: 96 96 💬 |
976 | BMS-986004 1500 mg IV | - | - | - | - | 1件: 63 63 💬 |
977 | BMS-986089-01 (RO7239361) , anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
978 | BMS-986089-01 (RO7239361) Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
979 | BMS-986089-01 (RO7239361) Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
980 | BMS-986089-01 (RO7239361) Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
981 | BMS-986089-01 (RO7239361) Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
982 | BMS-986089-01 (RO7239361), anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
983 | BMS-986089-01 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
984 | BMS-986089-01 Injections, 35 mg/Syringe (50 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
985 | BMS-986089-01 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
986 | BMS-986089-01 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
987 | BMS-986089-01, Anti-myostatin | - | - | - | - | 1件: 113 113 💬 |
988 | BMS-986256-06, TLR7/8 Antagonist | 1件: Afimetoran Afimetoran | 1件: Afimetoran
Afimetoran
💬 | - | - | 1件: 49 49 💬 |
989 | Bosentan 125 mg | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
990 | Bosutinib (Phase 1 part) | 1件: Bosutinib Bosutinib | 1件: Bosutinib
Bosutinib
💬 | 2件: ABL1 ABL1, SRC 💬 | 49件: Adherens junction Adherens junction, Axon guidance, Bacterial invasion of epithelial cells, Bladder cancer, C-type lectin receptor signaling pathway, Cell cycle, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, GABAergic synapse, Gap junction, GnRH signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, MicroRNAs in cancer, Mitophagy - animal, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Prolactin signaling pathway, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis, Thyroid hormone signaling pathway, Tight junction, Tuberculosis, VEGF signaling pathway, Viral carcinogenesis, Viral myocarditis, Yersinia infection 💬 | 1件: 2 2 💬 |
991 | BOTOX 100 UNITES ALLERGAN (PR1) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 2 2 💬 |
992 | Botox 100 UNT Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
993 | BOTOX 100U in normal saline | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 226 226 💬 |
994 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
995 | BPLG-003 | - | - | - | - | 1件: 78 78 💬 |
996 | BRAMICIL - 100 MG/ 2 ML SOLUZIONE INIETTABILE 10 FIALE DA 2 ML | - | - | - | - | 1件: 299 299 💬 |
997 | BRAMITOB - 300 MG/4 ML SOLUZIONE DA NEBULIZZARE 56 CONTENITORI MONODOSE 4 ML | - | - | - | - | 1件: 299 299 💬 |
998 | Bramitob 300mg/4ml Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
999 | BRAMITOB*NEBUL 28F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
1000 | BRAMITOB*NEBUL 56F 300MG/4ML | - | - | - | - | 1件: 299 299 💬 |
1001 | Bramitob® administered by PARI LC® PLUS nebulizer | - | - | - | - | 1件: 299 299 💬 |
1002 | Brazikumab low dose | 1件: Brazikumab Brazikumab | 1件: Brazikumab
Brazikumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1003 | Break in L-carnitine treatment | 1件: Levocarnitine Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 316 316 💬 |
1004 | Bredinin tablet 150mg | 1件: Mizoribine Mizoribine | 1件: Mizoribine
Mizoribine
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 46 46 💬 |
1005 | Brensocatib 10 mg | 1件: Brensocatib Brensocatib | 1件: Brensocatib
Brensocatib
💬 | 1件: CTSC CTSC 💬 | 2件: Apoptosis Apoptosis, Lysosome 💬 | 1件: 299 299 💬 |
1006 | BRL-049653 | - | - | - | - | 1件: 46 46 💬 |
1007 | Bronchoalveolar lavage fluid collection | - | - | - | - | 1件: 229 229 💬 |
1008 | Bryostatin 1 | 1件: Bryostatin 1 Bryostatin 1 | - | - | - | 1件: 62 62 💬 |
1009 | BSF 208075 or LU 208075 | - | - | - | - | 1件: 86 86 💬 |
1010 | BT-11 | - | - | - | - | 2件: 96 96, 97 💬 |
1011 | BT-11 (1000 mg) | - | - | - | - | 1件: 97 97 💬 |
1012 | BT-11 (500 mg) | - | - | - | - | 1件: 97 97 💬 |
1013 | BT-11 (Omilancor) | - | - | - | - | 1件: 96 96 💬 |
1014 | BT-11 1,000 mg | - | - | - | - | 1件: 96 96 💬 |
1015 | BT-11 1000mg | - | - | - | - | 3件: 96 96, 97, 98 💬 |
1016 | BT-11 500 mg | - | - | - | - | 2件: 96 96, 97 💬 |
1017 | BT-11 500mg | - | - | - | - | 1件: 98 98 💬 |
1018 | BT-11 Active | - | - | - | - | 2件: 96 96, 97 💬 |
1019 | BTT-1023 | - | - | - | - | 1件: 46 46 💬 |
1020 | Budesonide 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1021 | Budesonide 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1022 | Budesonide 0.5mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1023 | Budesonide 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1024 | Budesonide 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1025 | Budesonide 1 mg orodispersible tablets (BUL 1 mg) | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1026 | Budesonide 1mg orodispersible tablet twice daily | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1027 | Budesonide [0.4mg/ml] viscous suspension | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1028 | Budesonide oral suspension [0.2 mg/ml] | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1029 | BUET 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
1030 | BUET 1 mg | - | - | - | - | 1件: 98 98 💬 |
1031 | BUET 1mg | - | - | - | - | 1件: 98 98 💬 |
1032 | BUL 0.5 mg | - | - | - | - | 1件: 98 98 💬 |
1033 | BUL 1 mg | - | - | - | - | 1件: 98 98 💬 |
1034 | Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 46 46 💬 |
1035 | Bupivacaine Injection 0.5% | 1件: Bupivacaine Bupivacaine | 1件: Bupivacaine
Bupivacaine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 168 168 💬 |
1036 | Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine | 3件: Bupivacaine Bupivacaine, Clonidine, Epinephrine | 3件: Epinephrine
Epinephrine
,
Clonidine
,
Bupivacaine
💬 | 14件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Taste transduction, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬 |
1037 | Bupivacaïne HCl 0,125% / Sufentanil 50 µg flacon à 50 ml | 1件: Sufentanil Sufentanil | 1件: Sufentanil
Sufentanil
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 💬 |
1038 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
1039 | BUU 0.4mg/ml | - | - | - | - | 1件: 98 98 💬 |
1040 | BV-101 | - | - | - | - | 1件: 8 8 💬 |
1041 | BX-1 | - | - | - | - | 1件: 13 13 💬 |
1042 | C-028380 | - | - | - | - | 1件: 106 106 💬 |
1043 | C-11 PiB | 1件: Pittsburgh Compound B Pittsburgh Compound B | - | - | - | 1件: 127 127 💬 |
1044 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 💬 |
1045 | C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
1046 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
1047 | Cabaseril, 1,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
1048 | Cabaseril, 2,0 mg Tablette | - | - | - | - | 1件: 6 6 💬 |
1049 | Cabotegravir - Injectable Suspension (CAB LA) | 1件: Cabotegravir Cabotegravir | 1件: Cabotegravir
Cabotegravir
💬 | - | - | 1件: 256 256 💬 |
1050 | CAEL-101 | - | - | - | - | 1件: 28 28 💬 |
1051 | Caffeine 100-200 mg BID | 1件: Caffeine Caffeine | 2件: Caffeine
Caffeine
,
Caffeine hydrate
💬 | 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1052 | CALCIUM D3 SANDOZ - 1000 MG + 880 U.I. COMPRESSE EFFERVESCENTI 30 COMPRESSE DIVISIBILI | 2件: Calcium Calcium, Calcium carbonate | 2件: Calcium carbonate
Calcium carbonate
,
Calcium carbonate
💬 | - | - | 1件: 274 274 💬 |
1053 | Calcium lactate | 2件: Calcium Calcium, Calcium lactate | 2件: Calcium lactate
Calcium lactate
,
Calcium lactate hydrate
💬 | - | - | 1件: 235 235 💬 |
1054 | Calcium levofolinate | 1件: Calcium Calcium | - | - | - | 1件: 13 13 💬 |
1055 | Calvan® 100 mg | - | - | - | - | 1件: 8 8 💬 |
1056 | CALY-002 | - | - | - | - | 1件: 98 98 💬 |
1057 | Camoteskimab (CERC-007, AVTX-007, AEVI-007) | - | - | - | - | 1件: 107 107 💬 |
1058 | Campath -1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 65 65 💬 |
1059 | Campath 1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 4件: 60 60, 65, 164, 285 💬 |
1060 | Campath-1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 6件: 19 19, 20, 60, 234, 285, 326 💬 |
1061 | CAMPATH-1H (Alemtuzumab) | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 60 60 💬 |
1062 | Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US. | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
1063 | Cannabidiol tablet 10 mg | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 46 46, 271 💬 |
1064 | Cannabis sativa L., folium cum flore | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 19 19 💬 |
1065 | CAP-1002 | 1件: CAP-1002 CAP-1002 | - | - | - | 1件: 113 113 💬 |
1066 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
1067 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab, Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬 | 1件: VWF VWF 💬 | 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | 1件: 64 64 💬 |
1068 | Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1069 | Capsules with 160 mg Teavigo (at least 94% EGCG) | 1件: Epigallocatechin gallate Epigallocatechin gallate | - | - | - | 1件: 13 13 💬 |
1070 | Carbidopa and Levodopa 25mg/100mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1071 | Carbidopa and Levodopa Controlled Release Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1072 | Carbidopa and Levodopa Tablets, USP | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1073 | CARBIDOPA LEVODOPA | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1074 | Carbidopa, levodopa, entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1075 | Carbidopa- Levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1076 | Carbidopa-4'-Monophosphate | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
1077 | Carbidopa-Levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1078 | Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1079 | Carbidopa/l-dopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1080 | Carbidopa/l-dopa/entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1081 | Carbidopa/levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1082 | Carbidopa/levodopa, as prescribed by treating physician | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1083 | Carbidopa/Levodopa, immediate release | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1084 | Carbidopa/Levodopa/Entacapone | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1085 | CARBODOPA LEVADOPA | - | - | - | - | 1件: 6 6 💬 |
1086 | Carbodopa/levadopa | - | - | - | - | 1件: 6 6 💬 |
1087 | CARBOLITHIUM*100CPS 150MG | - | - | - | - | 1件: 2 2 💬 |
1088 | Carbon-14 BIA 28-6156 | 2件: Activated charcoal Activated charcoal, BIA | - | - | - | 1件: 6 6 💬 |
1089 | Carbonate de lithium | 1件: Carbonate ion Carbonate ion | - | - | - | 1件: 2 2 💬 |
1090 | CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
1091 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
1092 | CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one | - | - | - | - | 1件: 58 58 💬 |
1093 | CAS No.: 7758-16-9 | - | - | - | - | 1件: 166 166 💬 |
1094 | CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid) | - | - | - | - | 1件: 254 254 💬 |
1095 | CAT-1004 | - | - | - | - | 1件: 113 113 💬 |
1096 | Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) | - | - | - | - | 1件: 85 85 💬 |
1097 | Cayston 75 mg Pulver und Lösungsmittel zur Herstellung einer Lösung für einen Vernebler | 1件: Aztreonam Aztreonam | 1件: Aztreonam
Aztreonam
💬 | - | - | 1件: 299 299 💬 |
1098 | CB-01-02 | - | - | - | - | 1件: 97 97 💬 |
1099 | CB-01-05-MMX | - | - | - | - | 1件: 97 97 💬 |
1100 | CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution, | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 158 158 💬 |
1101 | CC-100004 | - | - | - | - | 1件: 84 84 💬 |
1102 | CC-10004 | - | - | - | - | 5件: 46 46, 56, 97, 162, 271 💬 |
1103 | CC-220 0.3 mg Daily | - | - | - | - | 1件: 84 84 💬 |
1104 | CC-220 0.6mg Daily | - | - | - | - | 1件: 84 84 💬 |
1105 | CC-4047 | - | - | - | - | 2件: 28 28, 51 💬 |
1106 | CCD 1042 | - | - | - | - | 1件: 152 152 💬 |
1107 | CCD 1042, MD 9150000, Mepalon 1042, SPT316 | - | - | - | - | 2件: 152 152, 206 💬 |
1108 | CCD 1042, MD 9150000, Mepalon 1042, SPT3162 | - | - | - | - | 1件: 152 152 💬 |
1109 | CCP-020 | - | - | - | - | 1件: 36 36 💬 |
1110 | CCP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
1111 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 💬 |
1112 | CD-LD CR | - | - | - | - | 1件: 6 6 💬 |
1113 | CD-LD IR | - | - | - | - | 1件: 6 6 💬 |
1114 | CD3/CD19 depleted leukocytes | - | - | - | - | 1件: 284 284 💬 |
1115 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
1116 | CD45RA depleted leukocytes | - | - | - | - | 1件: 284 284 💬 |
1117 | CDP870 100mg | - | - | - | - | 1件: 46 46 💬 |
1118 | CDP870 400mg | - | - | - | - | 1件: 46 46 💬 |
1119 | CDX-1135 | - | - | - | - | 1件: 222 222 💬 |
1120 | Celecoxib 400 milligrams | 1件: Celecoxib Celecoxib | 1件: Celecoxib
Celecoxib
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
1121 | Cellavita HD Lower Dose | - | - | - | - | 1件: 8 8 💬 |
1122 | Cellule CD34+ autologhe trasdotte con IDUA LV codificante per il cDNA dell'alfa-L-iduronidasi | - | - | - | - | 1件: 19 19 💬 |
1123 | Cenerimod 0.5 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
1124 | Cenerimod 1 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
1125 | Cenerimod 4 mg | 1件: Cenerimod Cenerimod | 1件: Cenerimod
Cenerimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 49 49 💬 |
1126 | Cenicriviroc 150 mg | 1件: Cenicriviroc Cenicriviroc | 1件: Cenicriviroc
Cenicriviroc
💬 | 2件: CCR2 CCR2, CCR5 💬 | 11件: Chemokine signaling pathway Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Toxoplasmosis, Viral carcinogenesis, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 94 94 💬 |
1127 | CEP-1347 | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1128 | CEP-1347 10mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1129 | CEP-1347 50mg | 1件: CEP-1347 CEP-1347 | - | - | - | 1件: 6 6 💬 |
1130 | CER-001 | - | - | - | - | 1件: 79 79 💬 |
1131 | CERC-006 | - | - | - | - | 1件: 278 278 💬 |
1132 | CERE-120 | - | - | - | - | 1件: 6 6 💬 |
1133 | CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | - | - | - | - | 1件: 6 6 💬 |
1134 | CERE-120: AAV2-NTN | - | - | - | - | 1件: 6 6 💬 |
1135 | CERE-120: Adeno-Associated Virus Delivery of Neurturin | - | - | - | - | 1件: 6 6 💬 |
1136 | Cerezyme 400 Units Powder for concentrate for solution for infusion | 1件: Imiglucerase Imiglucerase | 1件: Imiglucerase
Imiglucerase
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1137 | Certican 0,5 | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1138 | Certican 0,5 mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1139 | Certican 0,75mg | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1140 | Certican 0,75mg Tabletten | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 228 228 💬 |
1141 | Certican 1 mg tablets | 1件: Everolimus Everolimus | 1件: Everolimus
Everolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
1142 | Certolizumab Pegol (CZP) 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1143 | Certolizumab pegol 400 mg | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1144 | CETIRIZINA SANDOZ - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE IN BLISTER PVC/ALU | 1件: Cetirizine Cetirizine | 1件: Cetirizine
Cetirizine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 300 300 💬 |
1145 | CF101 1 mg | - | - | - | - | 1件: 46 46 💬 |
1146 | CFZ533 active - Cohort 1 | - | - | - | - | 1件: 53 53 💬 |
1147 | CH-1504 | - | - | - | - | 1件: 46 46 💬 |
1148 | CH-4051 | - | - | - | - | 1件: 46 46 💬 |
1149 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
1150 | ChAdOx1 nCoV-19 | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
1151 | CHF6333 (Part 1 - SAD) | - | - | - | - | 1件: 299 299 💬 |
1152 | CHIMERIC FIBRIL-REACTIVE IGG1K MONOCLONAL ANTIBODY 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
1153 | Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 | - | - | - | - | 1件: 28 28 💬 |
1154 | Cholecalciferol 10,000 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
1155 | Cholecalciferol 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
1156 | Cholecalciferol and C. Xanthorrhiza | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
1157 | CHR-1103 / GBR500 | - | - | - | - | 1件: 13 13 💬 |
1158 | Chronocort 10mg | - | - | - | - | 1件: 81 81 💬 |
1159 | Chronocort® 10 mg | - | - | - | - | 1件: 81 81 💬 |
1160 | CHS-0214 | - | - | - | - | 1件: 46 46 💬 |
1161 | CI-984, 17AA70, PD 132301-2 | - | - | - | - | 1件: 81 81 💬 |
1162 | Cialis 10 mg film-coated tablets | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 113 💬 |
1163 | Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
1164 | Cilostazol 100 MG | 1件: Cilostazol Cilostazol | 1件: Cilostazol
Cilostazol
💬 | 3件: PDE3A PDE3A, PDE3B, TBXA2R 💬 | 14件: Apelin signaling pathway Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1165 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1166 | CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL | 1件: Certolizumab pegol Certolizumab pegol | 1件: Certolizumab pegol
Certolizumab pegol
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1167 | CIPROXIN - 500 MG COMPRESSE RIVESTITE 14 COMPRESSE | - | - | - | - | 1件: 299 299 💬 |
1168 | CIRCADIN 2 mg comprimidos de liberación prolongada | 1件: Melatonin Melatonin | 1件: Melatonin
Melatonin
💬 | 2件: MTNR1A MTNR1A, MTNR1B 💬 | 2件: Circadian entrainment Circadian entrainment, Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 💬 |
1169 | Cis-4-Hydroxy-L-Proline | 1件: Proline Proline | 1件: Proline
Proline
💬 | - | - | 1件: 94 94 💬 |
1170 | CITICOLIN*1G/4ML IM IV 5 F | - | - | - | - | 1件: 6 6 💬 |
1171 | Citicolina 1000 mg/die | 1件: Citicoline Citicoline | 1件: Citicoline
Citicoline
💬 | - | - | 1件: 6 6 💬 |
1172 | CJNJ-68150420-ZZZ-G001 (ACT- 064992D) | - | - | - | - | 1件: 86 86 💬 |
1173 | CJNJ-68150420-ZZZ-G001 (ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
1174 | CJNJ-68150420-ZZZ-G001(ACT-064992D) | - | - | - | - | 1件: 86 86 💬 |
1175 | CK-3773274 (10 - 30 mg) | - | - | - | - | 1件: 58 58 💬 |
1176 | CK-3773274 (5 - 15 mg) | - | - | - | - | 1件: 58 58 💬 |
1177 | CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg) | - | - | - | - | 1件: 58 58 💬 |
1178 | Clarithromycin (Not used as of 4/2020) | 1件: Clarithromycin Clarithromycin | 1件: Clarithromycin
Clarithromycin
💬 | - | - | 1件: 6 6 💬 |
1179 | Clemastine Milstein 1 mg, tabletten | 1件: Clemastine Clemastine | 1件: Clemastine
Clemastine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
1180 | Clobazam Low Dose | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
1181 | Clobazam Tablets 10mg | 1件: Clobazam Clobazam | 1件: Clobazam
Clobazam
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 144 144 💬 |
1182 | Clobetasol 0.05% ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 39 39 💬 |
1183 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
1184 | Clonidine HCl CF 0,150 mg, tabletten | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 78 78 💬 |
1185 | CM-101 | - | - | - | - | 1件: 94 94 💬 |
1186 | CME-LEM4 | - | - | - | - | 1件: 117 117 💬 |
1187 | CNP-104 | - | - | - | - | 1件: 93 93 💬 |
1188 | Cnp-MS-0601 | - | - | - | - | 1件: 13 13 💬 |
1189 | CNSA-001 | - | - | - | - | 1件: 240 240 💬 |
1190 | CNT-02 | - | - | - | - | 1件: 160 160 💬 |
1191 | CNTO 1275 | - | - | - | - | 2件: 13 13, 96 💬 |
1192 | CNTO 136 | - | - | - | - | 2件: 41 41, 46 💬 |
1193 | CNTO 136 100 mg | - | - | - | - | 1件: 46 46 💬 |
1194 | CNTO 136 25 mg | - | - | - | - | 1件: 46 46 💬 |
1195 | CNTO 136 50 mg | - | - | - | - | 1件: 46 46 💬 |
1196 | CNTO 136 IgG | - | - | - | - | 1件: 46 46 💬 |
1197 | CNTO 148 | - | - | - | - | 4件: 46 46, 84, 97, 271 💬 |
1198 | CNTO 148 (Golimumab) | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1199 | CNTO 1959 | - | - | - | - | 1件: 46 46 💬 |
1200 | CNTO 1959 + MTX (Group 4) | - | - | - | - | 1件: 46 46 💬 |
1201 | CNTO 1959 + MTX (Group 5) | - | - | - | - | 1件: 46 46 💬 |
1202 | CNTO 1959 IgG | - | - | - | - | 1件: 46 46 💬 |
1203 | CNTO 6785 100 mg | - | - | - | - | 1件: 46 46 💬 |
1204 | CNTO 6785 15 mg | - | - | - | - | 1件: 46 46 💬 |
1205 | CNTO 888 1 mg/kg | - | - | - | - | 1件: 85 85 💬 |
1206 | CNTO 888 15 mg/kg | - | - | - | - | 1件: 85 85 💬 |
1207 | CNTO-148 | - | - | - | - | 1件: 97 97 💬 |
1208 | CO-14 | - | - | - | - | 1件: 13 13 💬 |
1209 | Coagulation factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1210 | Coagulation factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1211 | Cod liver oil | 1件: Cod liver oil Cod liver oil | 1件: Cod liver oil
Cod liver oil
💬 | - | - | 1件: 46 46 💬 |
1212 | Coenzyme Q-10 | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1213 | Coenzyme Q-10 in Normal Control subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1214 | Coenzyme Q-10 in Pulmonary Hypertension subjects | 1件: Ubidecarenone Ubidecarenone | 1件: Ubidecarenone
Ubidecarenone
💬 | - | - | 1件: 86 86 💬 |
1215 | Coenzyme Q10 and Lisinopril | 2件: Lisinopril Lisinopril, Ubidecarenone | 3件: Lisinopril
Lisinopril
,
Ubidecarenone
,
Lisinopril
💬 | 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 113 113 💬 |
1216 | Cofactor supplementation (thiamine, riboflavin, L-carnitine) | 3件: Levocarnitine Levocarnitine, Riboflavin, Thiamine | 3件: Riboflavin
Riboflavin
,
Levocarnitine
,
Thiamine
💬 | - | - | 1件: 265 265 💬 |
1217 | Cohort 1 0.225g | - | - | - | - | 1件: 240 240 💬 |
1218 | Cohort 1: 1.0 x 10^8 PolyTregs | - | - | - | - | 1件: 35 35 💬 |
1219 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1220 | Cohort 1:Nilotinib Oral Capsules (150mg or 300mg) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1221 | Cohort 2 0.75g | - | - | - | - | 1件: 240 240 💬 |
1222 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1223 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
1224 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
1225 | COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
1226 | Colchicine 1 MG Oral Tablet | 1件: Colchicine Colchicine | 1件: Colchicine
Colchicine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 2 2 💬 |
1227 | COLIMICINA - 1000000 U/4 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 4 ML | - | - | - | - | 1件: 299 299 💬 |
1228 | Colistin Forest - Trockenstechampullen mit Lösungsmittel | 1件: Colistin Colistin | 1件: Colistin
Colistin
💬 | - | - | 1件: 299 299 💬 |
1229 | Collect of 10 ml of peripheric blood for DNA extraction | - | - | - | - | 1件: 46 46 💬 |
1230 | Combination Product: L-dopa 140 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1231 | Combination Product: L-dopa 35 mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1232 | Combination Product: L-dopa 70mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1233 | Combination Product: L-dopa 70mg/carbidopa 7mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1234 | Combination Product: Laser, exercise, and methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
1235 | Combination Product: lipid injectable emulsion with Fish oil | 1件: Fish oil Fish oil | - | - | - | 1件: 294 294 💬 |
1236 | Combivir (zidovudine [AZT] / lamivudine [3TC]) | 2件: Lamivudine Lamivudine, Zidovudine | 2件: Lamivudine
Lamivudine
,
Zidovudine
💬 | - | - | 1件: 265 265 💬 |
1237 | Comparator: levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1238 | Compound 1a | - | - | - | - | 2件: 246 246, 299 💬 |
1239 | Compound thrombosis capsule sig: 1.5g/tid | - | - | - | - | 1件: 90 90 💬 |
1240 | Compressa effervescente 0,5 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1241 | Compressa effervescente 1 mg di budesonide per uso orodispersibile | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
1242 | Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d | 1件: Conjugated estrogens Conjugated estrogens | 1件: Estrogens, conjugated
Estrogens, conjugated
💬 | - | - | 1件: 49 49 💬 |
1243 | Continuous intrajejunal infusion of levodopa-carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1244 | Continuous Subcutaneous Lisuride Infusion | 1件: Lisuride Lisuride | 1件: Lisuride
Lisuride
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1245 | Control Group 0.9% Isotonic Saline | - | - | - | - | 1件: 299 299 💬 |
1246 | Controlled-release levodopa / carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1247 | Conventional therapy users for the last 5 years | - | - | - | - | 1件: 271 271 💬 |
1248 | COP-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1249 | COP-1/Copolymer-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1250 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1251 | COPAXONE - 40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1252 | Copaxone 40 mg/ml | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1253 | Copaxone 40 mg/ml solution for injection, pre-filled syringe | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1254 | Copolymer 1 | - | - | - | - | 1件: 13 13 💬 |
1255 | Copolymer-1 | 1件: Glatiramer Glatiramer | - | - | - | 1件: 13 13 💬 |
1256 | COR-003 | - | - | - | - | 1件: 75 75 💬 |
1257 | Cortancyl ® 1 mg | 1件: Prednisone acetate Prednisone acetate | 1件: Prednisone acetate
Prednisone acetate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
1258 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
1259 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
1260 | COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 107 107 💬 |
1261 | Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin | 2件: Tetracosactide Tetracosactide, Vigabatrin | 2件: Cosyntropin
Cosyntropin
,
Vigabatrin
💬 | 2件: ABAT ABAT, MC2R 💬 | 12件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, Metabolic pathways, Neuroactive ligand-receptor interaction, Propanoate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, cAMP signaling pathway 💬 | 1件: 145 145 💬 |
1262 | Cosyntropin Injectable Suspension, 1 mg/mL | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 145 145 💬 |
1263 | COVID-19 mRNA Vaccine (nucleoside modified) | - | - | - | - | 3件: 13 13, 46, 51 💬 |
1264 | COVID-19 mRNA vaccine (nucleoside-modified) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
1265 | COVID-19 mRNA vaccine Moderna (CX-024414) | - | - | - | - | 4件: 13 13, 46, 51, 299 💬 |
1266 | COVID-19 vaccination | - | - | - | - | 1件: 13 13 💬 |
1267 | COVID-19 vaccine | - | - | - | - | 3件: 46 46, 49, 51 💬 |
1268 | COVID-19 vaccine (Ad26.COV2-S [recombinant]) | - | - | - | - | 1件: 299 299 💬 |
1269 | COVID-19 Vaccine (ChAdOx1-S [recombinant]) | - | - | - | - | 3件: 46 46, 51, 299 💬 |
1270 | COVID-19 Vaccine AstraZeneca | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 53 💬 |
1271 | COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 3件: 46 46, 51, 299 💬 |
1272 | COVID-19 Vaccine AstraZeneca suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant]) | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 53 53 💬 |
1273 | Covid-19 Vaccine Janssen | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
1274 | COVID-19 Vaccine Janssen suspension for injection | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 1件: 299 299 💬 |
1275 | COVID-19 Vaccine Janssen suspension for injection COVID-19 vaccine (Ad26.COV2-S [recombinant]) | 1件: Janssen COVID-19 Vaccine Janssen COVID-19 Vaccine | 1件: COVID-19 vaccine
COVID-19 vaccine
💬 | - | - | 2件: 53 53, 299 💬 |
1276 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 4件: 46 46, 51, 65, 299 💬 |
1277 | COVID-19 Vaccine Moderna dispersion for injection | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 299 299 💬 |
1278 | COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula | 1件: Losartan Losartan | 1件: Losartan
Losartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
1279 | CP-195,543 | - | - | - | - | 1件: 46 46 💬 |
1280 | CP-461 | - | - | - | - | 1件: 96 96 💬 |
1281 | CP-690, 550 - 10 | - | - | - | - | 1件: 46 46 💬 |
1282 | CP-690, 550-10 | - | - | - | - | 2件: 97 97, 107 💬 |
1283 | CP-690,55-10 | - | - | - | - | 1件: 46 46 💬 |
1284 | CP-690,550 10 mg | - | - | - | - | 1件: 97 97 💬 |
1285 | CP-690,550 – 10 | - | - | - | - | 1件: 46 46 💬 |
1286 | CP-690,550-10 | - | - | - | - | 5件: 46 46, 96, 97, 107, 271 💬 |
1287 | CP-690-550-10 | - | - | - | - | 1件: 107 107 💬 |
1288 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 💬 |
1289 | CPL500036 - low dose | - | - | - | - | 1件: 6 6 💬 |
1290 | CR 1 | - | - | - | - | 1件: 46 46 💬 |
1291 | CR002 Liquid API | 1件: CR002 CR002 | - | - | - | 1件: 299 299 💬 |
1292 | CR845 1.0 mg | - | - | - | - | 1件: 93 93 💬 |
1293 | CRC3357, ZK-355322, Leukoton | - | - | - | - | 1件: 299 299 💬 |
1294 | CRD-TMH-001 | - | - | - | - | 1件: 113 113 💬 |
1295 | Creatine-13C | 1件: Creatine Creatine | - | - | - | 1件: 113 113 💬 |
1296 | Crema de rapamicina al 1% y excipientes | - | - | - | - | 1件: 157 157 💬 |
1297 | Creon 10.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1298 | Creon 10000 | - | - | - | - | 2件: 298 298, 299 💬 |
1299 | CREON 10000 Capsules | - | - | - | - | 1件: 299 299 💬 |
1300 | Creon 25.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1301 | Creon 40.000, hårde enterokapsler | - | - | - | - | 1件: 299 299 💬 |
1302 | Creon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
1303 | Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist. | 1件: Corticotropin Corticotropin | 1件: Corticotropin
Corticotropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 81 81 💬 |
1304 | CRx-102 | - | - | - | - | 1件: 46 46 💬 |
1305 | CRx-102 (2.7/180) | - | - | - | - | 1件: 46 46 💬 |
1306 | CRx-102 (2.7/360) | - | - | - | - | 1件: 46 46 💬 |
1307 | CRX-139 | 1件: CRx-139 CRx-139 | - | - | - | 1件: 46 46 💬 |
1308 | CRx-150 | - | - | - | - | 1件: 46 46 💬 |
1309 | CRYOPRESERVED AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 💬 |
1310 | Cryopreserved EFS-ADA LV transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
1311 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
1312 | CS-0777 tablets | - | - | - | - | 1件: 13 13 💬 |
1313 | CST-103 | - | - | - | - | 1件: 6 6 💬 |
1314 | CST-107 | - | - | - | - | 1件: 6 6 💬 |
1315 | CST-139 | - | - | - | - | 1件: 6 6 💬 |
1316 | CTI-1601 | 1件: CTI-1601 CTI-1601 | - | - | - | 1件: 18 18 💬 |
1317 | CTNS-RD-04 or CTNS-RD-04-LB (where the suffix -LB stands for LentiBOOST) | - | - | - | - | 1件: 19 19 💬 |
1318 | CTX-4430 | - | - | - | - | 1件: 299 299 💬 |
1319 | Cudetaxestat (BLD-0409) | - | - | - | - | 1件: 85 85 💬 |
1320 | Cuprior 150 mg | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1321 | Cuprior 150 mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1322 | Cuprior 150mg film-coated tablets | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
1323 | Cura-100 | - | - | - | - | 1件: 46 46 💬 |
1324 | Curcuma Longa | 1件: Turmeric Turmeric | - | - | - | 2件: 96 96, 299 💬 |
1325 | Curcuma Longa Extract | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
1326 | Curcuma Longa Extract cpl formaat 00 23,2 x 8,5 mm 723 mg | 1件: Turmeric Turmeric | - | - | - | 1件: 299 299 💬 |
1327 | CURCUMA LONGA RHIZOMA | 1件: Turmeric Turmeric | - | - | - | 1件: 96 96 💬 |
1328 | Curcumin (Longvida™) | 1件: Curcumin Curcumin | - | - | - | 1件: 46 46 💬 |
1329 | Current lipid-lowering treatment | - | - | - | - | 1件: 79 79 💬 |
1330 | CVT-301 (Dose Level 1) | - | - | - | - | 1件: 6 6 💬 |
1331 | CVT-301 (Dose Level 2) | - | - | - | - | 1件: 6 6 💬 |
1332 | CVT-301 Low Dose | - | - | - | - | 1件: 6 6 💬 |
1333 | CVT-301, LIP | - | - | - | - | 1件: 6 6 💬 |
1334 | CVXL-0107 | - | - | - | - | 1件: 6 6 💬 |
1335 | CX-016492 | - | - | - | - | 1件: 245 245 💬 |
1336 | CX-017950 | - | - | - | - | 1件: 245 245 💬 |
1337 | CX-4945 oral formulation | - | - | - | - | 1件: 331 331 💬 |
1338 | CXA-10 | 1件: CXA-10 CXA-10 | - | - | - | 2件: 86 86, 222 💬 |
1339 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate | - | - | - | - | 1件: 75 75 💬 |
1340 | Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate | - | - | - | - | 1件: 75 75 💬 |
1341 | Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate | - | - | - | - | 1件: 75 75 💬 |
1342 | Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) | - | - | - | - | 1件: 75 75 💬 |
1343 | CYCLO[L-ALANYL-L-SERYL-L-ISOLEUCYL-L-PROLYL-L-PROLYL-L-GLUTAMINYL-L-LYSYL-L-TYROSYL-D-PROLYL-L-PROLYL-(2S)-2-AMINODECANOYL-L-ALPHA-GLUTAMYL-L-THREONYL] | - | - | - | - | 1件: 299 299 💬 |
1344 | Cyclophosphamide (CY) (Plan 1) | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 60 60, 285 💬 |
1345 | Cyclophosphamide 100mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
1346 | Cyclophosphamide 150mg | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 60 60 💬 |
1347 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
1348 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1349 | Cyclophosphamide Dose Level 2 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1350 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1351 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
1352 | Cyclophosphamide Injection 1g | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 50 50, 51, 52 💬 |
1353 | Cyclosporin, low dose steroid | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
1354 | Cyclosporine 0.09% Ophthalmic Solution | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 53 53 💬 |
1355 | Cyclosporine 5 mg/kg bid days 0-14 | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 38 38, 39 💬 |
1356 | CYSTADROPS 0.55% eye drops, solution | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
1357 | Cystagon 150mg | 1件: Cysteamine Cysteamine | 1件: Cysteamine
Cysteamine
💬 | - | - | 1件: 19 19 💬 |
1358 | Cápsulas de Laquinimod 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
1359 | Células madre mesenquimales | - | - | - | - | 1件: 13 13 💬 |
1360 | Células madre mesenquimales de tejido adiposo autólogo | - | - | - | - | 1件: 2 2 💬 |
1361 | Células madre mesenquimales haploidénticas derivadas de médula ósea | - | - | - | - | 1件: 36 36 💬 |
1362 | Células Mesenquimales de tejido adiposo | - | - | - | - | 1件: 2 2 💬 |
1363 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas | - | - | - | - | 1件: 274 274 💬 |
1364 | Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada PEI nº 12-088) | - | - | - | - | 1件: 274 274 💬 |
1365 | Células mesenquimales troncales adultas autólogas de medula ósea expandidas | - | - | - | - | 1件: 117 117 💬 |
1366 | Células mesenquimales troncales adultas autólogas de médula ósea expandidas | - | - | - | - | 1件: 117 117 💬 |
1367 | Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea | - | - | - | - | 1件: 2 2 💬 |
1368 | D-a-tocopheryl PEG 1000 succinate | - | - | - | - | 1件: 299 299 💬 |
1369 | D-glucitol, 1-deoxy-1-(methylamino)-, 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
1370 | D-glucitol, 1-deoxy-1-(methylamino)-,2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate (1:1) | 1件: Sorbitol Sorbitol | 1件: Sorbitol solution
Sorbitol solution
💬 | - | - | 1件: 28 28 💬 |
1371 | D-penicillamine 150mg | 1件: Penicillamine Penicillamine | 1件: Penicillamine
Penicillamine
💬 | - | - | 1件: 171 171 💬 |
1372 | D.3.6.2.1 - valore: 45 / 0.45 mg/ml | - | - | - | - | 1件: 97 97 💬 |
1373 | D.3.6.2.1 - valore: 5 o 10 mg/kg | - | - | - | - | 1件: 97 97 💬 |
1374 | D9421-C, 15mg | - | - | - | - | 1件: 96 96 💬 |
1375 | DA-9805 45mg | - | - | - | - | 1件: 6 6 💬 |
1376 | Dacepton 5 mg/ml infuusioneste, liuos | - | - | - | - | 1件: 6 6 💬 |
1377 | Daily ingestion of Lactobacillus plantarum PS128 | 1件: Lactobacillus plantarum Lactobacillus plantarum | - | - | - | 1件: 6 6 💬 |
1378 | Dalfampridine ER, 10 Mg Oral Tablet, Extended Release | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1379 | Dalfampridine-ER 10mg | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1380 | DAND (14-Deoxyandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1381 | Dapagliflozin 10 MG [Farxiga] | 1件: Dapagliflozin Dapagliflozin | 1件: Dapagliflozin
Dapagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 2件: 86 86, 88 💬 |
1382 | Dapagliflozin 10mg Tab | 1件: Dapagliflozin Dapagliflozin | 1件: Dapagliflozin
Dapagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 1件: 19 19 💬 |
1383 | Darifenacin (BAY79-4998) | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
1384 | DAS-001 | - | - | - | - | 1件: 11 11 💬 |
1385 | Davunetide (AL-108, NAP) | 1件: Davunetide Davunetide | 1件: Davunetide
Davunetide
💬 | - | - | 3件: 5 5, 7, 127 💬 |
1386 | Dazucorilant 150 mg | - | - | - | - | 1件: 2 2 💬 |
1387 | DB adalimumab 40 mg eow | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1388 | DB adalimumab 40 mg ew | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1389 | DCI 1020 | - | - | - | - | 1件: 299 299 💬 |
1390 | DCR-1171X | - | - | - | - | 1件: 234 234 💬 |
1391 | DCR-L1360 | - | - | - | - | 1件: 234 234 💬 |
1392 | DDAND (14-deoxy-11,12-didehydroandrographolide) | - | - | - | - | 1件: 97 97 💬 |
1393 | Decortin H 1 mg | - | - | - | - | 1件: 97 97 💬 |
1394 | Decortin H 10mg | - | - | - | - | 1件: 97 97 💬 |
1395 | Defanyl 50 and 100 mg | - | - | - | - | 1件: 46 46 💬 |
1396 | DEFLAN*10CPR 6MG | - | - | - | - | 1件: 113 113 💬 |
1397 | Dehydroepiandrosterone 100 and 400 mg | 1件: Prasterone Prasterone | 1件: Prasterone
Prasterone
💬 | 3件: AR AR, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 113 113 💬 |
1398 | Dekristol 20.000 ie | - | - | - | - | 1件: 96 96 💬 |
1399 | Dekristol® 400-Tabletten | - | - | - | - | 1件: 13 13 💬 |
1400 | Dekristol®-Tablette 1 (400 IE) | - | - | - | - | 1件: 13 13 💬 |
1401 | Deltacortene 10 cpr 25mg | - | - | - | - | 1件: 97 97 💬 |
1402 | DELTACORTENE FORTE*10CPR 25MG | - | - | - | - | 2件: 46 46, 97 💬 |
1403 | DELTACORTENE*10CPR 25MG | - | - | - | - | 1件: 84 84 💬 |
1404 | Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
1405 | Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
1406 | Depo-Medrol 40Mg/Ml Suspension for Injection | - | - | - | - | 1件: 70 70 💬 |
1407 | Depot leuprolide acetate 3.75 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 51 51 💬 |
1408 | Descartes-08 | - | - | - | - | 1件: 11 11 💬 |
1409 | Desmopressine nasal spray 10 mg/ml, flacon 60 doses | 1件: Desmopressin Desmopressin | 1件: Desmopressin
Desmopressin
💬 | 2件: AVPR2 AVPR2, F8 💬 | 4件: Complement and coagulation cascades Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 225 225 💬 |
1410 | Desmotabs® 0,2 mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
1411 | Desmotabs® 0,2mg Tabletten | - | - | - | - | 1件: 6 6 💬 |
1412 | Dexamethasone (1 cycle) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
1413 | Dexamethasone (4 cycles) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 63 63 💬 |
1414 | Dexamethasone (50mg 1dd6, 3 consecutive days/month) | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 35 35 💬 |
1415 | Dexamethasone 0,1 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1416 | Dexamethasone 0,5mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1417 | Dexamethasone 0.5mg Tablet | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1418 | Dexamethasone 0.5mg/5ml solution | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
1419 | Dexamethasone 0.5mg/5ml solution in Mucolox™ | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 35 35, 162 💬 |
1420 | Dexamethasone 1,5 mg Tablets | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1421 | Dexamethasone 4 mg JENAPHARM | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
1422 | Dexamethasone Oral, 10 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
1423 | Dexamethasone sodium phosphate 250 mg/ 10 ml | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
1424 | Dexamethasone sodium phosphate 250 mg/10 ml solution | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 299 299 💬 |
1425 | Dexamethasone, 40 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 28 28 💬 |
1426 | Dexmedetomidine 1 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬 |
1427 | Dexmedetomidine Hcl 100 Mcg/mL Inj | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬 |
1428 | Dexpramipexole (dose 1) | 1件: Dexpramipexole Dexpramipexole | 1件: Dexpramipexole
Dexpramipexole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
1429 | DEXTRAN 1 FOR INJECTION | 1件: Dextran Dextran | 1件: Dextran 1
Dextran 1
💬 | - | - | 1件: 97 97 💬 |
1430 | Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS) | 2件: Dextran Dextran, Sulfate ion | 1件: Dextran 1
Dextran 1
💬 | - | - | 1件: 2 2 💬 |
1431 | Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
1432 | Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg | 3件: Dextromethorphan Dextromethorphan, Quinidine, Sulfate ion | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 2件: 2 2, 13 💬 |
1433 | Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) | 2件: Dextromethorphan Dextromethorphan, Quinidine | 2件: Dextromethorphan
Dextromethorphan
,
Quinidine
💬 | 11件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
1434 | DI-17E6 | - | - | - | - | 1件: 51 51 💬 |
1435 | Diacerein 1% Ointment | 1件: Diacerein Diacerein | 1件: Diacerein
Diacerein
💬 | - | - | 1件: 36 36 💬 |
1436 | DIBASE*IM OS 2F 1ML 300000UI/M | - | - | - | - | 1件: 46 46 💬 |
1437 | Diet 1 | - | - | - | - | 1件: 96 96 💬 |
1438 | Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 107 107 💬 |
1439 | Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphtalen-2-ylmethyl]-ammonium chloride mon | 2件: Ammonium chloride Ammonium chloride, Chloride ion | 1件: Ammonium chloride
Ammonium chloride
💬 | - | - | 1件: 96 96 💬 |
1440 | Digoxin 0.25 mg | 1件: Digoxin Digoxin | 1件: Digoxin
Digoxin
💬 | 4件: ATP1A1 ATP1A1, ATP1A2, ATP1A3, ATP1A4 💬 | 18件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Bile secretion, Carbohydrate digestion and absorption, Cardiac muscle contraction, Endocrine and other factor-regulated calcium reabsorption, Gastric acid secretion, Insulin secretion, Mineral absorption, Pancreatic secretion, Protein digestion and absorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Thyroid hormone signaling pathway, Thyroid hormone synthesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
1441 | Dimebon (latrepirdine) | 1件: Latrepirdine Latrepirdine | 1件: Latrepirdine
Latrepirdine
💬 | 6件: ACHE ACHE, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 22件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Glycerophospholipid metabolism, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
1442 | Diovan 160 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1443 | Diovan 40 mg | 1件: Valsartan Valsartan | 1件: Valsartan
Valsartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 💬 |
1444 | DISC-1459 | - | - | - | - | 1件: 254 254 💬 |
1445 | Disodium Pamidronate 15mg (15mg strength) | 1件: Pamidronic acid Pamidronic acid | 1件: Pamidronic acid
Pamidronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
1446 | DIURF-006 | - | - | - | - | 1件: 81 81 💬 |
1447 | DM-1992 | - | - | - | - | 1件: 6 6 💬 |
1448 | DNL593 Sterile Lyophilisate | - | - | - | - | 1件: 127 127 💬 |
1449 | DNS-7801 (low-dose) | - | - | - | - | 1件: 6 6 💬 |
1450 | Docosahexaenoic acid administration: 50 mg/kg/day during 12 months | 1件: Doconexent Doconexent | - | - | - | 1件: 299 299 💬 |
1451 | Dolutegravir / Lamivudine Oral Tablet | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
1452 | Dolutegravir, Abacavir and Lamivudine | 3件: Abacavir Abacavir, Dolutegravir, Lamivudine | 3件: Lamivudine
Lamivudine
,
Abacavir
,
Dolutegravir
💬 | - | - | 1件: 2 2 💬 |
1453 | Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO] | 2件: Dolutegravir Dolutegravir, Lamivudine | 2件: Lamivudine
Lamivudine
,
Dolutegravir
💬 | - | - | 1件: 265 265 💬 |
1454 | Donor Lymphocyte Infusion (DLI) | - | - | - | - | 1件: 60 60 💬 |
1455 | Donor lymphocytes | - | - | - | - | 1件: 28 28 💬 |
1456 | Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] | 4件: Doravirine Doravirine, Lamivudine, Tenofovir, Tenofovir disoproxil | 3件: Lamivudine
Lamivudine
,
Tenofovir
,
Doravirine
💬 | - | - | 1件: 265 265 💬 |
1457 | Dose level 1 | - | - | - | - | 1件: 46 46 💬 |
1458 | Dose level 2 | - | - | - | - | 1件: 46 46 💬 |
1459 | Dose level 3 | - | - | - | - | 1件: 46 46 💬 |
1460 | Dose level 4 | - | - | - | - | 1件: 46 46 💬 |
1461 | Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
1462 | Dose-Establishing Study 1 Niacin 250mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
1463 | Dose-Establishing Study 1 Niacin 500mg | 1件: Niacin Niacin | 1件: Niacin
Niacin
💬 | - | - | 1件: 78 78 💬 |
1464 | Dotarem 0,5mmol/ml, | 1件: Gadoteric acid Gadoteric acid | 1件: Gadoteric acid
Gadoteric acid
💬 | - | - | 1件: 13 13 💬 |
1465 | Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase | 4件: Asparaginase Escherichia coli Asparaginase Escherichia coli, Cyclophosphamide, Doxorubicin, Methotrexate | 4件: Methotrexate
Methotrexate
,
Cyclophosphamide
,
Doxorubicin
,
Cyclophosphamide
💬 | 4件: DHFR DHFR, DHFR2, TOP2A, TOP2B 💬 | 6件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate, Platinum drug resistance 💬 | 1件: 65 65 💬 |
1466 | Doxycycline 100 mg Capsules | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 89 89 💬 |
1467 | Doxycycline 100-200mg capsules daily for 6 months | 1件: Doxycycline Doxycycline | 2件: Doxycycline
Doxycycline
,
Doxycycline
💬 | - | - | 1件: 167 167 💬 |
1468 | DoxyHEXAL® tabs 100 mg Tabletten | - | - | - | - | 1件: 28 28 💬 |
1469 | Dr. Reddy’s Rituximab (DRL_RI) 100mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
1470 | Droxidopa 100 MG [Northera] | 1件: Droxidopa Droxidopa | 1件: Droxidopa
Droxidopa
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
1471 | Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom | - | - | - | - | 2件: 46 46, 49 💬 |
1472 | Drug-Carbamazepine (Tegretol XR) | 1件: Carbamazepine Carbamazepine | 1件: Carbamazepine
Carbamazepine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 231 231 💬 |
1473 | DS-1211b | - | - | - | - | 1件: 166 166 💬 |
1474 | Dulaglutide 0.75Mg/0.5Ml Inj Pen | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1475 | Dummy Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
1476 | DUOC-01 | - | - | - | - | 3件: 13 13, 19, 20 💬 |
1477 | Duodopa LD/CD 20/5 mg/mL | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1478 | Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1479 | Dupilumab (open-label) | 1件: Dupilumab Dupilumab | 1件: Dupilumab
Dupilumab
💬 | 1件: IL4R IL4R 💬 | 8件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 98 98 💬 |
1480 | DW1809-1 | - | - | - | - | 1件: 46 46 💬 |
1481 | DYNE-101 | - | - | - | - | 1件: 113 113 💬 |
1482 | E. coli Nissle 1917 (Mutaflor®) | - | - | - | - | 1件: 97 97 💬 |
1483 | E5501 40 mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
1484 | E5501 40 mg 2 x 20-mg tablets, orally, with food | - | - | - | - | 1件: 63 63 💬 |
1485 | E5501 40mg 2 x 20-mg tablets, orally, fasted | - | - | - | - | 1件: 63 63 💬 |
1486 | E6011 10 mg/kg | - | - | - | - | 1件: 96 96 💬 |
1487 | E6011 15 mg/kg | - | - | - | - | 1件: 96 96 💬 |
1488 | EB-101 | - | - | - | - | 1件: 36 36 💬 |
1489 | EB-101 Surgical application of RDEB wounds | - | - | - | - | 1件: 36 36 💬 |
1490 | Ebetrex 15 mg = 0,75 ml, oplossing voor injectie in voorgevulde injectiespuit 20 mg/ml | - | - | - | - | 1件: 96 96 💬 |
1491 | EC 3.1.3.1 | - | - | - | - | 1件: 46 46 💬 |
1492 | EDG-5506 Dose 1 | - | - | - | - | 1件: 113 113 💬 |
1493 | EDG-5506 Dose 4 | - | - | - | - | 1件: 113 113 💬 |
1494 | EDP-305 Dose 1 | - | - | - | - | 1件: 93 93 💬 |
1495 | EDS-EP dose range of ~14-22 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
1496 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
1497 | EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
1498 | EF1aS-ADA lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
1499 | Efexor XL 75 mg | - | - | - | - | 1件: 46 46 💬 |
1500 | Efexor XL 75 mg (venlafaxine) | 1件: Venlafaxine Venlafaxine | 1件: Venlafaxine
Venlafaxine
💬 | 2件: SLC6A2 SLC6A2, SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
1501 | Efficacy of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
1502 | Efficacy of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
1503 | Efmody 10 mg modified release hard capsules | 2件: Hydrocortisone Hydrocortisone, Manganese citrate | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1504 | EGB 761 (r) 120 mg | - | - | - | - | 1件: 18 18 💬 |
1505 | EGb 761 120 mg | - | - | - | - | 1件: 18 18 💬 |
1506 | EHP-101 25 mg BID | - | - | - | - | 1件: 13 13 💬 |
1507 | EHP-101 25 mg OD | - | - | - | - | 1件: 13 13 💬 |
1508 | EHP-101 50 mg BID | - | - | - | - | 1件: 13 13 💬 |
1509 | EHP-101 50 mg OD | - | - | - | - | 1件: 13 13 💬 |
1510 | EK-12 | - | - | - | - | 1件: 13 13 💬 |
1511 | Elafibranor 120 mg | 1件: Elafibranor Elafibranor | 1件: Elafibranor
Elafibranor
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 2件: 93 93, 94 💬 |
1512 | Elamipretide (low dose) | 1件: Elamipretide Elamipretide | 1件: Elamipretide
Elamipretide
💬 | - | - | 1件: 21 21 💬 |
1513 | Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening | 3件: Elexacaftor Elexacaftor, Ivacaftor, Tezacaftor | 3件: Ivacaftor
Ivacaftor
,
Tezacaftor
,
Elexacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
1514 | Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM] | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
1515 | Eltrombopag 12.5 mg | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 60 60 💬 |
1516 | Eltrombopag olamine (SB-497115-GR) | 1件: Eltrombopag Eltrombopag | - | - | - | 1件: 63 63 💬 |
1517 | ELX (VX-445)/TEZ (VX-661)/IVA (VX-770) | - | - | - | - | 1件: 299 299 💬 |
1518 | ELX-02 | 1件: ELX-02 ELX-02 | - | - | - | 3件: 19 19, 218, 299 💬 |
1519 | EMD 128130 | - | - | - | - | 2件: 6 6, 156 💬 |
1520 | EMEA/H/C/000109 | - | - | - | - | 1件: 203 203 💬 |
1521 | EMEA/H/C/000125 | - | - | - | - | 1件: 299 299 💬 |
1522 | EMEA/H/C/000240 | - | - | - | - | 2件: 96 96, 97 💬 |
1523 | EMEA/H/C/000481 | - | - | - | - | 1件: 97 97 💬 |
1524 | EMEA/H/C/000638 | - | - | - | - | 1件: 113 113 💬 |
1525 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 💬 |
1526 | EMEA/H/C/000712 | - | - | - | - | 1件: 227 227 💬 |
1527 | EMEA/H/C/002576 | - | - | - | - | 1件: 96 96 💬 |
1528 | EMEA/H/C/002778 | - | - | - | - | 1件: 96 96 💬 |
1529 | EMEA/H/C/004214 | - | - | - | - | 1件: 46 46 💬 |
1530 | EMIXUSTAT HYDROCHLORIDE (ACU-4429) | 1件: Emixustat Emixustat | 1件: Emixustat
Emixustat
💬 | - | - | 1件: 301 301 💬 |
1531 | Empagliflozin 10 MG | 1件: Empagliflozin Empagliflozin | 1件: Empagliflozin
Empagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 2件: 58 58, 97 💬 |
1532 | EMSELEX 15 mg Retardtabletten | 1件: Darifenacin Darifenacin | 1件: Darifenacin
Darifenacin
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 💬 |
1533 | EnaHexal®, 10mg | - | - | - | - | 1件: 113 113 💬 |
1534 | ENB-0040 | - | - | - | - | 1件: 172 172 💬 |
1535 | ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1536 | ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1537 | Enbrel liquid | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1538 | ENBREL*BB SC 4FL 25MG 1ML+4SIR | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 💬 |
1539 | ENBREL*SC 4FL 25MG+4SIR 1ML | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 60, 285 💬 |
1540 | ENBREL*SC 4FL 50MG+4SIR+4AGHI+ | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1541 | ENBREL*SC 4SIR 25MG 0,5ML+8TAM | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1542 | ENBREL*SC 4SIR 50MG 1ML+8TAMP | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1543 | End-of-life nursing education consortium-pediatric palliative care as web based-training plus usual care | - | - | - | - | 2件: 113 113, 299 💬 |
1544 | ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA | - | - | - | - | 1件: 51 51 💬 |
1545 | ENDOPROST 0,05MG/0,5ML 1F | - | - | - | - | 1件: 51 51 💬 |
1546 | ENDOPROST 50*INFUS 1F 0,050MG/ | - | - | - | - | 1件: 51 51 💬 |
1547 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 💬 |
1548 | ENOS transfected EPCs will be delivered via a PA line | - | - | - | - | 1件: 86 86 💬 |
1549 | Enpatoran low dose | - | - | - | - | 1件: 49 49 💬 |
1550 | ENT-01 | - | - | - | - | 1件: 6 6 💬 |
1551 | Entacapone 400mg oral dose | 1件: Entacapone Entacapone | 1件: Entacapone
Entacapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 2件: 6 6, 17 💬 |
1552 | EnteraBio's Oral Parathyroid Hormone (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
1553 | ENTYVIO - 300 MG - POLVERE PE RCONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
1554 | ENTYVIO - 300 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) (20ML) - 1 FLACONCINO | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
1555 | Eosinophilic Esophagitis (EoE) food introduction-1st | - | - | - | - | 1件: 98 98 💬 |
1556 | EP-104IAR | - | - | - | - | 1件: 98 98 💬 |
1557 | EPARMEFOLIN 30 CPR 0,1/0,5MG | - | - | - | - | 1件: 13 13 💬 |
1558 | EPAX 6000 EE 1000mg (0.6 gr DHA+EPA) | - | - | - | - | 1件: 46 46 💬 |
1559 | EPI-743 400mg | - | - | - | - | 1件: 6 6 💬 |
1560 | Epidiolex 100 mg/mL Oral Solution | 1件: Cannabidiol Cannabidiol | 1件: Cannabidiol
Cannabidiol
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 2件: 140 140, 144 💬 |
1561 | Epratuzumab 100 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1562 | Epratuzumab 1200 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1563 | Epratuzumab 400 mg | 1件: Epratuzumab Epratuzumab | 1件: Epratuzumab
Epratuzumab
💬 | 1件: CD22 CD22 💬 | 3件: B cell receptor signaling pathway B cell receptor signaling pathway, Cell adhesion molecules, Hematopoietic cell lineage 💬 | 1件: 49 49 💬 |
1564 | EPREX IV SC 1FL 1ML 40000 UI | - | - | - | - | 1件: 2 2 💬 |
1565 | EPREX*1FL 40000UI/ML 1ML | - | - | - | - | 1件: 18 18 💬 |
1566 | EPREX*1SIR 10000UI 1ML | - | - | - | - | 1件: 18 18 💬 |
1567 | EPREX*1SIR 40000UI/ML 1ML | - | - | - | - | 2件: 2 2, 18 💬 |
1568 | EPX-100 | - | - | - | - | 1件: 140 140 💬 |
1569 | EPX-100 (Clemizole HCl) | 1件: Clemizole Clemizole | - | - | - | 1件: 140 140 💬 |
1570 | EPX-100 (Clemizole Hydrochloride) | 1件: Clemizole Clemizole | - | - | - | 1件: 140 140 💬 |
1571 | ER CD-LD | - | - | - | - | 1件: 6 6 💬 |
1572 | ER tablet 100 mg AZD3241 | - | - | - | - | 1件: 6 6 💬 |
1573 | ERB-041 | - | - | - | - | 3件: 46 46, 96, 226 💬 |
1574 | Ergocalciferol 1.25 mg tablet | 1件: Ergocalciferol Ergocalciferol | 1件: Ergocalciferol
Ergocalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 46 46 💬 |
1575 | ERMM-1 | - | - | - | - | 1件: 46 46 💬 |
1576 | Escitalopram 10mg | 1件: Escitalopram Escitalopram | 1件: Escitalopram
Escitalopram
💬 | 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
1577 | ESO-101 | - | - | - | - | 1件: 98 98 💬 |
1578 | Essential amino acid intake + Leucine vs total AA supplement | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 299 299 💬 |
1579 | Estimation of P.Gingivalis levels | - | - | - | - | 1件: 46 46 💬 |
1580 | Etanercept (50mg per week, for 4 weeks) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1581 | Etanercept 50 mg sc day 0 and day 3 | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 38 38, 39 💬 |
1582 | Etanercept Liquid | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1583 | Ethylmethylcarbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester (**See other 2 names below) | - | - | - | - | 1件: 6 6 💬 |
1584 | Etrasimod L-arginine | 3件: Arginine Arginine, Etrasimod, L-arginine | 2件: Arginine
Arginine
,
Etrasimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 96 96, 97, 98 💬 |
1585 | EU Orphan Designation Number EU/3/02/120 | - | - | - | - | 1件: 299 299 💬 |
1586 | EU/1/03/256/001 | - | - | - | - | 1件: 107 107 💬 |
1587 | EU/1/03/268/002 | - | - | - | - | 1件: 96 96 💬 |
1588 | EU/1/06/362/003: 5µg (1 pen) | - | - | - | - | 1件: 193 193 💬 |
1589 | EU/1/07/389/001 | - | - | - | - | 1件: 107 107 💬 |
1590 | EU/1/08/454/001-002, EU/1/08/454/005-007 | - | - | - | - | 1件: 13 13 💬 |
1591 | EU/1/14/980/002 | - | - | - | - | 1件: 269 269 💬 |
1592 | EU/1/14/980/003 | - | - | - | - | 1件: 269 269 💬 |
1593 | EU/1/95/003/005-010 | - | - | - | - | 1件: 13 13 💬 |
1594 | EU/1/97/033/002 | - | - | - | - | 1件: 13 13 💬 |
1595 | EU/1/98/063/001-003 | - | - | - | - | 1件: 13 13 💬 |
1596 | EU/1/98/063/004-006 | - | - | - | - | 1件: 13 13 💬 |
1597 | EU/1/99/116/003 | - | - | - | - | 1件: 96 96 💬 |
1598 | EU/1/99/126/001 | - | - | - | - | 1件: 107 107 💬 |
1599 | EU/1/99/126/017 | - | - | - | - | 1件: 46 46 💬 |
1600 | EU/1/99/126/020 | - | - | - | - | 1件: 46 46 💬 |
1601 | EU/3/13/1208 orphan | - | - | - | - | 1件: 301 301 💬 |
1602 | EU1/97/031-032 | - | - | - | - | 1件: 18 18 💬 |
1603 | EU1/97/031/031-032 | - | - | - | - | 1件: 18 18 💬 |
1604 | EUR-1008 | - | - | - | - | 1件: 299 299 💬 |
1605 | EUR-1008 (APT-1008) | - | - | - | - | 1件: 299 299 💬 |
1606 | EUR-1008 (APT-1008) High Dose | - | - | - | - | 1件: 298 298 💬 |
1607 | EUR-1008 (APT-1008) Low Dose | - | - | - | - | 1件: 298 298 💬 |
1608 | EUR-1008 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
1609 | EUR-1066-A | - | - | - | - | 1件: 298 298 💬 |
1610 | EUR-1066-B | - | - | - | - | 1件: 298 298 💬 |
1611 | EUR-1100 | - | - | - | - | 1件: 98 98 💬 |
1612 | Evenity 105mg | 1件: Romosozumab Romosozumab | 1件: Romosozumab
Romosozumab
💬 | 1件: SOST SOST 💬 | 2件: Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Wnt signaling pathway 💬 | 1件: 274 274 💬 |
1613 | Evobrutinib 10mg | 1件: Evobrutinib Evobrutinib | 1件: Evobrutinib
Evobrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 13 13 💬 |
1614 | Evolocumab (AMG 145) | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
1615 | EVP-0334 | - | - | - | - | 1件: 127 127 💬 |
1616 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 💬 |
1617 | Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA. | - | - | - | - | 1件: 36 36 💬 |
1618 | EXCL-100, 600 MG Oral Tablet | - | - | - | - | 1件: 85 85 💬 |
1619 | Exelon 1,5 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1620 | Exelon 3,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1621 | Exelon 4.6 mg/24 h transdermal patch | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
1622 | Exelon 6,0 mg Hartkapseln | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 5 5 💬 |
1623 | Exenatide 10 micrograms | 1件: Exenatide Exenatide | 1件: Exenatide
Exenatide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1624 | EXN-32 (CARBIDOPA E LEVODOPA) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1625 | EXN-44 | - | - | - | - | 1件: 6 6 💬 |
1626 | EXN-44(LEVODOPA) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1627 | Expanded human first trimester fetal liver-derived mesenchymal stem cells | - | - | - | - | 1件: 274 274 💬 |
1628 | Extavia (interferon beta-1b), Novartis Pharma AG | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1629 | EXTAVIA*SC 15FL 250MCG/ML+15SI | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1630 | Ezetimibe + other lipid-lowering medication(s) | 1件: Ezetimibe Ezetimibe | 1件: Ezetimibe
Ezetimibe
💬 | 1件: NPC1L1 NPC1L1 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 1件: 260 260 💬 |
1631 | F 18 T807 | - | - | - | - | 2件: 2 2, 127 💬 |
1632 | F-18 | - | - | - | - | 2件: 5 5, 127 💬 |
1633 | F-18 3F4AP | - | - | - | - | 1件: 13 13 💬 |
1634 | F-18 AV 1451 | - | - | - | - | 2件: 5 5, 127 💬 |
1635 | F-18 FDG | - | - | - | - | 1件: 127 127 💬 |
1636 | F-18 FEDAA1106 (BAY85-8101) | - | - | - | - | 1件: 13 13 💬 |
1637 | F-18 FPCIT | - | - | - | - | 1件: 6 6 💬 |
1638 | Fabrazyme (agalsidase beta) 1 mg/kg | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1639 | FABRAZYME - 35 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO | 1件: Agalsidase beta Agalsidase beta | 1件: Agalsidase beta
Agalsidase beta
💬 | 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
1640 | FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1641 | Factor XIIa antagonist monoclonal antibody | - | - | - | - | 1件: 85 85 💬 |
1642 | Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 3件: 51 51, 97, 288 💬 |
1643 | Factor XIII Concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1644 | Factor XIII Concentrate (Human), Pasteurized | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
1645 | FamC-1 | - | - | - | - | 1件: 2 2 💬 |
1646 | FAMPYRA - 10 MG - COMPRESSA A RILASCIO PROLUNGATO - USO ORALE - FLACONE (HDPE) 56 COMPRESSE (4 FLACONI DA 14) | 1件: Dalfampridine Dalfampridine | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1647 | Fampyra 10 mg prolonged-release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1648 | Fampyra 10mg prolonged release tablets | 2件: Dalfampridine Dalfampridine, Manganese citrate | 1件: Dalfampridine
Dalfampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 1件: 13 13 💬 |
1649 | FANHDI 100 UI | - | - | - | - | 1件: 288 288 💬 |
1650 | Fanhdi 100 UI FVIII-120 UI FVW | - | - | - | - | 1件: 288 288 💬 |
1651 | FANHDI 250UI*1F 250UI+F 10ML | - | - | - | - | 1件: 288 288 💬 |
1652 | Fasudil (WP-0512) | 1件: Fasudil Fasudil | 1件: Fasudil
Fasudil
💬 | 2件: ROCK1 ROCK1, ROCK2 💬 | 23件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, MicroRNAs in cancer, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, TGF-beta signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
1653 | FB-101 | - | - | - | - | 1件: 6 6 💬 |
1654 | FBX-101 | - | - | - | - | 1件: 19 19 💬 |
1655 | FCX-007 | - | - | - | - | 1件: 36 36 💬 |
1656 | FCX-013 | - | - | - | - | 1件: 51 51 💬 |
1657 | Femoston 1/10 | - | - | - | - | 1件: 13 13 💬 |
1658 | Femoston 2/10 | - | - | - | - | 1件: 13 13 💬 |
1659 | Fenofibrate 160mg | 1件: Fenofibrate Fenofibrate | 1件: Fenofibrate
Fenofibrate
💬 | 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 97 97 💬 |
1660 | Fentanyl (Low Dose) | 1件: Fentanyl Fentanyl | 1件: Fentanyl
Fentanyl
💬 | 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 215 215 💬 |
1661 | Fentanyl (Low Dose) + Dexmedetomidine | 2件: Dexmedetomidine Dexmedetomidine, Fentanyl | 2件: Fentanyl
Fentanyl
,
Dexmedetomidine
💬 | 4件: ADRA2A ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 | 4件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬 |
1662 | FERRIPROX*100CPR RIV 500MG | 1件: Deferiprone Deferiprone | 1件: Deferiprone
Deferiprone
💬 | - | - | 1件: 120 120 💬 |
1663 | FG-3019 10mg/mL in 10 mL vials | - | - | - | - | 1件: 85 85 💬 |
1664 | Fibrogammin® 1250 | - | - | - | - | 1件: 51 51 💬 |
1665 | Fibrogammin®P, coagulation factor XIII concentrate (Human) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 51 51 💬 |
1666 | Fingolimod 0.5 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1667 | Fingolimod 0.5mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1668 | Fingolimod 1.25 mg | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1669 | Firategrast 150 mg | 1件: Firategrast Firategrast | 1件: Firategrast
Firategrast
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
1670 | FIRDAPSE - 10 MG - COMPRESSE - USO ORALE - BLISTER(ALU/PVC/PVDC) 100 X 1 COMPRESSE | 1件: Amifampridine Amifampridine | 1件: Amifampridine
Amifampridine
💬 | 4件: KCNA4 KCNA4, KCNC3, KCND2, KCND3 💬 | 4件: Cortisol synthesis and secretion Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬 | 2件: 3 3, 11 💬 |
1671 | First line DMT | - | - | - | - | 1件: 13 13 💬 |
1672 | Fish oil, gamma-linolenic acid | 3件: Fish oil Fish oil, Gamolenic acid, alpha-Linolenic acid | 1件: Gamolenic acid
Gamolenic acid
💬 | - | - | 1件: 46 46 💬 |
1673 | FK506 level 2-3 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1674 | FK506 level 3-5 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1675 | FK506 level < 2 ng/ml | - | - | - | - | 1件: 86 86 💬 |
1676 | Flaxseed lignan-enriched complex (FLC) | 1件: Flax seed Flax seed | - | - | - | 1件: 97 97 💬 |
1677 | FLORBETABEN (18F) | - | - | - | - | 1件: 6 6 💬 |
1678 | Florbetapir (18F) | - | - | - | - | 1件: 127 127 💬 |
1679 | Florbetapir 18F | - | - | - | - | 1件: 127 127 💬 |
1680 | Florbetapir 18F Injection | - | - | - | - | 1件: 127 127 💬 |
1681 | Florbetapir F 18 | - | - | - | - | 1件: 6 6 💬 |
1682 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
1683 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
1684 | FLUORINE (18F) FLUDEOXYGLUCOSE | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: Fludeoxyglucose F 18
Fludeoxyglucose F 18
💬 | - | - | 2件: 84 84, 85 💬 |
1685 | FLUORINE-18 | 1件: Fluorine F-18 Fluorine F-18 | 1件: Sodium fluoride F 18
Sodium fluoride F 18
💬 | - | - | 1件: 41 41 💬 |
1686 | Foliglurax 10 mg (treatment A) | 1件: Foliglurax Foliglurax | - | - | - | 1件: 6 6 💬 |
1687 | FORLAX 4 g, poudre pour solution buvable en sachet | - | - | - | - | 1件: 299 299 💬 |
1688 | FORMISTIN - 10 MG COMPRESSE RIVESTITE CON FILM 20 COMPRESSE | - | - | - | - | 1件: 13 13 💬 |
1689 | Formistin 10 mg | - | - | - | - | 1件: 13 13 💬 |
1690 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 💬 |
1691 | Fosmetpantotenate (RE-024) | - | - | - | - | 1件: 120 120 💬 |
1692 | Fospropofol (Lusedra®) 10 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1693 | Fospropofol (Lusedra®) 12 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1694 | Fospropofol (Lusedra®) 6.5 | 1件: Fospropofol Fospropofol | - | - | - | 1件: 226 226 💬 |
1695 | Fostamatinib 100 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1696 | Fostamatinib 100 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1697 | Fostamatinib 150 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1698 | Fostamatinib 150 mg bid | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 61 61 💬 |
1699 | Fostamatinib 150 mg tablet | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1700 | Fostamatinib Disodium tablet 100 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1701 | Fostamatinib Disodium tablet 150 mg | 1件: Fostamatinib Fostamatinib | 1件: Fostamatinib
Fostamatinib
💬 | 1件: SYK SYK 💬 | 17件: B cell receptor signaling pathway B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Coronavirus disease - COVID-19, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Herpes simplex virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, NF-kappa B signaling pathway, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Osteoclast differentiation, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Platelet activation, Tuberculosis, Viral carcinogenesis 💬 | 1件: 66 66 💬 |
1702 | FP-110 | - | - | - | - | 1件: 97 97 💬 |
1703 | FP-CYA-050 | - | - | - | - | 1件: 97 97 💬 |
1704 | FP-CYA-053 | - | - | - | - | 1件: 97 97 💬 |
1705 | FPFS-1169 | - | - | - | - | 1件: 6 6 💬 |
1706 | FRISIUM*30CPS 10MG | - | - | - | - | 1件: 140 140 💬 |
1707 | FRM-0334 | - | - | - | - | 1件: 127 127 💬 |
1708 | Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the a-L-iduronidase cDNA, in their final formulation medium. | - | - | - | - | 1件: 19 19 💬 |
1709 | FT011 100 mg | - | - | - | - | 1件: 51 51 💬 |
1710 | FTX-1821 | - | - | - | - | 1件: 113 113 💬 |
1711 | Fully human IgG2 lambda monoclonal antibody | - | - | - | - | 1件: 172 172 💬 |
1712 | Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
1713 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 💬 |
1714 | G2019S LRRK2 | - | - | - | - | 1件: 6 6 💬 |
1715 | GA 40 mg/mL | - | - | - | - | 1件: 13 13 💬 |
1716 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 💬 |
1717 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 💬 |
1718 | Gaboxadol (HLX-0206) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 💬 |
1719 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1720 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1721 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: Gaboxadol
Gaboxadol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 💬 |
1722 | Gadolinium For lower back | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 💬 |
1723 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 💬 |
1724 | Gadovist 1.0 mmol/ml Injektionslösung | 1件: Gadobutrol Gadobutrol | 1件: Gadobutrol
Gadobutrol
💬 | - | - | 1件: 13 13 💬 |
1725 | Gamma-Linolenic acid | 2件: Gamolenic acid Gamolenic acid, alpha-Linolenic acid | 1件: Gamolenic acid
Gamolenic acid
💬 | - | - | 1件: 46 46 💬 |
1726 | GAMMAGARD LIQUID | - | - | - | - | 1件: 65 65 💬 |
1727 | Gammanorm 165 mg/mL | - | - | - | - | 1件: 65 65 💬 |
1728 | Gammaplex 10 | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
1729 | GAMUNEX 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 💬 |
1730 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1731 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: Ganaxolone
Ganaxolone
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 💬 |
1732 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: Obinutuzumab
Obinutuzumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
1733 | GB-0998 | - | - | - | - | 1件: 50 50 💬 |
1734 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 💬 |
1735 | GB224 10mg | - | - | - | - | 1件: 46 46 💬 |
1736 | GB224 15mg | - | - | - | - | 1件: 46 46 💬 |
1737 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 💬 |
1738 | GCK 100 mg | - | - | - | - | 1件: 46 46 💬 |
1739 | GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
1740 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1741 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 💬 |
1742 | GED-0301 | - | - | - | - | 2件: 96 96, 97 💬 |
1743 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1744 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1745 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 💬 |
1746 | Gene Therapy-vMCO-010 | - | - | - | - | 1件: 301 301 💬 |
1747 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 💬 |
1748 | Genistein (Unconjugated Isoflavones 100) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
1749 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 💬 |
1750 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 💬 |
1751 | Genotropin (PN-180,307) Somatropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1752 | Genotropin 12 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1753 | GENOTROPIN 12 mg powder and solvent for solution for injection. | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1754 | Genotropin 12 mg/ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1755 | Genotropin 12mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1756 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1757 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1758 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 💬 |
1759 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1760 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1761 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1762 | Genotropin Miniquick 1.2mg | 1件: Somatotropin Somatotropin | - | - | - | 3件: 74 74, 75, 78 💬 |
1763 | GENOTROPIN*1TBF 5,3MG (16UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 274 274 💬 |
1764 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 1件: Gentamicin
Gentamicin
💬 | - | - | 1件: 36 36 💬 |
1765 | Genz-112638 | - | - | - | - | 1件: 19 19 💬 |
1766 | Gevokizumab open-label | 1件: Gevokizumab Gevokizumab | 1件: Gevokizumab
Gevokizumab
💬 | 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 269 269 💬 |
1767 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 💬 |
1768 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1769 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1770 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1771 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1772 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 💬 |
1773 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: Fingolimod
Fingolimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
1774 | Glatiramer Acetate (GA) 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1775 | Glatiramer acetate 150mg enteric coated tablets | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1776 | Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1777 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1778 | Glatiramer acetate 40 mg | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1779 | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | 2件: Acetate Acetate, Glatiramer | - | - | - | 1件: 13 13 💬 |
1780 | Glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
1781 | Glial Cell Line-Derived Neurotrophic Factor (GDNF) | - | - | - | - | 1件: 6 6 💬 |
1782 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 💬 |
1783 | GLIVEC 100 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 34 34, 86 💬 |
1784 | Glivec 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 💬 |
1785 | Glivec 100 mg Hartkapsel | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
1786 | GLIVEC 400 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
1787 | Glivec® 100 mg Filmtabletten | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
1788 | GLP-1 | - | - | - | - | 1件: 299 299 💬 |
1789 | GLPG1837 dose 1 | - | - | - | - | 1件: 299 299 💬 |
1790 | GLPG2222 100 mg | - | - | - | - | 1件: 299 299 💬 |
1791 | GLPG2222 150 mg q.d. | - | - | - | - | 1件: 299 299 💬 |
1792 | GLPG2222 400 mg | - | - | - | - | 1件: 299 299 💬 |
1793 | GLWL-01 | - | - | - | - | 1件: 193 193 💬 |
1794 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: Glycerin
Glycerin
💬 | - | - | 1件: 13 13 💬 |
1795 | Glyceryl tri-(4-phenylbutyrate) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 251 251 💬 |
1796 | Glyceryl tri-(4-phenylbutyrate)(GT4P) | 2件: Glycerol phenylbutyrate Glycerol phenylbutyrate, Phenylbutyric acid | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 251 251 💬 |
1797 | GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) | - | - | - | - | 1件: 299 299 💬 |
1798 | GM-CSF [Leukine (Sargramostim)] | 1件: Sargramostim Sargramostim | 1件: Sargramostim
Sargramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 💬 |
1799 | GNR-055 | - | - | - | - | 1件: 19 19 💬 |
1800 | GNR-055 1.0-2.0-3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1801 | GNR-055 2.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1802 | GNR-055 3.0 mg/kg | - | - | - | - | 1件: 19 19 💬 |
1803 | GNR-069 | - | - | - | - | 1件: 63 63 💬 |
1804 | Golimumab (CNTO 148) | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
1805 | Golimumab 1 mg per kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1806 | Golimumab 100 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 97 💬 |
1807 | Golimumab 100 mg injections | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1808 | Golimumab 4 mg per kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1809 | Golimumab 400 mg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1810 | Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1811 | Golimumab Dose 1 | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1812 | Golimumab liquid in prefilled pen | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1813 | Golimumab liquid in prefilled pen or Prefilled Syringe | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1814 | Golimumab Liquid in prefilled syringe | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 84, 97, 107 💬 |
1815 | Golimumab Liquid in Vial | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 💬 |
1816 | Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | 1件: Golodirsen Golodirsen | 1件: Golodirsen
Golodirsen
💬 | 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 💬 |
1817 | GPI 1485 | - | - | - | - | 1件: 6 6 💬 |
1818 | GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 💬 |
1819 | Granocyte Lenograstim | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 💬 |
1820 | GRC 4039 | - | - | - | - | 1件: 46 46 💬 |
1821 | GREEN TEA LEAF | 2件: Green tea leaf Green tea leaf, Tea leaf | 1件: Green tea leaf
Green tea leaf
💬 | - | - | 1件: 17 17 💬 |
1822 | Group 1 or Orencia treated group | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
1823 | Group 1- Control Diet | - | - | - | - | 1件: 97 97 💬 |
1824 | Group 2 ustekinumab 130 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
1825 | Growth hormone - LB03002 | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1826 | Growth hormone releasing hormone (GHRH) 1-44 | 2件: Somatorelin Somatorelin, Somatotropin | 1件: Somatorelin
Somatorelin
💬 | 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 💬 |
1827 | GS-4059 | - | - | - | - | 1件: 53 53 💬 |
1828 | GS-4875 | - | - | - | - | 1件: 97 97 💬 |
1829 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 💬 |
1830 | GS-4997 2 mg | - | - | - | - | 1件: 86 86 💬 |
1831 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 💬 |
1832 | GS-9674 100 mg | - | - | - | - | 1件: 93 93 💬 |
1833 | GSK1265744B (sodium salt) containing 14C-GSK1265744B | - | - | - | - | 1件: 265 265 💬 |
1834 | GSK1550188 1mg/kg or 10mg/kg | - | - | - | - | 1件: 49 49 💬 |
1835 | GSK2330672/linerixibat 40 mg | - | - | - | - | 1件: 93 93 💬 |
1836 | GSK2330811 Solution for Injection, 100mg/ml | - | - | - | - | 1件: 51 51 💬 |
1837 | GSK2586184 100 mg | - | - | - | - | 1件: 49 49 💬 |
1838 | GSK2586184 400 mg | - | - | - | - | 1件: 49 49 💬 |
1839 | GSK2586184 400mg | - | - | - | - | 1件: 97 97 💬 |
1840 | GSK2831781 - Open Label phase | - | - | - | - | 1件: 97 97 💬 |
1841 | GSK315234 Injection 100mg/mL | - | - | - | - | 1件: 46 46 💬 |
1842 | GSK3196165 Dose 1 | - | - | - | - | 1件: 46 46 💬 |
1843 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
1844 | GTX-102 | 1件: GTX-102 GTX-102 | - | - | - | 2件: 65 65, 201 💬 |
1845 | GTX-102 high dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1846 | GTX-102 low dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1847 | GTX-102 medium dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1848 | GTX-102 medium dose slow Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
1849 | Guna-Anti Interleukin 1 | - | - | - | - | 1件: 46 46 💬 |
1850 | Guna-Antiinterleukin 1 alfa | - | - | - | - | 1件: 46 46 💬 |
1851 | Guna-Antiinterleukin 1 beta | - | - | - | - | 1件: 46 46 💬 |
1852 | Guna-Interleukin 10 | - | - | - | - | 1件: 46 46 💬 |
1853 | Guna-Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
1854 | Guselkumab 100 mg | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 37 37 💬 |
1855 | Guselkumab Dose 1 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 💬 |
1856 | Guselkumab Dose 4 | 1件: Guselkumab Guselkumab | 1件: Guselkumab
Guselkumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
1857 | GW-1000-02 | - | - | - | - | 1件: 13 13 💬 |
1858 | GWP42003-P 10 mg/kg/day Dose | - | - | - | - | 1件: 140 140 💬 |
1859 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 💬 |
1860 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 💬 |
1861 | H-116PI-DE.pdf | - | - | - | - | 1件: 18 18 💬 |
1862 | H5.001CBCFTR | - | - | - | - | 1件: 299 299 💬 |
1863 | H5G1.1-mAb | - | - | - | - | 3件: 13 13, 50, 62 💬 |
1864 | HA 1A ANTICORPO MONOCLONALE UMANO CLASSE IGM | - | - | - | - | 2件: 6 6, 49 💬 |
1865 | HA20 (IMMU-106) | - | - | - | - | 1件: 46 46 💬 |
1866 | Haemocomplettan(R) P 1g/2g | - | - | - | - | 1件: 65 65 💬 |
1867 | HBVAXPRO 5 micrograms/0.5 ml | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1868 | HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA) | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1869 | HBVAXPRO® 40 micrograms | 1件: Hepatitis B Vaccine (Recombinant) Hepatitis B Vaccine (Recombinant) | - | - | - | 1件: 46 46 💬 |
1870 | Hemay007 1200 mg QD group | - | - | - | - | 1件: 46 46 💬 |
1871 | Heparin & Alkalinized Lidocaine Bladder Instillation | 2件: Heparin Heparin, Lidocaine | 3件: Lidocaine
Lidocaine
,
Adomiparin
,
Lidocaine hydrochloride monohydrate
💬 | 6件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 | 4件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction 💬 | 1件: 226 226 💬 |
1872 | Heterologous Human Adult Liver-derived Progenitor Cells | - | - | - | - | 1件: 251 251 💬 |
1873 | Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC) | - | - | - | - | 1件: 251 251 💬 |
1874 | HGS1006, LymphoStat-B | - | - | - | - | 1件: 53 53 💬 |
1875 | HGS1006, LymphoStat-B, monoclonal anti-BLyS, LSB, BENLYSTA | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 49 49, 53 💬 |
1876 | HGT-1110 | - | - | - | - | 1件: 19 19 💬 |
1877 | HGT-1111 | - | - | - | - | 1件: 19 19 💬 |
1878 | HGT-1410 | - | - | - | - | 1件: 19 19 💬 |
1879 | HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML | 1件: Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen | - | - | - | 3件: 61 61, 62, 66 💬 |
1880 | HIDONAC*EV 1FL 5G 25ML | - | - | - | - | 1件: 51 51 💬 |
1881 | High Dose Aspirin (1300 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
1882 | High dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
1883 | High dose lactulose | 1件: Lactulose Lactulose | 1件: Lactulose
Lactulose
💬 | - | - | 1件: 291 291 💬 |
1884 | High dose levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
1885 | High Dose LX2006 | - | - | - | - | 1件: 18 18 💬 |
1886 | High Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
1887 | High dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
1888 | High/Low Sodium Diet | - | - | - | - | 1件: 13 13 💬 |
1889 | HK-001 | - | - | - | - | 1件: 2 2 💬 |
1890 | HL-085 | - | - | - | - | 1件: 34 34 💬 |
1891 | HLADQA1*05A>G screening | - | - | - | - | 2件: 96 96, 97 💬 |
1892 | HLB-001 | - | - | - | - | 1件: 246 246 💬 |
1893 | HLL2,IMMU-103 | - | - | - | - | 1件: 49 49 💬 |
1894 | HMI-102 | - | - | - | - | 1件: 240 240 💬 |
1895 | HMI-103 | - | - | - | - | 1件: 240 240 💬 |
1896 | HMPL-004 | - | - | - | - | 2件: 96 96, 97 💬 |
1897 | HMPL-004 1800 mg/day | - | - | - | - | 1件: 97 97 💬 |
1898 | HMPL-004 2400 mg/day | - | - | - | - | 1件: 97 97 💬 |
1899 | HMPL-004 high dose | - | - | - | - | 1件: 97 97 💬 |
1900 | HMPL-004 low dose | - | - | - | - | 1件: 97 97 💬 |
1901 | HMR 1726D | - | - | - | - | 1件: 13 13 💬 |
1902 | Hookworm larvae | - | - | - | - | 1件: 13 13 💬 |
1903 | HOV-12020 (Palm tocotrienols complex) | - | - | - | - | 1件: 124 124 💬 |
1904 | HP 129Xe | - | - | - | - | 1件: 299 299 💬 |
1905 | Hp 129Xenon | - | - | - | - | 1件: 228 228 💬 |
1906 | HPN-100 | - | - | - | - | 1件: 251 251 💬 |
1907 | HT-100 | - | - | - | - | 1件: 113 113 💬 |
1908 | Hu Leptin (A-100) | 1件: Leptin Leptin | - | - | - | 1件: 265 265 💬 |
1909 | Hu MiK-Beta-1 | - | - | - | - | 1件: 26 26 💬 |
1910 | HuCNS-SC transplant in the lead-in phase | - | - | - | - | 1件: 139 139 💬 |
1911 | Humalog Mix50 100 U/ml sospensione iniettabile | - | - | - | - | 1件: 78 78 💬 |
1912 | Human anti-IL 12/23 monoclonal antibody | - | - | - | - | 1件: 84 84 💬 |
1913 | Human Anti-IL-12 Antibody | - | - | - | - | 1件: 96 96 💬 |
1914 | Human anti-IL-12 IgG1 Mab | - | - | - | - | 1件: 13 13 💬 |
1915 | Human anti-IL-12 Mab | - | - | - | - | 1件: 13 13 💬 |
1916 | Human anti-LINGO-1 monoclonal antibody | - | - | - | - | 1件: 13 13 💬 |
1917 | Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | - | - | - | - | 1件: 51 51 💬 |
1918 | Human Coagulation FACTOR X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1919 | Human factor X | 1件: Coagulation factor X human Coagulation factor X human | - | - | - | 1件: 288 288 💬 |
1920 | Human Growth Hormone (1-134) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
1921 | Human Heterologous Liver Cells | - | - | - | - | 1件: 251 251 💬 |
1922 | Human heterologous liver cells (for infusion) | - | - | - | - | 1件: 251 251 💬 |
1923 | Human interferon beta 1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1924 | Human interferon beta-1a and glatiramer acetate | 4件: Acetate Acetate, Glatiramer, Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
1925 | HUMAN LEUCOCYTE INTERFERON-ALPHA | - | - | - | - | 1件: 13 13 💬 |
1926 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 💬 |
1927 | Human monoclonal antibody (CNTO 1275) to interleukin-12p40 | - | - | - | - | 1件: 13 13 💬 |
1928 | Human normal 10% immunoglobulin for intravenous administration | - | - | - | - | 1件: 14 14 💬 |
1929 | Human normal 10% immunoglobulin for intravenous administrationn | - | - | - | - | 1件: 14 14 💬 |
1930 | Human Recombinant IgG1, lambda | - | - | - | - | 1件: 46 46 💬 |
1931 | Human recombinant leptin (metreleptin) | 2件: Leptin Leptin, Metreleptin | 1件: Metreleptin
Metreleptin
💬 | 1件: LEPR LEPR 💬 | 6件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease 💬 | 1件: 265 265 💬 |
1932 | Human T Lymphoid Progenitor (HTLP) injection | - | - | - | - | 1件: 65 65 💬 |
1933 | Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody | - | - | - | - | 1件: 46 46 💬 |
1934 | Humanized recombinant IgG4 monoclonal antibody against CD-127 | - | - | - | - | 1件: 97 97 💬 |
1935 | Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten | 1件: Somatotropin Somatotropin | - | - | - | 1件: 193 193 💬 |
1936 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 💬 |
1937 | Humira (adalimumab) 40 mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1938 | Humira (adalimumab) 40 mg s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1939 | Humira (adalimumab) 40mg in 0.4 ml s.c. injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1940 | Humira (adalimumab) 40mg in 0.4ml s.c.injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1941 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 97 💬 |
1942 | HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1943 | HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1944 | Humira 20 mg solution for injection in pre-filled syringe (20 mg/0.2mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1945 | Humira 40 mg injekcní roztok v predplnené injekcní stríkacce | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1946 | Humira 40 mg injeksjonsvæske, oppløsning, i ferdigfylt sprøyte | - | - | - | - | 1件: 46 46 💬 |
1947 | HUMIRA 40 mg solución inyectable en jeringa precargada | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1948 | Humira 40 mg solution for injection in pre-filled pen | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1949 | Humira 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 💬 |
1950 | Humira 40 mg solution for injection in pre-filled syringe (40 mg/0.4 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1951 | Humira 40 mg solution for injection in pre-filled syringes | - | - | - | - | 1件: 97 97 💬 |
1952 | Humira 40 mg/0.8 ml solution for injection | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
1953 | Humira 40 mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1954 | Humira 40mg Injektionslösung | - | - | - | - | 1件: 46 46 💬 |
1955 | HUMIRA 40Mg Solution for Injection | - | - | - | - | 2件: 96 96, 97 💬 |
1956 | Humira 40mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1957 | Humira 40mg solution for injection in pre-filled syringe (adalimumab) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1958 | Humira 40mg/0.4ml pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1959 | Humira 40mg/0.8 ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1960 | Humira 40mg/0.8ml solution for injection for paediatric use | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
1961 | Humira 40mg/0.8ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1962 | Humira 80 mg solution for injection in pre-filled syringe (80 mg/0.8 mL) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
1963 | Humira ® (Adalimumab) 40mg/0.8mL Pre-filled Syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1964 | HUMIRA*SC 2SIR+F 40MG 0,8ML+2T | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 💬 |
1965 | Humira, 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1966 | Humira® 40 mg Injektionslösung in Fertigspritze | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1967 | Humira® 40 mg solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1968 | Humira® 40 mg/ 0.8 ml solution for injection in pre-filled syringe | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
1969 | Hydrocortison 100 mg (Pfizer®) in 2 ml solvent | - | - | - | - | 1件: 83 83 💬 |
1970 | Hydrocortisone 100mg/ml | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
1971 | Hydrocortisone 10mg | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
1972 | Hydrocortisone 10mg Tablet | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1973 | Hydrocortisone 10mg Tablets | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
1974 | Hydrocortisone cream 1% | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
1975 | Hydrocortisone cream 10mg/g FNA Fagron | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
1976 | Hydroxychloroquine + low-dose prednisone | 2件: Hydroxychloroquine Hydroxychloroquine, Prednisone | 2件: Prednisone
Prednisone
,
Hydroxychloroquine
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
1977 | Hydroxychloroquine 400mg/d | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 53 53 💬 |
1978 | Hydroxychloroquine lower dose | 1件: Hydroxychloroquine Hydroxychloroquine | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 90 90 💬 |
1979 | Hydroxychloroquine Sulfate 100 milligram (mg) Tab | 2件: Hydroxychloroquine Hydroxychloroquine, Sulfate ion | 1件: Hydroxychloroquine
Hydroxychloroquine
💬 | - | - | 1件: 218 218 💬 |
1980 | Hyperglycemic clamp with concurrent GLP-1 infusion | - | - | - | - | 1件: 299 299 💬 |
1981 | Hyperimmune caprine serum against HIV lysate | - | - | - | - | 1件: 13 13 💬 |
1982 | Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1983 | Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1984 | Hyperpolarized 129-Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 85 85 💬 |
1985 | Hyperpolarized 129Xe | - | - | - | - | 1件: 86 86 💬 |
1986 | Hyperpolarized 13C-Pyruvate | - | - | - | - | 1件: 58 58 💬 |
1987 | Hyperpolarized [1-13C]pyruvate | - | - | - | - | 2件: 2 2, 67 💬 |
1988 | Hyperpolarized Xe129 | - | - | - | - | 4件: 51 51, 85, 86, 299 💬 |
1989 | Hyperpolarized Xenon | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1990 | Hyperpolarized Xenon 129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1991 | Hyperpolarized Xenon gas | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1992 | Hyperpolarized xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
1993 | Hypertonic saline (7 %) and isotonic saline (0.9%) | - | - | - | - | 1件: 299 299 💬 |
1994 | HyQvia 100 mg/ml solution for infusion for subcutaneous use | 2件: Human immunoglobulin G Human immunoglobulin G, Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 💬 |
1995 | I 123 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 6 6 💬 |
1996 | I-123 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 2件: 2 2, 6 💬 |
1997 | I-123-5-IA85380 | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 6 6 💬 |
1998 | I-123] ADAM | 1件: Iodide I-123 Iodide I-123 | - | - | - | 1件: 2 2 💬 |
1999 | IA-14069 | - | - | - | - | 1件: 46 46 💬 |
2000 | IB 1001 | - | - | - | - | 1件: 65 65 💬 |
2001 | Ibuprofen Sandoz 400 mg Filmtabletten | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
2002 | ICI 182,780 (Faslodex) | 1件: Fulvestrant Fulvestrant | 1件: Fulvestrant
Fulvestrant
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 💬 |
2003 | ICP-022 | - | - | - | - | 2件: 46 46, 49 💬 |
2004 | ICS+LABA | - | - | - | - | 1件: 299 299 💬 |
2005 | ICX-RHY-013 | - | - | - | - | 1件: 36 36 💬 |
2006 | Idebenone 150 mg film-coated tablets | 1件: Idebenone Idebenone | 1件: Idebenone
Idebenone
💬 | - | - | 1件: 113 113 💬 |
2007 | IDEC-C2B8, Ro 45-2294 | - | - | - | - | 1件: 64 64 💬 |
2008 | Identification of COMT HH, COMT HL or COMT LL genes | - | - | - | - | 1件: 6 6 💬 |
2009 | IdeS (0.25 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
2010 | IdeS (0.50 mg/kg) | 1件: Imlifidase Imlifidase | 1件: Imlifidase
Imlifidase
💬 | - | - | 1件: 64 64 💬 |
2011 | IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G | - | - | - | - | 1件: 272 272 💬 |
2012 | IDROCORTISONE ACETATO DYNACREN 1% CREMA | - | - | - | - | 1件: 272 272 💬 |
2013 | Idursulfase IT (1 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2014 | Idursulfase IT (10 mg) | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2015 | Idursulfase(12S)-IT | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2016 | IFB-088 | - | - | - | - | 1件: 2 2 💬 |
2017 | IFB-088 50mg/day | - | - | - | - | 1件: 2 2 💬 |
2018 | IFN beta 1a 44 mcg TIW | - | - | - | - | 1件: 13 13 💬 |
2019 | IFN beta-1a | - | - | - | - | 1件: 13 13 💬 |
2020 | IFN ß-1a | - | - | - | - | 1件: 13 13 💬 |
2021 | IFN-beta-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2022 | IFN-beta-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2023 | IFN-ß-1a (Rebif®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2024 | IFN-ß-1a, (Avonex®) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2025 | IFX-1 | 1件: Vilobelimab Vilobelimab | 1件: Vilobelimab
Vilobelimab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 43 43, 44, 269 💬 |
2026 | Ig VENA (10g/200mL) | - | - | - | - | 1件: 50 50 💬 |
2027 | Ig VENA 100 ml vial | - | - | - | - | 1件: 63 63 💬 |
2028 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 💬 |
2029 | IGF-1 | - | - | - | - | 1件: 113 113 💬 |
2030 | IgG2/4? | - | - | - | - | 1件: 109 109 💬 |
2031 | IGIV, 10% | - | - | - | - | 2件: 14 14, 65 💬 |
2032 | IGIV-C 10% | - | - | - | - | 1件: 65 65 💬 |
2033 | IGIV3I Grifols 10% | - | - | - | - | 1件: 63 63 💬 |
2034 | IgNextGen 10% | - | - | - | - | 1件: 63 63 💬 |
2035 | IgNextGen 16% | - | - | - | - | 1件: 65 65 💬 |
2036 | IgPro20 (low dose) | - | - | - | - | 1件: 14 14 💬 |
2037 | IGSC 20% 150 mg/kg | - | - | - | - | 1件: 65 65 💬 |
2038 | IGSC, 16% | - | - | - | - | 1件: 65 65 💬 |
2039 | IGVENA*FL 200ML 10G+SET | - | - | - | - | 2件: 14 14, 50 💬 |
2040 | IkT-148009 | - | - | - | - | 1件: 6 6 💬 |
2041 | IL-1 Trap | - | - | - | - | 1件: 266 266 💬 |
2042 | IL-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2043 | IL-6R Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 46 46 💬 |
2044 | ILB: 100mg/ml solution for injection and infusion | - | - | - | - | 1件: 2 2 💬 |
2045 | Iloprost low dose | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
2046 | Iloprost PD-15 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2047 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
2048 | ILT-101 | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 49 49 💬 |
2049 | ILV-094 | - | - | - | - | 1件: 46 46 💬 |
2050 | Imatinib Mesylate 400Mg Capsule | 1件: Imatinib Imatinib | 1件: Imatinib
Imatinib
💬 | 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 89 89 💬 |
2051 | IMB-1018972 | - | - | - | - | 1件: 58 58 💬 |
2052 | IMCY-0141 | 1件: IMCY-0141 IMCY-0141 | - | - | - | 1件: 13 13 💬 |
2053 | Immediate release carbidopa/levodopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2054 | Immediate Release carbidopa/levodopa 10/100 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2055 | Immediate Release carbidopa/levodopa 25/100 mg | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2056 | IMMU-103 | - | - | - | - | 1件: 49 49 💬 |
2057 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 11 11 💬 |
2058 | Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) | - | - | - | - | 1件: 11 11 💬 |
2059 | Immune Globulin 10% Intravenous Solution | - | - | - | - | 1件: 14 14 💬 |
2060 | Immune Globulin Infusion (Human), 10% | - | - | - | - | 1件: 65 65 💬 |
2061 | Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | - | - | - | - | 1件: 65 65 💬 |
2062 | Immune Globulin Intravenous (human), 10% | - | - | - | - | 2件: 14 14, 65 💬 |
2063 | Immune Globulin Intravenous (Human), 10% Solution | - | - | - | - | 1件: 65 65 💬 |
2064 | Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution | - | - | - | - | 1件: 63 63 💬 |
2065 | Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution | - | - | - | - | 1件: 65 65 💬 |
2066 | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 💬 |
2067 | Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 14 14 💬 |
2068 | Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 13 13 💬 |
2069 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 💬 |
2070 | Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer | - | - | - | - | 1件: 2 2 💬 |
2071 | Immunosuppression Only Conditioning -Closed with amendment L | - | - | - | - | 1件: 65 65 💬 |
2072 | Imnovid 1 mg hard capsules | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 51 51 💬 |
2073 | IMO-8400 Dose Group 1 | - | - | - | - | 1件: 50 50 💬 |
2074 | IMP will be labeled as ''PF-04236921 106mg/vial, Clonal SC lyophilized form''. | - | - | - | - | 1件: 96 96 💬 |
2075 | IMP will be labeled as PF-04236921 106mg/vial, Clonal SC lyophilized form | - | - | - | - | 1件: 96 96 💬 |
2076 | Imsidolimab low dose | 1件: Imsidolimab Imsidolimab | 1件: Imsidolimab
Imsidolimab
💬 | 1件: IL1RL2 IL1RL2 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 37 37 💬 |
2077 | IMU-838 (45 mg/day) | - | - | - | - | 1件: 13 13 💬 |
2078 | IMUKIN - 6 FLACONI 0.5 ML 100 MCG | - | - | - | - | 2件: 18 18, 58 💬 |
2079 | IMUKIN*SC 6F 0,5ML 100MCG | - | - | - | - | 1件: 18 18 💬 |
2080 | In open-label phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 💬 |
2081 | Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus | - | - | - | - | 1件: 53 53 💬 |
2082 | INALOSSIN - 800 PPM MOL/MOL GAS MEDICINALE COMPRESSO BOMBOLA IN ALLUMINIO CON VALVOLA VI DA 20 LITRI | - | - | - | - | 1件: 294 294 💬 |
2083 | INBRX-101/rhAAT-Fc | - | - | - | - | 1件: 231 231 💬 |
2084 | INCB050465 0.3 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2085 | INCB050465 0.3mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2086 | INCB050465 1 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
2087 | INCB050465 1.0 mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2088 | INCB050465 1.0mg | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 35 35 💬 |
2089 | IncobotulinumtoxinA (100 Units) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
2090 | INCRELEX 10 mg/ml | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
2091 | INCRELEX 10 mg/ml, solución inyectable | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 78 78 💬 |
2092 | Increlex 10mg/ml solution for injection | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2093 | INCRELEX*SC 1FL 4ML 10MG/ML | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
2094 | IND 127861 | - | - | - | - | 2件: 51 51, 53 💬 |
2095 | Indium 111-radiolabelled anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 💬 |
2096 | Indium-111 Pentreotide | 1件: Indium Indium | - | - | - | 1件: 84 84 💬 |
2097 | Indium 111 labelled Anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 💬 |
2098 | INDUSIL*OS GTT FL 30MG+FL 15ML | - | - | - | - | 1件: 299 299 💬 |
2099 | INF beta-1a | - | - | - | - | 1件: 13 13 💬 |
2100 | Infigratinib 0.016 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2101 | Infigratinib 0.032 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2102 | Infigratinib 0.064 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2103 | Infigratinib 0.128 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2104 | Infigratinib 0.25 mg/kg | 1件: Infigratinib Infigratinib | 1件: Infigratinib
Infigratinib
💬 | 3件: FGFR1 FGFR1, FGFR2, FGFR3 💬 | 21件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells, Thermogenesis 💬 | 1件: 276 276 💬 |
2105 | INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 56 56 💬 |
2106 | Inflectra 100 mg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
2107 | Inflectra 100 mg powder for concentrate for solution for infusion | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
2108 | Infliximab (BCD-055) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
2109 | Infliximab (Remicade): 100 mg of lyophilized infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2110 | Infliximab 10 mg/kg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 96, 97 💬 |
2111 | Infliximab and azathioprine combination at week 0 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2112 | Infliximab and azathioprine combination at week 14 | 2件: Azathioprine Azathioprine, Infliximab | 2件: Azathioprine
Azathioprine
,
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2113 | Infusion of ADR-001 (Mesenchymal stem cell) | - | - | - | - | 1件: 66 66 💬 |
2114 | Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 💬 |
2115 | Infusion of autologous EFS-ADA LV CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
2116 | Infusion of lentiviral TYF-CGD-modified autologous stem cells | - | - | - | - | 1件: 65 65 💬 |
2117 | Inhaled dry powder treprostinil (LIQ861) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2118 | Inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 85 85 💬 |
2119 | INN Parathyroid Hormone (1-84) human | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
2120 | INOmax 400ppm mol/mol inhalation gas | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 2件: 85 85, 299 💬 |
2121 | INS1007 10 mg oral tablet | - | - | - | - | 1件: 299 299 💬 |
2122 | Insulin like growth factor, type 1 | - | - | - | - | 1件: 2 2 💬 |
2123 | Inteferone Beta-1A | - | - | - | - | 1件: 13 13 💬 |
2124 | Interferon alpha oral lozenge | - | - | - | - | 1件: 85 85 💬 |
2125 | INTERFERON BETA - 1A | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2126 | Interferon beta - 1a (IFN) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2127 | Interferon beta -1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2128 | Interferon Beta 1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2129 | Interferon Beta 1-A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2130 | Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2131 | Interferon Beta 1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2132 | Interferon beta 1a 30 ug IM once weekly | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2133 | Interferon Beta 1a pegilado | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2134 | Interferon beta 1a, oral doxycycline | 3件: Doxycycline Doxycycline, Human interferon beta, Interferon beta-1a | 3件: Doxycycline
Doxycycline
,
Interferon beta-1a
,
Doxycycline
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2135 | Interferon beta 1B | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2136 | Interferon beta 1b (Betaseron, BAY86-5046) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2137 | Interferon beta-1 a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2138 | INTERFERON BETA-1A | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 4件: 13 13, 26, 96, 97 💬 |
2139 | Interferon beta-1a (Avonex) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2140 | INTERFERON BETA-1A (Avonex®) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2141 | Interferon beta-1a (current approved manufacturing process invloving FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2142 | Interferon beta-1a (new process, manufactured without FBS) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2143 | Interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2144 | Interferon beta-1a (Rebif®) alone | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2145 | Interferon beta-1a 30 µg | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2146 | Interferon beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2147 | Interferon beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2148 | Interferon beta-1a FBS-free/HSA-free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2149 | Interferon beta-1a HSA+ biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2150 | Interferon beta-1a HSA-free biosimilar | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2151 | Interferon beta-1a original | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2152 | Interferon Beta-1A Prefilled Syringe | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2153 | Interferon beta-1a, 30 µg/0.5 ml | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2154 | INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2155 | Interferon beta-1b (Betaferon, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2156 | Interferon beta-1b (Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2157 | Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2158 | Interferon beta-1b (Betaferon®, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2159 | Interferon beta-1b (Betaseron, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2160 | Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2161 | Interferon beta-1b (PF530, Betaferon) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2162 | Interferon beta-1b and Tacrolimus | 3件: Human interferon beta Human interferon beta, Interferon beta-1b, Tacrolimus | 3件: Tacrolimus
Tacrolimus
,
Interferon beta-1b
,
Tacrolimus
💬 | 7件: IFNAR1 IFNAR1, IFNAR2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 48件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Epstein-Barr virus infection, Glucagon signaling pathway, Glutamatergic synapse, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
2163 | Interferon beta-1b group | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2164 | Interferon beta-1b, (Betaseron BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2165 | Interferon beta-1b, FRP about 6 weeks after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2166 | Interferon beta-1b, FRP within 15 days after randomization | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2167 | Interferon beta-1b/Atorvastatin group | 3件: Atorvastatin Atorvastatin, Human interferon beta, Interferon beta-1b | 2件: Interferon beta-1b
Interferon beta-1b
,
Atorvastatin
💬 | 3件: HMGCR HMGCR, IFNAR1, IFNAR2 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Terpenoid backbone biosynthesis, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2168 | Interferon gamma 1b | 1件: Interferon Gamma Interferon Gamma | - | - | - | 1件: 228 228 💬 |
2169 | INTERFERON GAMMA-1B | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: Interferon gamma-1b
Interferon gamma-1b
💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 7件: 18 18, 65, 85, 228, 299, 301, 326 💬 |
2170 | Interferon gamma-1b (Actimmune) | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: Interferon gamma-1b
Interferon gamma-1b
💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 1件: 85 85 💬 |
2171 | Interferon ß-1a | - | - | - | - | 1件: 13 13 💬 |
2172 | Interferon ß-1a 30 µg | - | - | - | - | 1件: 13 13 💬 |
2173 | Interferon ß-1b | - | - | - | - | 1件: 13 13 💬 |
2174 | Interferon-1beta (Betaseron, BAY86-5046) | 1件: Interferon beta-1b Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2175 | Interferon-alpha lozenges | - | - | - | - | 1件: 85 85 💬 |
2176 | Interferon-beta 1a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2177 | Interferon-beta 1a FBS-free/HSA free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2178 | Interferon-beta 1a FBS-free/HSA-free, RNF | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2179 | Interferon-beta 1b | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2180 | Interferon-beta 1b (Betaseron) | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2181 | Interferon-beta and human leukocyte Interferon-a | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2182 | Interferon-beta-1 | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 13 13 💬 |
2183 | Interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 💬 |
2184 | Interferon-beta-1a (Avonex) plus methylprednisolone | 3件: Human interferon beta Human interferon beta, Interferon beta-1a, Methylprednisolone | 2件: Methylprednisolone
Methylprednisolone
,
Interferon beta-1a
💬 | 3件: IFNAR1 IFNAR1, IFNAR2, NR3C1 💬 | 19件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2185 | Interferon-beta-1a FBS-free/HSA free, RNF | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2186 | Interferon-beta-1a FBS-free/HSA-free | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2187 | Interferon-beta-1a, 44 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
2188 | Interferon-beta-1a, 66 microgram | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 97 97 💬 |
2189 | Interferon-beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2190 | Interferon-beta-1b (BETASERON, BAY 86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2191 | Interferon-gamma 1b | - | - | - | - | 1件: 85 85 💬 |
2192 | Interferon-ß-1 | - | - | - | - | 1件: 13 13 💬 |
2193 | Interferon-ß-1a | - | - | - | - | 1件: 13 13 💬 |
2194 | Interferon-ß-1b | - | - | - | - | 1件: 13 13 💬 |
2195 | Interferone beta 1a | - | - | - | - | 1件: 13 13 💬 |
2196 | INTERFERONE BETA 1B | - | - | - | - | 1件: 13 13 💬 |
2197 | Interferone beta-1a | - | - | - | - | 1件: 13 13 💬 |
2198 | Interferone Beta-1B | - | - | - | - | 1件: 13 13 💬 |
2199 | Interferón beta 1a | - | - | - | - | 1件: 13 13 💬 |
2200 | Interferón beta 1a pegilado | - | - | - | - | 1件: 13 13 💬 |
2201 | Interferón Beta-1a pegilado | - | - | - | - | 1件: 13 13 💬 |
2202 | Interleukin 10 | - | - | - | - | 1件: 46 46 💬 |
2203 | Interleukin 11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2204 | Interleukin 4 | - | - | - | - | 1件: 46 46 💬 |
2205 | Interleukin-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 2件: 96 96, 288 💬 |
2206 | Intermediate dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
2207 | Intervention for incipient patients at low risk of disease progression | - | - | - | - | 1件: 66 66 💬 |
2208 | Intracerebral administration of AAVrh.10cuARSA | - | - | - | - | 1件: 19 19 💬 |
2209 | Intracerebral LV gene therapy | - | - | - | - | 1件: 20 20 💬 |
2210 | Intralipid 10% | - | - | - | - | 1件: 96 96 💬 |
2211 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2212 | Intravenous administration of 1 million of MSC | - | - | - | - | 1件: 2 2 💬 |
2213 | Intravenous administration of 4 million of MSC | - | - | - | - | 1件: 2 2 💬 |
2214 | Intravenous Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2215 | Intravenous immunoglobulin (IVIG), 10% solution for infusion | - | - | - | - | 1件: 63 63 💬 |
2216 | Intravenous Levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2217 | Intrinsically labelled protein | - | - | - | - | 1件: 96 96 💬 |
2218 | IODIO IOFLUPANO-123I | - | - | - | - | 1件: 6 6 💬 |
2219 | IOFLUPANE (123I) | - | - | - | - | 1件: 6 6 💬 |
2220 | Ioflupane 123I | - | - | - | - | 1件: 2 2 💬 |
2221 | Ioflupane 123I (DATSCAN®) | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
2222 | Ioflupane [123 I] | - | - | - | - | 1件: 6 6 💬 |
2223 | Ioflupane [123I] | - | - | - | - | 1件: 6 6 💬 |
2224 | Ioflupane I 123 | 2件: Iodide I-123 Iodide I-123, Ioflupane I-123 | - | - | - | 1件: 6 6 💬 |
2225 | IPI 145 | - | - | - | - | 1件: 46 46 💬 |
2226 | IPI-145 | - | - | - | - | 1件: 46 46 💬 |
2227 | IPN60130 10 mg capsules | - | - | - | - | 1件: 272 272 💬 |
2228 | Iptacopan (LNP023) | 1件: Iptacopan Iptacopan | 1件: Iptacopan
Iptacopan
💬 | 1件: CFB CFB 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 1件: 62 62 💬 |
2229 | IPX054 100 mg | - | - | - | - | 1件: 6 6 💬 |
2230 | IPX054 150 mg | - | - | - | - | 1件: 6 6 💬 |
2231 | IPX056 10 mg | - | - | - | - | 1件: 13 13 💬 |
2232 | IPX056 40 mg | - | - | - | - | 1件: 13 13 💬 |
2233 | IPX056-10 mg | - | - | - | - | 1件: 13 13 💬 |
2234 | IPX056-40 mg | - | - | - | - | 1件: 13 13 💬 |
2235 | IPX066 145 mg | - | - | - | - | 1件: 6 6 💬 |
2236 | IPX066 145 mg LD | - | - | - | - | 1件: 6 6 💬 |
2237 | IPX066 195 mg | - | - | - | - | 1件: 6 6 💬 |
2238 | IPX066 195 mg LD | - | - | - | - | 1件: 6 6 💬 |
2239 | IPX066 245 mg LD | - | - | - | - | 1件: 6 6 💬 |
2240 | IPX066 95 mg LD | - | - | - | - | 1件: 6 6 💬 |
2241 | IPX066-145 | - | - | - | - | 1件: 6 6 💬 |
2242 | IPX066-195 | - | - | - | - | 1件: 6 6 💬 |
2243 | IPX203 140 mg | - | - | - | - | 1件: 6 6 💬 |
2244 | IPX203 180 mg | - | - | - | - | 1件: 6 6 💬 |
2245 | IPX203 ER CD-LD | - | - | - | - | 1件: 6 6 💬 |
2246 | IR CD-LD | - | - | - | - | 1件: 6 6 💬 |
2247 | IR CD-LD (carbidopa-levodopa) tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2248 | IR LD / CD | - | - | - | - | 1件: 6 6 💬 |
2249 | IR LD/CD | - | - | - | - | 1件: 6 6 💬 |
2250 | IRAK 4 | - | - | - | - | 1件: 46 46 💬 |
2251 | Irbesartan 150-300mg capsules daily for 6 months | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 167 167 💬 |
2252 | Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 💬 |
2253 | Irbesartan tablets (NDA 020 757) | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
2254 | Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2255 | IRT Laronidase | 1件: Laronidase Laronidase | 1件: Laronidase
Laronidase
💬 | 1件: IDUA IDUA 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2256 | ISIS 104838 | 1件: ISIS 104838 ISIS 104838 | - | - | - | 1件: 46 46 💬 |
2257 | ISIS 420915 | - | - | - | - | 1件: 28 28 💬 |
2258 | Isis 420915/GSK 299872 | - | - | - | - | 1件: 28 28 💬 |
2259 | ISIS 443139 10 mg | - | - | - | - | 1件: 8 8 💬 |
2260 | ISIS 443139 120 mg | - | - | - | - | 1件: 8 8 💬 |
2261 | ISIS 443139 30 mg | - | - | - | - | 1件: 8 8 💬 |
2262 | ISIS 443139 60 mg | - | - | - | - | 1件: 8 8 💬 |
2263 | ISIS 443139 90 mg | - | - | - | - | 1件: 8 8 💬 |
2264 | Isosorbide Dinitrate 40 mg | 2件: Isosorbide Isosorbide, Isosorbide dinitrate | 2件: Isosorbide
Isosorbide
,
Isosorbide dinitrate
💬 | - | - | 1件: 113 113 💬 |
2265 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 💬 |
2266 | Isotonic saline 0.9% | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
2267 | Isotopic Intravenous [13C]-Urea | 1件: Urea Urea | 2件: Urea
Urea
,
Urea C13
💬 | - | - | 1件: 251 251 💬 |
2268 | Isradipine CR 10mg | 1件: Isradipine Isradipine | 1件: Isradipine
Isradipine
💬 | 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
2269 | Istradefylline 20 mg or 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2270 | Istradefylline 40 mg | 1件: Istradefylline Istradefylline | 1件: Istradefylline
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2271 | ITF2357 10 mg/mL | - | - | - | - | 1件: 113 113 💬 |
2272 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. | 2件: Itraconazole Itraconazole, Terbinafine | 2件: Itraconazole
Itraconazole
,
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
2273 | IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one | - | - | - | - | 1件: 17 17 💬 |
2274 | IUPAC name: 2-[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylam ino]benzoyl]amino | - | - | - | - | 1件: 337 337 💬 |
2275 | IV Levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2276 | IV treatment with IGSC, 10% | - | - | - | - | 1件: 65 65 💬 |
2277 | Ivacaftor 125mg tablet | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2278 | Ivacaftor 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2279 | Ivacaftor 150 mg or 250 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2280 | Ivacaftor 75 mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2281 | Ivacaftor+lumacaftor | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2282 | IVIG-L | - | - | - | - | 1件: 63 63 💬 |
2283 | J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 | - | - | - | - | 1件: 96 96 💬 |
2284 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 💬 |
2285 | JBT-101 (lenabasum) | - | - | - | - | 1件: 299 299 💬 |
2286 | Jevity 1.0 | - | - | - | - | 1件: 2 2 💬 |
2287 | Jevity 1.5 | - | - | - | - | 1件: 2 2 💬 |
2288 | JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2289 | JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2290 | JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2291 | JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2292 | Jinarc 15 mg tablets, Jinarc 45 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2293 | Jinarc® 15mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2294 | JKB-122 | - | - | - | - | 1件: 95 95 💬 |
2295 | JKB-122 in capsule or tablet form | - | - | - | - | 1件: 95 95 💬 |
2296 | JM-010 | - | - | - | - | 1件: 6 6 💬 |
2297 | JM-4 | - | - | - | - | 1件: 13 13 💬 |
2298 | JNJ-16240159-AAC | - | - | - | - | 1件: 46 46 💬 |
2299 | JNJ-38518168 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
2300 | JNJ-38518168-ZBQ - film-coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
2301 | JNJ-38518168-ZBQ - film-coated tablet - 10mg | - | - | - | - | 1件: 46 46 💬 |
2302 | JNJ-39758979 (10 mg) | - | - | - | - | 1件: 46 46 💬 |
2303 | JNJ-39758979 (100 mg) | - | - | - | - | 1件: 46 46 💬 |
2304 | JNJ-39758979-AAC - enteric coated tablet - 10 mg | - | - | - | - | 1件: 46 46 💬 |
2305 | JNJ-39758979-AAC - enteric coated tablet - 100 mg | - | - | - | - | 1件: 46 46 💬 |
2306 | JNJ-40346527 | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 2件: 46 46, 96 💬 |
2307 | JNJ-40346527-AAC | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
2308 | JNJ-40346527-AAC - capsule - 50 mg | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 46 46 💬 |
2309 | JNJ-42160443 | - | - | - | - | 1件: 226 226 💬 |
2310 | JNJ-54781532 150 mg once daily | - | - | - | - | 1件: 97 97 💬 |
2311 | JNJ-54781532-AAD-10 mg | - | - | - | - | 1件: 97 97 💬 |
2312 | JNJ-67896062 / ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
2313 | JNJ-67896062/ ACT-064992 | - | - | - | - | 2件: 86 86, 88 💬 |
2314 | JNJ-67896062/ACT-064922 | - | - | - | - | 1件: 86 86 💬 |
2315 | JNJ-67896153/ACT-128800 | - | - | - | - | 1件: 13 13 💬 |
2316 | Jorveza 0.5 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2317 | Jorveza 0.5 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2318 | Jorveza 1 mg compresse orodispersibili | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2319 | Jorveza 1 mg orodispersible tablets | 1件: Budesonide Budesonide | 1件: Budesonide
Budesonide
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 💬 |
2320 | JP 1730 | - | - | - | - | 1件: 6 6 💬 |
2321 | JP-1730/F01 | - | - | - | - | 2件: 6 6, 17 💬 |
2322 | JP-1730/F02 | - | - | - | - | 2件: 6 6, 17 💬 |
2323 | JP-1730/F03 | - | - | - | - | 2件: 6 6, 17 💬 |
2324 | JR-141 | - | - | - | - | 1件: 19 19 💬 |
2325 | JR-141 or Idursulfase | 1件: Idursulfase Idursulfase | 1件: Idursulfase
Idursulfase
💬 | 1件: IDS IDS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
2326 | JR-171 (lepunafusp alfa) | - | - | - | - | 1件: 19 19 💬 |
2327 | JTE-051 | - | - | - | - | 1件: 46 46 💬 |
2328 | Jyseleca 100 mg film-coated tablets | 1件: Filgotinib Filgotinib | 1件: Filgotinib
Filgotinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2329 | JZP-110 | - | - | - | - | 1件: 6 6 💬 |
2330 | Kaletra (lopinavir [LPVr]) | 1件: Lopinavir Lopinavir | 1件: Lopinavir
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
2331 | Kalydeco 150 mg film-c | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2332 | Kalydeco 150 mg film-coated tablets | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2333 | Kalydeco 150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2334 | Kamada-AAT for Inhalation, 160mg | - | - | - | - | 1件: 231 231 💬 |
2335 | Kamillenblüten 3ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2336 | Kappa (light chain) | - | - | - | - | 1件: 61 61 💬 |
2337 | KCT-0809 ophthalmic solution | - | - | - | - | 1件: 53 53 💬 |
2338 | Kedrion IVIG 10% | - | - | - | - | 1件: 65 65 💬 |
2339 | Ketocal 4:1 liquid Nutricia (intervention) | - | - | - | - | 1件: 256 256 💬 |
2340 | Keyhole limpet hemocyanin | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 2件: 13 13, 46 💬 |
2341 | Keyhole limpet hemocyanin (KLH) | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 💬 |
2342 | Keyhole limpet hemocyanin (KLH) neo-antigen | 1件: Keyhole limpet hemocyanin Keyhole limpet hemocyanin | - | - | - | 1件: 13 13 💬 |
2343 | KHK4827 140mg SC | - | - | - | - | 1件: 37 37 💬 |
2344 | KIN-1901 | - | - | - | - | 1件: 271 271 💬 |
2345 | KIN-1902 | - | - | - | - | 1件: 84 84 💬 |
2346 | KINERET*SC 7SIR 100MG 0,67ML | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 3件: 28 28, 46, 107 💬 |
2347 | KIOVIG 100 mg/ml solution for infusion | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 💬 |
2348 | Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 14 14 💬 |
2349 | KN019, 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
2350 | Koselugo 10mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2351 | KPL-404 | - | - | - | - | 1件: 46 46 💬 |
2352 | KPS-0373 | - | - | - | - | 1件: 18 18 💬 |
2353 | KPS-0373, High dose | - | - | - | - | 1件: 18 18 💬 |
2354 | KPS-0373, Low dose | - | - | - | - | 1件: 18 18 💬 |
2355 | Kreon 25 000 | - | - | - | - | 1件: 299 299 💬 |
2356 | Kreon 25,000 Units | - | - | - | - | 1件: 299 299 💬 |
2357 | KREON de Liberación Inmediata | - | - | - | - | 1件: 299 299 💬 |
2358 | Kreon® 25,000 | - | - | - | - | 1件: 299 299 💬 |
2359 | KRP-116D | - | - | - | - | 1件: 226 226 💬 |
2360 | Kuvan 100mg soluble tablet | 1件: Sapropterin Sapropterin | 1件: Sapropterin
Sapropterin
💬 | - | - | 1件: 240 240 💬 |
2361 | KVD900 100 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
2362 | KW-0761 | - | - | - | - | 1件: 26 26 💬 |
2363 | KW-0761 0.3 mg/kg IV | - | - | - | - | 1件: 26 26 💬 |
2364 | KW-6356 Low Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2365 | KW-6356 X Dose | 1件: KW-6356 KW-6356 | - | - | - | 1件: 6 6 💬 |
2366 | Kümmel 2ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2367 | L 44 | - | - | - | - | 1件: 96 96 💬 |
2368 | L-000124467 | - | - | - | - | 2件: 13 13, 46 💬 |
2369 | L-000124467 (freebase) | - | - | - | - | 1件: 46 46 💬 |
2370 | L-000124467-009J (succinat | - | - | - | - | 1件: 46 46 💬 |
2371 | L-000883191 | - | - | - | - | 1件: 46 46 💬 |
2372 | L-001069957 | - | - | - | - | 1件: 46 46 💬 |
2373 | L-123 Ioflupane | - | - | - | - | 1件: 6 6 💬 |
2374 | L-3-(3,4-Dihydroxyphenyl)alanine | 1件: Alanine Alanine | 1件: Alanine
Alanine
💬 | - | - | 1件: 6 6 💬 |
2375 | L-Citrulline and Metformin & L-Citrulline | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
2376 | L-leucine | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 284 284 💬 |
2377 | L-Lysine N acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
2378 | L-Lysine N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
2379 | L-Lysine- N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
2380 | L-Lysine-N-acetyl-L-cysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
2381 | L-Lysine-N-acetylcysteinate | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 299 299 💬 |
2382 | L-Lysyl-D-Prolyl-L-Threonine Acetate | 2件: Acetate Acetate, Threonine | 1件: Threonine
Threonine
💬 | - | - | 1件: 97 97 💬 |
2383 | L-Lysyl-D-Prolyl-LThreonine acetate, lyophilisate | 1件: Acetate Acetate | - | - | - | 1件: 97 97 💬 |
2384 | L-METHIONINE ([11C]METHYL) | 1件: Methionine Methionine | 1件: Methionine
Methionine
💬 | - | - | 1件: 84 84 💬 |
2385 | L03 AB 08 | - | - | - | - | 1件: 13 13 💬 |
2386 | L606 (Liposomal Treprostinil) Inhalation Solution 51ug | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2387 | LABA/LAMA | - | - | - | - | 1件: 299 299 💬 |
2388 | LABP-104 250mg | - | - | - | - | 1件: 49 49 💬 |
2389 | Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: Lactomin
Lactomin
💬 | - | - | 1件: 6 6 💬 |
2390 | Lactobacillus casei rhamnosus (Lcr35) | 1件: Lactobacillus casei Lactobacillus casei | 1件: Lactobacillus casei
Lactobacillus casei
💬 | - | - | 1件: 296 296 💬 |
2391 | Lactobacilus acidophilus & bifidobacterium animalis/lactis | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: Lactomin
Lactomin
💬 | - | - | 1件: 97 97 💬 |
2392 | Lamotrigin ”Nordic Prime 100 mg | - | - | - | - | 1件: 114 114 💬 |
2393 | Lantus 100 units/ml solution for injection in a cartridge | - | - | - | - | 1件: 299 299 💬 |
2394 | Lantus® 100 Units/ml solution for injection in a vial. Lantus® 100 Units/ml solution for injection in a cartridge. Lantus® 100 Units/ml solution for injection in a pre-filled pen | - | - | - | - | 1件: 299 299 💬 |
2395 | Lapaquistat acetate and current lipid-lowering treatment | 2件: Acetate Acetate, Lapaquistat | - | - | - | 1件: 79 79 💬 |
2396 | Lapine T-Lymphocyte Immune Globulin | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 4件: 62 62, 65, 283, 286 💬 |
2397 | Laquinimod 0.3 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2398 | Laquinimod 0.6 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2399 | Laquinimod 1.2 | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2400 | Laquinimod Capsulas 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2401 | Laquinimod Capsules 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2402 | Laquinimod capsules 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 2件: 8 8, 96 💬 |
2403 | Laquinimod Capsules 0.6 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2404 | Laquinimod Cápsulas 0.5 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 96 96 💬 |
2405 | Laquinimod Tablets 0.3 mg | 1件: Laquinimod Laquinimod | - | - | - | 1件: 13 13 💬 |
2406 | Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP | 5件: Dapsone Dapsone, Mycophenolate mofetil, Mycophenolic acid, Prednisolone, Triamcinolone | 5件: Triamcinolone
Triamcinolone
,
Prednisolone
,
Dapsone
,
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
2407 | LAX-101 | 1件: LAX-101 LAX-101 | - | - | - | 1件: 8 8 💬 |
2408 | LC51-0255 | - | - | - | - | 1件: 97 97 💬 |
2409 | LCI699, 1 mg | - | - | - | - | 1件: 75 75 💬 |
2410 | LCI699, 10 mg | - | - | - | - | 1件: 75 75 💬 |
2411 | LCZ696 100 mg | - | - | - | - | 1件: 58 58 💬 |
2412 | LDP-02 | - | - | - | - | 2件: 96 96, 97 💬 |
2413 | Leflunomide 20 mg+prednisone 0.5mg/kg/d | 2件: Leflunomide Leflunomide, Prednisone | 2件: Prednisone
Prednisone
,
Leflunomide
💬 | 2件: DHODH DHODH, NR3C1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism 💬 | 1件: 66 66 💬 |
2414 | Leflunomide(LEF) | 1件: Leflunomide Leflunomide | 1件: Leflunomide
Leflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 224 224 💬 |
2415 | LEMTRADA 12 mg Konzentrat zur Herstellung einer Infusionslösung | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2416 | Letairis 10 mg | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
2417 | Leuplin DPS 11.25mg | - | - | - | - | 1件: 76 76 💬 |
2418 | Leuprolide Acetate (LA) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2419 | Leuprolide acetate 11.25 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2420 | Leuprolide Acetate 45 mg | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2421 | Levemir 100 U/ml solution for injection in a cartridge, Levemir 100 U/ml solution for injection in a pre-filled pen | 1件: Insulin detemir Insulin detemir | 1件: Insulin detemir
Insulin detemir
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
2422 | Levodopa (L-dopa) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2423 | Levodopa (L-DOPA) + Standard care | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2424 | LEVODOPA (LD) | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2425 | Levodopa 100 mg / benserazide 25 mg | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2426 | Levodopa 100 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2427 | Levodopa 125 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2428 | Levodopa 150 mg A CAP | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2429 | Levodopa 25mg/100mg | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2430 | Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2431 | Levodopa carbidopa intestinal gel (LCIG) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2432 | Levodopa, carbidopa, ODM-104 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2433 | Levodopa-4'-Monophosphate | 2件: Foslevodopa Foslevodopa, Levodopa | 2件: Levodopa
Levodopa
,
Foslevodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2434 | Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2435 | Levodopa-carbidopa Immediate Release (LC-IR) Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2436 | Levodopa-Carbidopa Intestinal Gel (LCIG) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2437 | Levodopa-Carbidopa XL tablet (M) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2438 | Levodopa/benserazide 100/25 mg | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2439 | Levodopa/Carbidopa (4:1) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 201 201 💬 |
2440 | Levodopa/Carbidopa (LD/CD) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2441 | Levodopa/carbidopa 100/25 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2442 | LEVOFOLENE 4 MG 30 CPR | 1件: Levoleucovorin Levoleucovorin | - | - | - | 1件: 13 13 💬 |
2443 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
2444 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
2445 | Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | 1件: Aminolevulinic acid Aminolevulinic acid | 1件: Aminolevulinic acid
Aminolevulinic acid
💬 | - | - | 1件: 34 34 💬 |
2446 | Lidocaine 1% Injectable Solution | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 34 34 💬 |
2447 | Lidocaine Releasing Intravesical System - LiRIS® | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 226 226 💬 |
2448 | Linerixibat (GSK2330672) 40 mg | - | - | - | - | 1件: 93 93 💬 |
2449 | Linerixibat (GSK2330672) 45 mg | - | - | - | - | 1件: 93 93 💬 |
2450 | Linerixibat (GSK2330672) 45mg | - | - | - | - | 1件: 93 93 💬 |
2451 | Liofen XL | - | - | - | - | 1件: 13 13 💬 |
2452 | LION-101 dose level 1 | - | - | - | - | 1件: 113 113 💬 |
2453 | LION-101 dose level 2 | - | - | - | - | 1件: 113 113 💬 |
2454 | LIORESAL*50CPR 10MG | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
2455 | Liothyronine I 131 | 2件: Liothyronine Liothyronine, Liothyronine I-131 | 1件: Liothyronine
Liothyronine
💬 | 2件: THRA THRA, THRB 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway 💬 | 2件: 210 210, 212 💬 |
2456 | Lipasa ácida lisosómica, esterasa, colesterol (gen humano LIPA), lipasa ácida lisosómica (gen humano LIPA) | - | - | - | - | 1件: 19 19 💬 |
2457 | LIPASE LIP2 | - | - | - | - | 1件: 299 299 💬 |
2458 | Lipase Lip2 from Yarrowia lipolytica | - | - | - | - | 1件: 299 299 💬 |
2459 | Lipid-lowering agents (Artovastatin) | - | - | - | - | 1件: 50 50 💬 |
2460 | Lipoic acid (LA) with fish oil and LA without fish oil | 2件: Fish oil Fish oil, Lipoic acid | - | - | - | 1件: 13 13 💬 |
2461 | Liposomal Cyclosporine A 10 mg | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 228 228 💬 |
2462 | Liposomal T4N5 lotion | - | - | - | - | 1件: 159 159 💬 |
2463 | LIQ861 100 µg | - | - | - | - | 1件: 86 86 💬 |
2464 | LIQ861 106 µg | - | - | - | - | 1件: 86 86 💬 |
2465 | LiRIS 400 mg | - | - | - | - | 1件: 226 226 💬 |
2466 | LiRIS low dose and LiRIS high dose | - | - | - | - | 1件: 226 226 💬 |
2467 | LiRIS® 400 mg | - | - | - | - | 1件: 226 226 💬 |
2468 | Lisinopril, losartan, and atorvastatin | 3件: Atorvastatin Atorvastatin, Lisinopril, Losartan | 4件: Lisinopril
Lisinopril
,
Atorvastatin
,
Lisinopril
,
Losartan
💬 | 3件: ACE ACE, AGTR1, HMGCR 💬 | 22件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Bile secretion, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Terpenoid backbone biosynthesis, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
2469 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 💬 |
2470 | Lisuride TTS 10cm² | 1件: Lisuride Lisuride | 1件: Lisuride
Lisuride
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2471 | Lithiumcarbonaat 400 PCH tabletten | - | - | - | - | 1件: 2 2 💬 |
2472 | LIV-GAMMA SN Inj.10% | - | - | - | - | 1件: 63 63 💬 |
2473 | Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules | 1件: Lactobacillus delbrueckii bulgaricus Lactobacillus delbrueckii bulgaricus | - | - | - | 1件: 6 6 💬 |
2474 | Live Hookworm Larvae | - | - | - | - | 1件: 13 13 💬 |
2475 | Live Necator americanus larvae | - | - | - | - | 1件: 13 13 💬 |
2476 | LJN452, 0,01 mg | - | - | - | - | 1件: 93 93 💬 |
2477 | LJN452, 0,03 mg | - | - | - | - | 1件: 93 93 💬 |
2478 | LJN452, 0,1 mg | - | - | - | - | 1件: 93 93 💬 |
2479 | Lloprost(Ventavis,BAYQ6252, 10 µg/mL) | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2480 | LMX 4 Topical Cream | - | - | - | - | 1件: 256 256 💬 |
2481 | Local Anesthesia (lidocaine hydrochloride) | 1件: Lidocaine Lidocaine | 2件: Lidocaine
Lidocaine
,
Lidocaine hydrochloride monohydrate
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
2482 | Local Trade Name, 4mg | - | - | - | - | 1件: 6 6 💬 |
2483 | Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) | 4件: Acetate Acetate, Estradiol, Ethinylestradiol, Norethisterone | 3件: Estradiol
Estradiol
,
Norethindrone
,
Ethinyl estradiol
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 💬 |
2484 | Lojuxta 10 mg hard capsules | 1件: Lomitapide Lomitapide | 1件: Lomitapide
Lomitapide
💬 | 1件: MTTP MTTP 💬 | 1件: Fat digestion and absorption Fat digestion and absorption 💬 | 1件: 79 79 💬 |
2485 | Long-Acting Growth Hormone (LAGH) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2486 | Long-circulating liposomal prednisolone | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2487 | Lopinavir/ritonavir + zidovudine + lamivudine | 4件: Lamivudine Lamivudine, Lopinavir, Ritonavir, Zidovudine | 4件: Lamivudine
Lamivudine
,
Zidovudine
,
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
2488 | Loratadina STADA 10 mg | 1件: Loratadine Loratadine | 1件: Loratadine
Loratadine
💬 | 1件: HRH1 HRH1 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬 | 1件: 89 89 💬 |
2489 | Lovastatin, then Minocycline/Lovastatin | 2件: Lovastatin Lovastatin, Minocycline | 2件: Lovastatin
Lovastatin
,
Minocycline
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 206 206 💬 |
2490 | Low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day | 1件: Vitamin D Vitamin D | - | - | - | 1件: 13 13 💬 |
2491 | Low Dose Aspirin (162 mg/day) | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: Aspirin
Aspirin
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
2492 | Low dose BIBF 1120 twice daily | - | - | - | - | 1件: 85 85 💬 |
2493 | Low dose levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2494 | Low dose LX2006 | - | - | - | - | 1件: 18 18 💬 |
2495 | Low Dose MT-1303 | - | - | - | - | 1件: 97 97 💬 |
2496 | Low dose ORTD-1 | - | - | - | - | 1件: 46 46 💬 |
2497 | Low immunogenic interferon-beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2498 | LP-08 20mg | - | - | - | - | 1件: 226 226 💬 |
2499 | LP-08 80mg | - | - | - | - | 1件: 226 226 💬 |
2500 | LP-168 tablet | - | - | - | - | 1件: 13 13 💬 |
2501 | LT-02 | - | - | - | - | 1件: 97 97 💬 |
2502 | LT-02 (modified-release PC pellets) | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 97 97 💬 |
2503 | LTS 0.25mg | - | - | - | - | 1件: 46 46 💬 |
2504 | LTS 0.5mg | - | - | - | - | 1件: 46 46 💬 |
2505 | LTS 1.0mg | - | - | - | - | 1件: 46 46 💬 |
2506 | Lu 00-800 | - | - | - | - | 1件: 6 6 💬 |
2507 | Lumacaftor/ivacaftor 100mg/125mg tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2508 | Lumacaftor/ivacaftor 200mg/125mg | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2509 | Lumacaftor/ivacaftor 200mg/125mg tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
2510 | Lumentin 44 | - | - | - | - | 1件: 96 96 💬 |
2511 | Lung Spheroid Stem Cells 100 million | - | - | - | - | 1件: 85 85 💬 |
2512 | Luphere depot 3.75mg(Leuprolide acetate 3.75mg) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2513 | Lupron (leuprolide acetate) | 2件: Acetate Acetate, Leuprolide | - | - | - | 1件: 76 76 💬 |
2514 | Lutein (10 or 30 mg/day) capsules | 1件: Lutein Lutein | - | - | - | 1件: 90 90 💬 |
2515 | LX3305 low dose | - | - | - | - | 1件: 46 46 💬 |
2516 | Lym-X-Sorb powder | - | - | - | - | 1件: 299 299 💬 |
2517 | LymphoStat-B®, monoclonal anti-BLyS, LSB, BENLYSTA® | 1件: Belimumab Belimumab | 1件: Belimumab
Belimumab
💬 | 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 💬 |
2518 | Lysomucil 10 % | - | - | - | - | 1件: 299 299 💬 |
2519 | Lysosomal acid lipase, Esterase cholesterol (human gene LIPA), Lysosomal acid lipase (human gene LIPA) | 1件: Cholesterol Cholesterol | 1件: Cholesterol
Cholesterol
💬 | - | - | 1件: 19 19 💬 |
2520 | Lysosomal acid lipase, Esterase, cholesterol (human gene LIPA), Lysosomal acid lipase (human gene LIPA) | 1件: Cholesterol Cholesterol | 1件: Cholesterol
Cholesterol
💬 | - | - | 1件: 19 19 💬 |
2521 | LYT-100 | - | - | - | - | 1件: 85 85 💬 |
2522 | M5049 low dose | - | - | - | - | 1件: 49 49 💬 |
2523 | MABCAMPATH 10 mg/ml concentrado para solución para perfusión | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2524 | MabCampath-1h | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 13 13 💬 |
2525 | MABTHERA - 1 FIALA 500 MG 50 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 14 14, 53 💬 |
2526 | MABTHERA - 2 FIALE 100 MG 10 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 19 19, 65 💬 |
2527 | MabThera 100 mg concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 💬 |
2528 | MabThera 100mg | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2529 | MabThera 500 mg (10 mg/ml) concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2530 | MabThera 500 mg (10mg/ml) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2531 | MABTHERA*EV 1FL 50ML 500MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 46 46, 222 💬 |
2532 | MabThera® 100MG | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 43 43 💬 |
2533 | MabThera®, 100 mg Concentrado para solución para perfusión | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2534 | MabThera®, 100 mg concentrate for solution for infusion | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
2535 | Macitentan (ACT-064992) | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2536 | Macitentan 10 mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 💬 |
2537 | Macitentan 10 mg tablet, once daily. | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
2538 | Macitentan 10mg | 1件: Macitentan Macitentan | 1件: Macitentan
Macitentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 88 💬 |
2539 | Macrogol 4000 | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
2540 | Madopar 125 mg T, tablets | - | - | - | - | 1件: 6 6 💬 |
2541 | Madopar 125 mg, orodispersible tablet | - | - | - | - | 1件: 6 6 💬 |
2542 | Madopar LT | - | - | - | - | 1件: 6 6 💬 |
2543 | Madopar Tab. 125 or Perkin Tab. 25-100mg | - | - | - | - | 1件: 6 6 💬 |
2544 | Madopar® 125 | - | - | - | - | 1件: 6 6 💬 |
2545 | Madopar® 125 mg T Tablets Levodopa 100 mg Benserazide 25 mg (as benserazide hydrochloride) | 2件: Benserazide Benserazide, Levodopa | 2件: Levodopa
Levodopa
,
Benserazide
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2546 | Madopar® HBS 125 | - | - | - | - | 1件: 6 6 💬 |
2547 | MANNITOLO 18% | - | - | - | - | 1件: 2 2 💬 |
2548 | MANNITOLO 18% LDB | - | - | - | - | 1件: 2 2 💬 |
2549 | MANTADAN*20CPR 100MG | - | - | - | - | 1件: 13 13 💬 |
2550 | Maralixibat (formely SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 3件: 296 296, 297, 338 💬 |
2551 | Maralixibat (formerly SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
2552 | Maralixibat (in precedenza SHP625 o LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
2553 | Masitinib (3.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2554 | Masitinib (4.5) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 13 💬 |
2555 | Masitinib (6.0) | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2556 | Masitinib 100 mg Tablets | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 2 2 💬 |
2557 | Masitinib 100mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 2件: 2 2, 5 💬 |
2558 | Masitinib 6.0 mg | 1件: Masitinib Masitinib | 1件: Masitinib
Masitinib
💬 | 1件: KIT KIT 💬 | 11件: Acute myeloid leukemia Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway 💬 | 1件: 46 46 💬 |
2559 | MATRICARIA RECUTITA L. FLOS | - | - | - | - | 1件: 97 97 💬 |
2560 | MAVENCLAD - 10 MG - COMPRESSA - USO ORALE - BLISTER (AL/AL) - 6 COMPRESSE | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2561 | MAVENCLAD 10 mg tablets | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2562 | Mavenclad tabletter 10 mg | 1件: Cladribine Cladribine | 1件: Cladribine
Cladribine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
2563 | Mavrilimumab 10 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2564 | Mavrilimumab 100 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2565 | Mavrilimumab 150 mg | 1件: Mavrilimumab Mavrilimumab | 1件: Mavrilimumab
Mavrilimumab
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 46 46 💬 |
2566 | Mayzent 0,25 mg Filmtabletten | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2567 | Mayzent 0.25 mg fi | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
2568 | MB-102 | - | - | - | - | 1件: 96 96 💬 |
2569 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
2570 | MBS2320 40 mg | - | - | - | - | 1件: 46 46 💬 |
2571 | MBX-8025 50 mg (Dose Escalation Period 1) | - | - | - | - | 1件: 79 79 💬 |
2572 | MBX-8025 50 mg or 100 mg (Dose Escalation Period 2) | - | - | - | - | 1件: 79 79 💬 |
2573 | MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3) | - | - | - | - | 1件: 79 79 💬 |
2574 | MCI-186 | - | - | - | - | 1件: 2 2 💬 |
2575 | MCI-186 in open label phase | - | - | - | - | 1件: 2 2 💬 |
2576 | MD-0901 | - | - | - | - | 1件: 97 97 💬 |
2577 | MD1003 100 mg capsule | - | - | - | - | 1件: 20 20 💬 |
2578 | MD1003 100mg capsule | - | - | - | - | 1件: 13 13 💬 |
2579 | MDGN-002 | - | - | - | - | 1件: 96 96 💬 |
2580 | MDX-1100 | - | - | - | - | 3件: 46 46, 96, 97 💬 |
2581 | MDX-1100 (anti-CXCL10 human monoclonal antibody) | - | - | - | - | 1件: 97 97 💬 |
2582 | MDX-1342 | - | - | - | - | 1件: 46 46 💬 |
2583 | Mecasermin [rDNA Origin] 10mg/ml solution | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2584 | MEDI-551 100 MG-IV | - | - | - | - | 1件: 13 13 💬 |
2585 | MEDI-570 0.03 MG | - | - | - | - | 1件: 49 49 💬 |
2586 | MEDI-570 0.1 MG | - | - | - | - | 1件: 49 49 💬 |
2587 | MEDI-570 0.3 MG | - | - | - | - | 1件: 49 49 💬 |
2588 | MEDI-570 1 MG | - | - | - | - | 1件: 49 49 💬 |
2589 | MEDI7183 low dose | - | - | - | - | 1件: 97 97 💬 |
2590 | MEDROL - 4 MG COMPRESSE 30 COMPRESSE | - | - | - | - | 1件: 56 56 💬 |
2591 | Medrol 4 mg tablets | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2592 | Medrol A 16 mg tablets | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
2593 | MEDROL*10CPR DIV 4MG | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
2594 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
2595 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: Melarsoprol
Melarsoprol
,
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
2596 | Melissenblätter 15ml/10ml | - | - | - | - | 1件: 97 97 💬 |
2597 | Meloxicam 0.125 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2598 | Meloxicam 0.25 mg/kg | 1件: Meloxicam Meloxicam | 1件: Meloxicam
Meloxicam
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2599 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2600 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2601 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae, Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 💬 |
2602 | MENTHA × PIPERITA L. FOLIUM | - | - | - | - | 1件: 97 97 💬 |
2603 | MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC | 9件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, Meningococcal polysaccharide vaccine group A, Meningococcal polysaccharide vaccine group C, Meningococcal polysaccharide vaccine group W-135, Meningococcal polysaccharide vaccine group Y, Neisseria meningitidis group a capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group c capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group w-135 capsular oligosaccharide diphtheria crm197 protein conjugate antigen, Neisseria meningitidis group y capsular oligosaccharide diphtheria crm197 protein conjugate antigen | 2件: Meningococcal polysaccharide vaccine group A
Meningococcal polysaccharide vaccine group A
,
Meningococcal polysaccharide vaccine group C
💬 | - | - | 2件: 62 62, 66 💬 |
2604 | Mepolizumab 100 mg | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 98 98 💬 |
2605 | Meropenem Fresenius Kabi 1 g poeder voor oplossing voor injectie of infusie | 1件: Meropenem Meropenem | 2件: Meropenem
Meropenem
,
Meropenem
💬 | - | - | 1件: 299 299 💬 |
2606 | Mesalamine Delayed Release Tablets 400mg | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2607 | Mesalazine - TID 1000 mg | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2608 | Mesalazine 1000 mg gastro-resistant tablets | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2609 | Mesalazine 4G Enema | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2610 | Mesalazine liquid enema | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2611 | Mesenchymal stem cell 0.5 | - | - | - | - | 1件: 228 228 💬 |
2612 | Mesenchymal stem cell 1.0 | - | - | - | - | 1件: 228 228 💬 |
2613 | Metalcaptase® 150 mg gastro-resistant tablet | - | - | - | - | 1件: 171 171 💬 |
2614 | Metex 10 mg/ml Injektionslösung, Fertigspritze | - | - | - | - | 1件: 46 46 💬 |
2615 | Metex 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
2616 | MetFORMIN 1000 Mg Oral Tablet | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
2617 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
2618 | Metformin and Metformin & L-Citrulline | 2件: Citrulline Citrulline, Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 113 113 💬 |
2619 | Metformin XR | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
2620 | Methotrexat Lachema 2,5mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2621 | Methotrexat Lachema 2,5mg tbl. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2622 | Methotrexat Lachema 5 inj. sol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2623 | METHOTREXAT Lederle - Tabletten | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2624 | Methotrexat Lederle 2.5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2625 | Methotrexate 'Lederle' 2,5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2626 | Methotrexate 'Lederle' 2.5mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2627 | Methotrexate 'Lederle' Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2628 | METHOTREXATE - 20 MG/0.8 ML SOLUZIONE INIETTABILE 4 SIRINGHE PRERIEMPITE MONOUSO DA 1.25 ML | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 96 96 💬 |
2629 | Methotrexate 10 mg | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2630 | Methotrexate 10 mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2631 | Methotrexate ``Lederle`` 2.5mg tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2632 | Methotrexate Lachema 5inj. sol | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2633 | Methotrexate Lederle 2.5 mg Tablets | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2634 | Methotrexate plus ERB-041 for 12 weeks | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2635 | METHOTREXATE*100CPR 2,5MG | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2636 | METHOTREXATE*10MG/1,33ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2637 | METHOTREXATE*15MG/2ML 4SIR | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2638 | METHOTREXATE*20MG/2,66ML 4S | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2639 | METHOTREXATE*7,5MG/ML 4SIR. | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2640 | Methotrexate, Leucovorin and BMS-986142 | 3件: BMS-986142 BMS-986142, Leucovorin, Methotrexate | 3件: Methotrexate
Methotrexate
,
Folinic acid
,
Folinic acid calcium salt pentahydrate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2641 | Methotrexate-Lachema | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2642 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-beta-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
2643 | Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-ß-Dribofuronamide | 1件: Adenine Adenine | 1件: Adenine
Adenine
💬 | - | - | 1件: 46 46 💬 |
2644 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo | - | - | - | - | 1件: 86 86 💬 |
2645 | Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb | - | - | - | - | 2件: 86 86, 88 💬 |
2646 | Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth | - | - | - | - | 2件: 86 86, 88 💬 |
2647 | Methylphenidate 10mg tablets | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 84 84 💬 |
2648 | Methylphenidate modified release 40 mg | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
2649 | Methylprednisolone 1250 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
2650 | Methylprednisolone bolus IV 15 mg/kg/d for 3 days. | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 💬 |
2651 | Methylprednisolone(intravenously in the 1st-2nd-3rd month ) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
2652 | Methylprednisolone(intravenously in the 1st-3rd-5th month) | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 66 66 💬 |
2653 | METILPREDNISOLONE HIKMA - 1000 MG POLVERE PER SOLUZIONE INIETTABILE 10 FLACONCINI IN VETRO | - | - | - | - | 1件: 300 300 💬 |
2654 | METOCLOPRAMIDE ACCORD - 10 MG COMPRESSE 28 COMPRESSE IN BLISTER PVC/PVDC/AL | 1件: Metoclopramide Metoclopramide | 1件: Metoclopramide
Metoclopramide
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 51 51 💬 |
2655 | MetoHEXAL® Succ ® 47,5 mg Retardtabletten | - | - | - | - | 1件: 113 113 💬 |
2656 | Metoject 10 mg/ml | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 💬 |
2657 | METOJECT 10 mg/ml, solution injectable en seringue pré-remplie | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 44 44 💬 |
2658 | METOTREXATO-LEDERLE 2,5 MG COMPRIMIDOS | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2659 | Mexiletine 167 mg | 1件: Mexiletine Mexiletine | 1件: Mexiletine
Mexiletine
💬 | 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 113 113 💬 |
2660 | Mezavant 1200 mg magensaftresistente Retardtabletten | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2661 | Mezavant XL | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2662 | Mezavant XL 1200 mg gastro-resistant prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2663 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2664 | Mezavant XL 1200 mg gastro-resistant, prolonged release tablets. | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2665 | Mezavant XL 1200mg gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2666 | Mezavant XL Gastro-resistant, prolonged release tablets | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2667 | MG-O-1002 | - | - | - | - | 1件: 11 11 💬 |
2668 | MH004 Ia(0.1%) | - | - | - | - | 1件: 46 46 💬 |
2669 | MH004 Ia(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2670 | MH004 Ia(1%) | - | - | - | - | 1件: 46 46 💬 |
2671 | MH004 Ib-1(0.1%) | - | - | - | - | 1件: 46 46 💬 |
2672 | MH004 Ib-1(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2673 | MH004 Ib-1(1%) | - | - | - | - | 1件: 46 46 💬 |
2674 | MH004 Ib-2(0.3%) | - | - | - | - | 1件: 46 46 💬 |
2675 | MH004 Ib-2(1%) | - | - | - | - | 1件: 46 46 💬 |
2676 | Migalastat HCl 150 mg | 1件: Migalastat Migalastat | 1件: Migalastat
Migalastat
💬 | - | - | 1件: 19 19 💬 |
2677 | MIN-102 | - | - | - | - | 2件: 18 18, 20 💬 |
2678 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: Deferoxamine
Deferoxamine
💬 | - | - | 2件: 51 51, 53 💬 |
2679 | Minocycline 100 mg Film-coated Tablets | 1件: Minocycline Minocycline | 1件: Minocycline
Minocycline
💬 | - | - | 1件: 13 13 💬 |
2680 | Minocycline 100mg | 1件: Minocycline Minocycline | 1件: Minocycline
Minocycline
💬 | - | - | 1件: 13 13 💬 |
2681 | Minocycline, then Minocycline/Lovastatin | 2件: Lovastatin Lovastatin, Minocycline | 2件: Lovastatin
Lovastatin
,
Minocycline
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 206 206 💬 |
2682 | Mirapex LA | - | - | - | - | 1件: 6 6 💬 |
2683 | MIRAPEXIN*30CPR 0,7MG | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2684 | Mirdametinib (PD-0325901) oral capsule or dispersible tablet | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2685 | Mitoxantrone Hydrochloride Liposome Injection | 1件: Mitoxantrone Mitoxantrone | 1件: Mitoxantrone
Mitoxantrone
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 13 13 💬 |
2686 | MK-0653 | - | - | - | - | 1件: 260 260 💬 |
2687 | MK-0663 | - | - | - | - | 2件: 46 46, 271 💬 |
2688 | MK-0859 | - | - | - | - | 1件: 79 79 💬 |
2689 | MK-0873 | 1件: MK-0873 MK-0873 | - | - | - | 1件: 46 46 💬 |
2690 | MK-4836 | - | - | - | - | 2件: 86 86, 88 💬 |
2691 | MK-8457 100 mg | - | - | - | - | 1件: 46 46 💬 |
2692 | MK0812 / Duration of Treatment: 12 Weeks | - | - | - | - | 1件: 46 46 💬 |
2693 | MM-093 | 1件: MM-093 MM-093 | - | - | - | 1件: 46 46 💬 |
2694 | MMX Mesalamine/Mesalazine (Low Dose) | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
2695 | MN-001 | - | - | - | - | 1件: 226 226 💬 |
2696 | MN-001 BID | - | - | - | - | 1件: 226 226 💬 |
2697 | MN-08 24 mg/day | - | - | - | - | 1件: 86 86 💬 |
2698 | MN-08 60 mg/day | - | - | - | - | 1件: 86 86 💬 |
2699 | MN-166 | - | - | - | - | 1件: 2 2 💬 |
2700 | MNK-1411 | - | - | - | - | 1件: 113 113 💬 |
2701 | Mobilization of stem cells to prepare for Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
2702 | MOD-4023 | - | - | - | - | 1件: 78 78 💬 |
2703 | Moderna COVID-19 Vaccine | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 1件: 46 46 💬 |
2704 | Moderna mRNA-1273 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2705 | Moderna mRNA-1273, Bivalent | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2706 | Modified lipid formulation | - | - | - | - | 1件: 299 299 💬 |
2707 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 💬 |
2708 | Modopar 125 | - | - | - | - | 1件: 6 6 💬 |
2709 | MOLI 1901 | - | - | - | - | 1件: 299 299 💬 |
2710 | Moli 1901 (2622U90, duramycin) | 1件: Lancovutide Lancovutide | - | - | - | 1件: 299 299 💬 |
2711 | Monomethyl fumarate 190 mg | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: Monomethyl fumarate
Monomethyl fumarate
💬 | - | - | 1件: 13 13 💬 |
2712 | Monotherapy (Lopinavir/ritonavir) | 2件: Lopinavir Lopinavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
2713 | Monotherapy (Lopinavir/ritonavir) + ABC/3TC | 2件: Lopinavir Lopinavir, Ritonavir | 2件: Ritonavir
Ritonavir
,
Lopinavir
💬 | - | - | 1件: 265 265 💬 |
2714 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 💬 |
2715 | MORAb-022 | - | - | - | - | 1件: 46 46 💬 |
2716 | MORF-057 | - | - | - | - | 1件: 97 97 💬 |
2717 | Moxifloxacin 400 mg | 1件: Moxifloxacin Moxifloxacin | 1件: Moxifloxacin
Moxifloxacin
💬 | - | - | 1件: 86 86 💬 |
2718 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
2719 | MP-376 (Levofloxacin Solution for Inhalation) | 1件: Levofloxacin Levofloxacin | 2件: Levofloxacin
Levofloxacin
,
Levofloxacin
💬 | - | - | 1件: 299 299 💬 |
2720 | MP-435(dose1) + Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
2721 | MR-MC-01 | - | - | - | - | 1件: 226 226 💬 |
2722 | MRA 003 US | - | - | - | - | 1件: 49 49 💬 |
2723 | MRC375 150mg | - | - | - | - | 1件: 46 46 💬 |
2724 | MRNA che codifica l’enzima umano deramificante del glicogeno formulato in una nanopaticella lipidica | - | - | - | - | 1件: 257 257 💬 |
2725 | MRNA encoding the human glycogen debranching enzyme formulated in a lipid nanoparticle delivery | - | - | - | - | 1件: 257 257 💬 |
2726 | MRX Drug Substance (formerly Maralixibat , SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
2727 | MRX Drug Substance (formerly Maralixibat, SHP625 or LUM001) | 1件: Maralixibat Maralixibat | 1件: Maralixibat
Maralixibat
💬 | 2件: SLC10A1 SLC10A1, SLC10A2 💬 | 2件: Bile secretion Bile secretion, Hepatitis B 💬 | 1件: 338 338 💬 |
2728 | MSC injection 01 | - | - | - | - | 1件: 96 96 💬 |
2729 | MSC injection 02 | - | - | - | - | 1件: 96 96 💬 |
2730 | MSC treatment 01 | - | - | - | - | 1件: 96 96 💬 |
2731 | MSC treatment 02 | - | - | - | - | 1件: 96 96 💬 |
2732 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 💬 |
2733 | MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046) | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2734 | MSI-1995 | - | - | - | - | 1件: 299 299 💬 |
2735 | MSTC-001 (MS-STAT) | - | - | - | - | 1件: 13 13 💬 |
2736 | MT-1186 | - | - | - | - | 1件: 2 2 💬 |
2737 | MT-1303 | - | - | - | - | 3件: 13 13, 96, 97 💬 |
2738 | MT-1303 [0.1] | - | - | - | - | 1件: 13 13 💬 |
2739 | MT-1303 [0.2] | - | - | - | - | 1件: 13 13 💬 |
2740 | MT-1303 [0.4] | - | - | - | - | 1件: 13 13 💬 |
2741 | MT-1303 High dose | - | - | - | - | 1件: 49 49 💬 |
2742 | MT-1303 Low dose | - | - | - | - | 1件: 49 49 💬 |
2743 | MT-1303-FormA | - | - | - | - | 1件: 13 13 💬 |
2744 | MT-1303-FormB | - | - | - | - | 1件: 13 13 💬 |
2745 | MT-1303-High | - | - | - | - | 1件: 13 13 💬 |
2746 | MT-1303-Low | - | - | - | - | 1件: 13 13 💬 |
2747 | MT-1303-Middle | - | - | - | - | 1件: 13 13 💬 |
2748 | MT-7117 Low Dose | - | - | - | - | 1件: 254 254 💬 |
2749 | MTC TRx0014-001 capsules | - | - | - | - | 1件: 127 127 💬 |
2750 | MTP-131 | - | - | - | - | 1件: 21 21 💬 |
2751 | MTX 12.5 | - | - | - | - | 1件: 97 97 💬 |
2752 | Multienzymes (lipase, protease etc.) | - | - | - | - | 2件: 298 298, 299 💬 |
2753 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
2754 | MultiStem low dose | 1件: MultiStem MultiStem | - | - | - | 1件: 97 97 💬 |
2755 | Mycophenolate mofetil orally 1000 mg twice a day (BID) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
2756 | Mycophenolate mofetil plus lower dose of Prednisone | 3件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid, Prednisone | 3件: Prednisone
Prednisone
,
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 3件: IMPDH1 IMPDH1, IMPDH2, NR3C1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Purine metabolism 💬 | 1件: 66 66 💬 |
2757 | Mycophenolate mofetil, low dose steroid | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
2758 | Myeloablative Conditioning-Closed with amendment L | - | - | - | - | 1件: 65 65 💬 |
2759 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
2760 | MYELOSTIM 34*1FL 263MCG+1SIR | - | - | - | - | 1件: 2 2 💬 |
2761 | Myfortic 180 mg | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
2762 | Myfortic 180 mg Filmtabletten | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 162 162 💬 |
2763 | Myfortic 180mg Tablets | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 2件: 66 66, 222 💬 |
2764 | Myfortic plus low-dose steroid | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 222 222 💬 |
2765 | MYK-461 | - | - | - | - | 1件: 58 58 💬 |
2766 | MYO-029 | 1件: Stamulumab Stamulumab | 1件: Stamulumab
Stamulumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
2767 | MYONAL*30CPR RIV 100MG | - | - | - | - | 1件: 2 2 💬 |
2768 | N Acetyl L Leucine | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 19 19 💬 |
2769 | N(4,5Bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
2770 | N,N,N',N'-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2771 | N,N,N?,N?-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2772 | N,N,N’,N’-tetramethyl-10H-phenothiazine-3,7-diaminium bis(methanesulfonate) | 1件: Phenothiazine Phenothiazine | 1件: Phenothiazine
Phenothiazine
💬 | - | - | 1件: 127 127 💬 |
2773 | N-(4,5-Bis methanesulfonyl-2-methyl-benzoyl)guanidine hydrochloride monohydrate | 1件: Guanidine Guanidine | - | - | - | 1件: 113 113 💬 |
2774 | N-(5-hydroxy-2,4- bis(trimethylsilyl)phenyl)-4-oxo- 1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2775 | N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2776 | N-(5-{4-[(3,3-dimethyl-1-azetidinyl)carbonyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide | - | - | - | - | 1件: 49 49 💬 |
2777 | N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide | - | - | - | - | 1件: 299 299 💬 |
2778 | N-0923 | - | - | - | - | 1件: 6 6 💬 |
2779 | N-3 LC-PUFA | - | - | - | - | 1件: 46 46 💬 |
2780 | N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide | 2件: Acetamide Acetamide, Pyrazole | - | - | - | 1件: 154 154 💬 |
2781 | N-Acetyl-L Leucine | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 19 19 💬 |
2782 | N-Acetyl-L-Leucine | 2件: L-Acetylleucine L-Acetylleucine, Leucine | 1件: Leucine
Leucine
💬 | - | - | 2件: 19 19, 65 💬 |
2783 | N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
2784 | N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium | - | - | - | - | 1件: 28 28 💬 |
2785 | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | - | - | - | - | 1件: 13 13 💬 |
2786 | N-trans-3-Hexenoyl] Human Growth Hormone Releasing Factor (1-44) Acetate | 2件: Acetate Acetate, Somatotropin | - | - | - | 1件: 265 265 💬 |
2787 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamide, sodium | - | - | - | - | 1件: 96 96 💬 |
2788 | N-{4-Chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl)benzenesulfonamidesodium | - | - | - | - | 1件: 96 96 💬 |
2789 | Nab-sirolimus (also known as ABI-009, nab-rapamycin, albumin-bound rapamycin) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 86 86 💬 |
2790 | Nabilone 0.25 mg | 1件: Nabilone Nabilone | 1件: Nabilone
Nabilone
💬 | 2件: CNR1 CNR1, CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 6 6 💬 |
2791 | NaCl 0.9% | - | - | - | - | 1件: 39 39 💬 |
2792 | NACOM 100 | - | - | - | - | 1件: 6 6 💬 |
2793 | NACOM levodopa+cardidopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2794 | Nanogam 100 mg/ml | - | - | - | - | 1件: 65 65 💬 |
2795 | Naproxen 10 mg/kg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
2796 | Natalizumab 300 MG in 15 ML Injection | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
2797 | National Drug Code: 59762-0074 | - | - | - | - | 1件: 81 81 💬 |
2798 | Natriumchlorid 0,9 % | 1件: Sodium chloride Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 288 288 💬 |
2799 | NBTX-001 | - | - | - | - | 1件: 6 6 💬 |
2800 | NC 1 cell therapy | - | - | - | - | 1件: 117 117 💬 |
2801 | ND-L02-s0201 | - | - | - | - | 1件: 85 85 💬 |
2802 | ND-L02-s0201 for injection | - | - | - | - | 1件: 85 85 💬 |
2803 | ND0612 (Levodopa/Carbidopa solution) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2804 | NDC0009-0436-01 | - | - | - | - | 1件: 78 78 💬 |
2805 | NEB/01-07 | - | - | - | - | 1件: 299 299 💬 |
2806 | Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection | 3件: Testosterone Testosterone, Testosterone undecanoate, Undecanoic acid | 2件: Testosterone
Testosterone
,
Testosterone undecanoate
💬 | 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 💬 |
2807 | Nebulization of Amikacin during NIV (RR: 15 cycles/minute) | 1件: Amikacin Amikacin | 1件: Amikacin
Amikacin
💬 | - | - | 1件: 299 299 💬 |
2808 | Needle biopsy of the vastus lateralis muscle | - | - | - | - | 1件: 113 113 💬 |
2809 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 💬 |
2810 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 💬 |
2811 | Neophyr 1000ppm mol/mol | - | - | - | - | 1件: 294 294 💬 |
2812 | NERIXIA*IM EV 1F 25MG | - | - | - | - | 1件: 6 6 💬 |
2813 | NERIXIA*INFUS IV CONC 2F 100MG | - | - | - | - | 1件: 274 274 💬 |
2814 | Neu-120 | - | - | - | - | 1件: 6 6 💬 |
2815 | Neumega (Oprelvekin, Interleukin 11, IL-11) | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
2816 | NEUPRO 4 mg/24 h parche transdérmico | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2817 | Neupro 4 mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2818 | Neupro 4mg/24 h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2819 | Neupro 4mg/24h transdermal patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2820 | Neupro 4Mg/24Hr Transdermal Patch | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2821 | NEUPRO*28CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2822 | NEUPRO*7CER 4MG/24H | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2823 | New Formulation of rebif - human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
2824 | Nexavar (BAY 43-9006) (Sorafenib) | 1件: Sorafenib Sorafenib | 1件: Sorafenib
Sorafenib
💬 | 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
2825 | NFC-1 | - | - | - | - | 1件: 203 203 💬 |
2826 | NFX-179 Gel | - | - | - | - | 1件: 34 34 💬 |
2827 | NG-Monomethyl-L-arginine | 3件: Arginine Arginine, L-arginine, Tilarginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 67 67 💬 |
2828 | Ng-monomethyl-L-arginine (drug) | 3件: Arginine Arginine, L-arginine, Tilarginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 67 67 💬 |
2829 | NGN-101 | - | - | - | - | 1件: 19 19 💬 |
2830 | NI-0101 | - | - | - | - | 1件: 46 46 💬 |
2831 | NI-03 | - | - | - | - | 1件: 298 298 💬 |
2832 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab | - | - | - | 1件: 96 96 💬 |
2833 | NI-0501 | - | - | - | - | 1件: 107 107 💬 |
2834 | NI-071 | - | - | - | - | 1件: 46 46 💬 |
2835 | NI-0801 | - | - | - | - | 1件: 93 93 💬 |
2836 | Nicorette 10mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2837 | Nicorette 15 mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2838 | Nicorette 5 mg/ 16 h | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2839 | Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) | 1件: Nicotine Nicotine | 1件: Nicotine
Nicotine
💬 | 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 8件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Virion - Lyssavirus 💬 | 1件: 6 6 💬 |
2840 | Nicotinell 17,5 mg/24-Stunden-Pflaster | - | - | - | - | 1件: 6 6 💬 |
2841 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
2842 | Nilotinib 150 MG | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 8 8 💬 |
2843 | Nilotinib 150mg oral capsule [Tasigna] | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
2844 | Nintedanib 150 mg and 100 mg soft capsules | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 227 227 💬 |
2845 | Nitisinone 10 mg Tablet High Compritol | 1件: Nitisinone Nitisinone | 1件: Nitisinone
Nitisinone
💬 | 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 💬 |
2846 | Nitric Oxide 160 ppm | 1件: Nitric Oxide Nitric Oxide | 1件: Nitric oxide
Nitric oxide
💬 | - | - | 1件: 299 299 💬 |
2847 | NLX-112 | - | - | - | - | 1件: 6 6 💬 |
2848 | NN 1841 | - | - | - | - | 1件: 288 288 💬 |
2849 | NNC 0109-0000-0012 | - | - | - | - | 1件: 46 46 💬 |
2850 | NNC 0141-0000-0100 | - | - | - | - | 1件: 46 46 💬 |
2851 | NNC 0142-0000-0002 | - | - | - | - | 2件: 46 46, 96 💬 |
2852 | NNC 0151-0000-0000 | - | - | - | - | 2件: 46 46, 49 💬 |
2853 | NNC 126-0083 | - | - | - | - | 1件: 78 78 💬 |
2854 | NNC 142-0002 | - | - | - | - | 1件: 46 46 💬 |
2855 | NNC0109-0012 | - | - | - | - | 1件: 46 46 💬 |
2856 | NNC0114-0000-0005 | - | - | - | - | 1件: 46 46 💬 |
2857 | NNC0114-0006 | - | - | - | - | 3件: 46 46, 49, 96 💬 |
2858 | NNC0142-0000-0002 | - | - | - | - | 1件: 96 96 💬 |
2859 | NNC0142-0002 | - | - | - | - | 1件: 46 46 💬 |
2860 | NNC0151-0000-0000 | - | - | - | - | 1件: 46 46 💬 |
2861 | NNC0195-0092 | - | - | - | - | 1件: 78 78 💬 |
2862 | NNC0195-0092 10 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
2863 | NNC0195-0092 15 mg/1.5 ml PDS290-15 | - | - | - | - | 1件: 78 78 💬 |
2864 | NNC0195-0092 5 mg/1.5 ml PDS290-10 | - | - | - | - | 1件: 78 78 💬 |
2865 | NNC0195-0092 DP 6.7 mg ml 3 ml cartridge | - | - | - | - | 1件: 78 78 💬 |
2866 | NNC0195-0092 PDS290 10 mg-1.5 ml | - | - | - | - | 1件: 78 78 💬 |
2867 | NNC0195-0092 PDS290 10 mg/1.5 ml | - | - | - | - | 1件: 78 78 💬 |
2868 | NNC0215-0384 | - | - | - | - | 2件: 46 46, 162 💬 |
2869 | NNC109-0012 | - | - | - | - | 1件: 46 46 💬 |
2870 | NNC126-0083 | 1件: Somatropin pegol Somatropin pegol | - | - | - | 1件: 78 78 💬 |
2871 | NNC142-0002 | - | - | - | - | 1件: 96 96 💬 |
2872 | NNC151-0000 | - | - | - | - | 1件: 46 46 💬 |
2873 | Norditropin FlexPro 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2874 | Norditropin FlexPro 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2875 | Norditropin FlexPro 10 mg/1.5 ml, solution for injection in pre-filled pen | 1件: Somatotropin Somatotropin | - | - | - | 1件: 195 195 💬 |
2876 | Norditropin FlexPro 5 mg/1.5 mL | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2877 | Norditropin FlexPro 5mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2878 | Norditropin NordiFlex® 10 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2879 | Norditropin NordiFlex® 10mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2880 | Norditropin SimplexX (5mg/1,5 ml) (INN:somatropin) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2881 | Norditropin SimpleXx 10 mg | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2882 | Norditropin SimpleXx 15 mg/1.5 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 3 3 💬 |
2883 | Norditropin SimpleXx 5mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 107 💬 |
2884 | Norditropin® SimpleXx® 5 mg/1.5ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2885 | Normal Saline 0.9% Infusion Solution | - | - | - | - | 1件: 22 22 💬 |
2886 | NORMIX*AD 12CPR RIV 200MG | - | - | - | - | 1件: 96 96 💬 |
2887 | Norvir 100 mg film-coated tablets | - | - | - | - | 1件: 299 299 💬 |
2888 | NovoNorm 0.5 mg | - | - | - | - | 1件: 299 299 💬 |
2889 | NovoNorm 1 mg | - | - | - | - | 1件: 299 299 💬 |
2890 | NovoRapid 100 U/ml, solution for injection in a vial. NovoRapid Penfill 100 U/ml, solution for injection in a cartridge. NovoRapid FlexPen 100 U/ml, solution for injection in a pre-filled pen. | - | - | - | - | 1件: 299 299 💬 |
2891 | NOXAFIL - 40 mg/ml oral suspension | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2892 | NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2893 | NOXAFIL - oral suspension 40 mg/ml | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2894 | Noxafil 100 mg | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2895 | Noxafil 100 mg Tablets Gastro-Resistant | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
2896 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 65 65 💬 |
2897 | NPB-01 | - | - | - | - | 3件: 13 13, 14, 162 💬 |
2898 | NPC-02 | - | - | - | - | 1件: 171 171 💬 |
2899 | NPC-09 | - | - | - | - | 1件: 30 30 💬 |
2900 | NPC-12G gel | - | - | - | - | 2件: 34 34, 158 💬 |
2901 | NPC-12Y gel | - | - | - | - | 1件: 158 158 💬 |
2902 | NPC-14 | - | - | - | - | 1件: 113 113 💬 |
2903 | NPI-001 | - | - | - | - | 2件: 90 90, 303 💬 |
2904 | NR2B NMDA Antagonist CP-101,606 (traxoprodil) | 1件: Ketamine Ketamine | 1件: Ketamine
Ketamine
💬 | 5件: GRIN1 GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 20件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
2905 | NRTX-1001 | - | - | - | - | 1件: 141 141 💬 |
2906 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
2907 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
2908 | NT 101 | - | - | - | - | 4件: 5 5, 6, 7, 17 💬 |
2909 | NT-KO-003 | - | - | - | - | 1件: 13 13 💬 |
2910 | Nucala 100 mg powder for solution for injection | 1件: Mepolizumab Mepolizumab | 1件: Mepolizumab
Mepolizumab
💬 | 1件: IL5 IL5 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 2件: 44 44, 45 💬 |
2911 | NutropinAq 10 mg/2 ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2912 | NutropinAq 10 mg/2 ml (30 UI) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2913 | NUTROPINAq 10 mg/2 ml (30 UI), solución inyectable | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
2914 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 💬 |
2915 | NutropinAq 10mg/2ml solution for injection | 1件: Somatotropin Somatotropin | - | - | - | 1件: 96 96 💬 |
2916 | NW-1015 | - | - | - | - | 1件: 6 6 💬 |
2917 | NW-1015E, EMD 1195686, MSC2191632B | - | - | - | - | 1件: 6 6 💬 |
2918 | NX-13 250 mg | - | - | - | - | 1件: 97 97 💬 |
2919 | NX-13 250mg IR | - | - | - | - | 1件: 97 97 💬 |
2920 | NX-13 500mg IR | - | - | - | - | 1件: 97 97 💬 |
2921 | NX-13 500mg MR | - | - | - | - | 1件: 97 97 💬 |
2922 | NYX-458 | - | - | - | - | 1件: 6 6 💬 |
2923 | O-15 Water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 6 6 💬 |
2924 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 💬 |
2925 | Obeticholic Acid 10 MG | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2926 | OBI-1 | - | - | - | - | 1件: 288 288 💬 |
2927 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 💬 |
2928 | OCA 0.1mg | - | - | - | - | 1件: 296 296 💬 |
2929 | OCA 1,5 mg | - | - | - | - | 1件: 94 94 💬 |
2930 | OCA 1.5mg | - | - | - | - | 1件: 296 296 💬 |
2931 | Ocaliva 10mg | 1件: Obeticholic acid Obeticholic acid | 1件: Obeticholic acid
Obeticholic acid
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
2932 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2933 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2934 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2935 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: Ocrelizumab
Ocrelizumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2936 | Octagam 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 50 50, 63, 65 💬 |
2937 | Octagam® 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 63 63 💬 |
2938 | OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 💬 |
2939 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 💬 |
2940 | Octaplas®LG | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 💬 |
2941 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
2942 | Octreotide LAR | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 2件: 67 67, 227 💬 |
2943 | Octreotide LAR / Sandostatin LAR (LAR=long acting release) | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 💬 |
2944 | Octreotide-LAR | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 67 67 💬 |
2945 | OCU400 Low Dose | - | - | - | - | 1件: 90 90 💬 |
2946 | ODM-101 | - | - | - | - | 1件: 6 6 💬 |
2947 | ODM-101 105mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2948 | ODM-101 65mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
2949 | ODM-104 | - | - | - | - | 1件: 6 6 💬 |
2950 | ODM-109 | - | - | - | - | 1件: 2 2 💬 |
2951 | ODM-109 capsule 1 mg | - | - | - | - | 1件: 2 2 💬 |
2952 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
2953 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
2954 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 💬 |
2955 | Ofatumumab 100 | 1件: Ofatumumab Ofatumumab | 1件: Ofatumumab
Ofatumumab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
2956 | Ofev 100 mg capsule | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
2957 | Ofev 150 mg capsule | 1件: Nintedanib Nintedanib | 1件: Nintedanib
Nintedanib
💬 | 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 💬 |
2958 | OL adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
2959 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 💬 |
2960 | OligoG CF-5/20 - 17.5 mg | - | - | - | - | 1件: 299 299 💬 |
2961 | OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 💬 |
2962 | Oligomero morfolino fosforodiamidato per skipping dell’esone 45 | - | - | - | - | 1件: 113 113 💬 |
2963 | Olokizumab 120 mg | 1件: Olokizumab Olokizumab | 1件: Olokizumab
Olokizumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
2964 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
2965 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 💬 |
2966 | OLUMIANT 4 mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2967 | OLUMIANT 4mg | 1件: Baricitinib Baricitinib | 1件: Baricitinib
Baricitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
2968 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 💬 |
2969 | Omaveloxolone Capsules, 10 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
2970 | Omaveloxolone Capsules, 150 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
2971 | Omaveloxolone Capsules, 160 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
2972 | Omaveloxolone Capsules, 40 mg | 1件: Omaveloxolone Omaveloxolone | 1件: Omaveloxolone
Omaveloxolone
💬 | 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 💬 |
2973 | OMB 157 | - | - | - | - | 1件: 13 13 💬 |
2974 | Omegaven (10% fish-oil emulsion | - | - | - | - | 1件: 46 46 💬 |
2975 | Omegaven 10% | - | - | - | - | 1件: 96 96 💬 |
2976 | Omeprazole (UK licensed generic product) | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 85 85 💬 |
2977 | Omeprazole 40 mg | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 96 96 💬 |
2978 | Omeprazole 40mg Capsule | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 💬 |
2979 | Omeprazole rectally 1mg/kg | 1件: Omeprazole Omeprazole | 1件: Omeprazole
Omeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 294 294 💬 |
2980 | OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 💬 |
2981 | OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: Narsoplimab
Narsoplimab
💬 | 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 💬 |
2982 | OMS721 Drug Product 185 mg/mL | - | - | - | - | 1件: 109 109 💬 |
2983 | ON 01910.NA | - | - | - | - | 1件: 36 36 💬 |
2984 | Onasemnogene Abeparvovec-xioi | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
2985 | One 20cm2/10cm2 autologous skin sheet graft | - | - | - | - | 1件: 160 160 💬 |
2986 | Only 1 arm: treatment with MSC-AFP | - | - | - | - | 1件: 96 96 💬 |
2987 | ONO-4059 | - | - | - | - | 1件: 35 35 💬 |
2988 | ONO-4641 | - | - | - | - | 1件: 13 13 💬 |
2989 | ONO-4641/ MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
2990 | ONO-4641/MSC2430913A | - | - | - | - | 1件: 13 13 💬 |
2991 | OPC-41061 | - | - | - | - | 1件: 67 67 💬 |
2992 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
2993 | Open Label (Avatrombopag tablets) | 1件: Avatrombopag Avatrombopag | 1件: Avatrombopag
Avatrombopag
💬 | 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 💬 |
2994 | Open label - AL001 | 1件: Latozinemab Latozinemab | 1件: Latozinemab
Latozinemab
💬 | 1件: SORT1 SORT1 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Neurotrophin signaling pathway 💬 | 1件: 127 127 💬 |
2995 | Open label Namilumab | 1件: Namilumab Namilumab | - | - | - | 1件: 84 84 💬 |
2996 | Open label RAD001 (only used for post-extension phase) | - | - | - | - | 1件: 158 158 💬 |
2997 | Open Label Topical Beremagene Geperpavec (B-VEC) | - | - | - | - | 1件: 36 36 💬 |
2998 | Open-label Abatacept | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
2999 | Open-label Adalimumab | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3000 | Open-Label CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: Chenodiol
Chenodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 💬 |
3001 | Open-label PTH(1-84) | - | - | - | - | 1件: 235 235 💬 |
3002 | Open-labelAdalimumabRescue | - | - | - | - | 1件: 46 46 💬 |
3003 | OPL-CCL2-LPM | - | - | - | - | 1件: 66 66 💬 |
3004 | Oprelvekin, Interleukin 11, IL-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
3005 | OPRX-106 | - | - | - | - | 1件: 97 97 💬 |
3006 | OPRX-106 (plant cells expressing TNFR-Fc) 2mg | - | - | - | - | 1件: 97 97 💬 |
3007 | OPRX-106 (plant cells expressing TNFR-Fc) 8mg | - | - | - | - | 1件: 97 97 💬 |
3008 | OPS-2071 150 mg | - | - | - | - | 1件: 96 96 💬 |
3009 | Opsumit 10 Mg Tablet | - | - | - | - | 1件: 51 51 💬 |
3010 | Oral levodopa and carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3011 | Oral Levodopa/Carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3012 | Oral LEVOSIMENDAN | 1件: Levosimendan Levosimendan | 1件: Levosimendan
Levosimendan
💬 | 2件: PDE3A PDE3A, PDE3B 💬 | 11件: Apelin signaling pathway Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
3013 | Oral lipoic acid (LA) | 1件: Lipoic acid Lipoic acid | - | - | - | 1件: 13 13 💬 |
3014 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 💬 |
3015 | Oral reduced l-glutathione | 1件: Glutathione Glutathione | 2件: Glutathione
Glutathione
,
Oxiglutatione
💬 | - | - | 1件: 299 299 💬 |
3016 | Oral SCIO-469 capsule | - | - | - | - | 1件: 46 46 💬 |
3017 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3018 | Orelabrutinib (Low Dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 💬 |
3019 | Orelabrutinib( lower dose) | 1件: Orelabrutinib Orelabrutinib | 1件: Orelabrutinib
Orelabrutinib
💬 | 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 💬 |
3020 | Orencia 125 mg | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3021 | ORENCIA 125 mg solution for injection | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3022 | ORENCIA 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 3件: 46 46, 49, 53 💬 |
3023 | ORENCIA 125 mg, solution injectable en seringue préremplie | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
3024 | ORENCIA® 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 65 65 💬 |
3025 | Orfadin oral suspension 4mg/ml | 1件: Nitisinone Nitisinone | 1件: Nitisinone
Nitisinone
💬 | 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 💬 |
3026 | Originator (legacy) drug | - | - | - | - | 4件: 46 46, 96, 97, 271 💬 |
3027 | Orkambi 100 mg/125 mg film-coated tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
3028 | Orkambi 200 mg/125 mg film-coated tablets | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
3029 | Orkambi: contains lumacaftor and ivacaftor | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: Ivacaftor
Ivacaftor
,
Lumacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
3030 | ORL-1B | - | - | - | - | 1件: 255 255 💬 |
3031 | ORM-12471 | - | - | - | - | 1件: 51 51 💬 |
3032 | ORM-12471 30mg | - | - | - | - | 1件: 51 51 💬 |
3033 | ORM-12741 | 1件: ORM-12741 ORM-12741 | - | - | - | 1件: 51 51 💬 |
3034 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: Estradiol
Estradiol
,
Ethinyl estradiol
,
Norgestimate
💬 | 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 💬 |
3035 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: Mestranol
Mestranol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 💬 |
3036 | OSE-127 | - | - | - | - | 2件: 53 53, 97 💬 |
3037 | Osilodrostat 10mg | 1件: Osilodrostat Osilodrostat | 1件: Osilodrostat
Osilodrostat
💬 | 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
3038 | Osilodrostat 1mg | 1件: Osilodrostat Osilodrostat | 1件: Osilodrostat
Osilodrostat
💬 | 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 💬 |
3039 | OsrhAAT 1 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3040 | OsrhAAT 10 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3041 | OsrhAAT 40 mg/kg IV | - | - | - | - | 1件: 231 231 💬 |
3042 | OSSM-001 | - | - | - | - | 1件: 96 96 💬 |
3043 | OST-122 | - | - | - | - | 1件: 97 97 💬 |
3044 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: Apremilast
Apremilast
💬 | 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 💬 |
3045 | OTL-101 | - | - | - | - | 1件: 65 65 💬 |
3046 | OTL-103 | - | - | - | - | 1件: 65 65 💬 |
3047 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 💬 |
3048 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
3049 | OV101 Regimen 1 | - | - | - | - | 1件: 201 201 💬 |
3050 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
3051 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
3052 | Ovastat 1000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
3053 | Over-encapsulated 150 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: Irbesartan
Irbesartan
💬 | 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 💬 |
3054 | OXB-102 | - | - | - | - | 1件: 6 6 💬 |
3055 | OXN 10 mg / 5 mg PR | - | - | - | - | 1件: 6 6 💬 |
3056 | OXN 10/5 mg PR | - | - | - | - | 1件: 226 226 💬 |
3057 | OXN 20 mg / 10 mg PR | - | - | - | - | 1件: 6 6 💬 |
3058 | OXN 20/10 mg PR | - | - | - | - | 1件: 226 226 💬 |
3059 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3060 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
3061 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3062 | Oxycodone/naloxone prolonged release tablets 20/10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: Oxycodone
Oxycodone
,
Naloxone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 💬 |
3063 | Oxycodonhydrochlorid ”Lannacher”, depot tablets | - | - | - | - | 1件: 298 298 💬 |
3064 | Oxycontin LP 10mg | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3065 | Oxycontin LP 20mg | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3066 | Oxycontin LP 5mg | 1件: Oxycodone Oxycodone | 1件: Oxycodone
Oxycodone
💬 | 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3067 | Oxygen 40 % | 1件: Oxygen Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 1件: 85 85 💬 |
3068 | Oxygen, liquid | 1件: Oxygen Oxygen | 1件: Oxygen
Oxygen
💬 | - | - | 2件: 86 86, 88 💬 |
3069 | Oxygen-15 Water | 2件: Oxygen Oxygen, Water | 2件: Water
Water
,
Oxygen
💬 | - | - | 1件: 6 6 💬 |
3070 | Oxytocin 48IU | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 206 206 💬 |
3071 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3072 | Ozanimod 1 mg | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3073 | P 140 | - | - | - | - | 1件: 49 49 💬 |
3074 | P-1037 | - | - | - | - | 1件: 299 299 💬 |
3075 | P-188 NF | - | - | - | - | 1件: 113 113 💬 |
3076 | P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3077 | P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), | 2件: Pramipexole Pramipexole, Rasagiline | 3件: Pramipexole
Pramipexole
,
Rasagiline
,
Rasagiline tartrate
💬 | 4件: DRD2 DRD2, DRD3, DRD4, MAOB 💬 | 18件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3078 | P38 (4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
3079 | P38 Inhibitor (4) | - | - | - | - | 1件: 46 46 💬 |
3080 | P38 Inhibitor (4) 150mg | - | - | - | - | 1件: 46 46 💬 |
3081 | P38 Inhibitor (4) 25mg | - | - | - | - | 1件: 46 46 💬 |
3082 | P38 Inhibitor (4) 300mg | - | - | - | - | 1件: 46 46 💬 |
3083 | P38 Inhibitor (4) 50mg | - | - | - | - | 1件: 46 46 💬 |
3084 | P38 Inhibitor (4) 75mg | - | - | - | - | 1件: 46 46 💬 |
3085 | P38(4) Map Kinase Inhibitor | - | - | - | - | 1件: 46 46 💬 |
3086 | PALOVAROTENE - 1.5mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3087 | PALOVAROTENE - 10 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3088 | PALOVAROTENE - 1mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3089 | PALOVAROTENE - 4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3090 | PALOVAROTENE 1.5 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3091 | Palovarotene dose level 1 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3092 | Palovarotene dose level 2 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3093 | Palovarotene dose level 3 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3094 | Palovarotene dose level 4 | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3095 | PALOVAROTENE-4 mg | 1件: Palovarotene Palovarotene | 1件: Palovarotene
Palovarotene
💬 | 1件: RARG RARG 💬 | - | 1件: 272 272 💬 |
3096 | Pancrease MT 10.5, or MT 21 | - | - | - | - | 1件: 299 299 💬 |
3097 | Panzytrat 25.000 | - | - | - | - | 1件: 298 298 💬 |
3098 | Panzytrat 25.000 FIP-E units of Lipase | - | - | - | - | 1件: 298 298 💬 |
3099 | Panzytrat® 25,000 | - | - | - | - | 1件: 299 299 💬 |
3100 | Paracetamol 120Mg/5mL Oral Suspension | 1件: Acetaminophen Acetaminophen | 1件: Acetaminophen
Acetaminophen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 3 3 💬 |
3101 | PARACETAMOLO DOC GENERICI - 1000 MG COMPRESSA 16 COMPRESSE | - | - | - | - | 1件: 19 19 💬 |
3102 | Parathyroid hormon 1-84 | - | - | - | - | 1件: 235 235 💬 |
3103 | Parathyroid Hormone (1-84) Human Recombinant | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3104 | Paroxetine hydrochloride 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: Prednisolone
Prednisolone
,
Paroxetine
💬 | 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
3105 | Paroxetine Hydrochloride tablets 10 & 20 mg and Prednisolone 1 mg BP | 2件: Paroxetine Paroxetine, Prednisolone | 2件: Prednisolone
Prednisolone
,
Paroxetine
💬 | 2件: NR3C1 NR3C1, SLC6A4 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 46 46 💬 |
3106 | Parsaclisib (1 mg) | 1件: Parsaclisib Parsaclisib | 1件: Parsaclisib
Parsaclisib
💬 | 1件: PIK3CD PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 1件: 61 61 💬 |
3107 | Part 1 Levulan injection | - | - | - | - | 1件: 34 34 💬 |
3108 | Part 1 Levulan surface application | - | - | - | - | 1件: 34 34 💬 |
3109 | Part 1 Levulan surface application twice | - | - | - | - | 1件: 34 34 💬 |
3110 | Part 1 Levulan surface application twice with microneedling | - | - | - | - | 1件: 34 34 💬 |
3111 | Part 1, JM-010 component Group A | - | - | - | - | 1件: 6 6 💬 |
3112 | Part 1, JM-010 component Group B | - | - | - | - | 1件: 6 6 💬 |
3113 | Part 1, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
3114 | Part 1: LJN452 | - | - | - | - | 1件: 93 93 💬 |
3115 | Part 2 Adult Alogabat High Dose (aged 15-17) | - | - | - | - | 1件: 201 201 💬 |
3116 | Part 2, JM-010 combination Group A | - | - | - | - | 1件: 6 6 💬 |
3117 | Part 2, JM-010 combination Group B | - | - | - | - | 1件: 6 6 💬 |
3118 | Part 2, JM-010 component Group C | - | - | - | - | 1件: 6 6 💬 |
3119 | Part 2: LJN452 Dose level 1 | - | - | - | - | 1件: 93 93 💬 |
3120 | Part 2: LJN452 Dose level 2 | - | - | - | - | 1件: 93 93 💬 |
3121 | Part A: 100 mg/mL GSK2618960 | - | - | - | - | 1件: 13 13 💬 |
3122 | Part B Open-Label Extension | - | - | - | - | 1件: 51 51 💬 |
3123 | Part I- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3124 | Part II- naproxen 1000 mg | 1件: Naproxen Naproxen | 1件: Naproxen
Naproxen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 💬 |
3125 | Pasireotide 0.3mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3126 | Pasireotide 0.6 MG/ML | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3127 | Pasireotide 0.6mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3128 | Pasireotide 0.9 mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3129 | Pasireotide 40mg | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 💬 |
3130 | Pasireotide LAR | 1件: Pasireotide Pasireotide | 1件: Pasireotide
Pasireotide
💬 | 4件: SSTR1 SSTR1, SSTR2, SSTR3, SSTR5 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 2件: 67 67, 75 💬 |
3131 | PAT-001, 0.1% | - | - | - | - | 1件: 160 160 💬 |
3132 | PAT-001, 0.2% | - | - | - | - | 1件: 160 160 💬 |
3133 | Patients will be randomized to receive EHP-101 | - | - | - | - | 1件: 51 51 💬 |
3134 | PB1046, VIP-ELP1-120, Vasomera | - | - | - | - | 1件: 86 86 💬 |
3135 | PBF-999 / 160 mg | - | - | - | - | 1件: 8 8 💬 |
3136 | PCCLchimGp91s lentiviral vector transduced CD34+ cells infusion | - | - | - | - | 1件: 65 65 💬 |
3137 | PD 0299685 | - | - | - | - | 1件: 226 226 💬 |
3138 | PD 0299685 at 15mg BID | - | - | - | - | 1件: 226 226 💬 |
3139 | PD 0299685 at 30mg BID | - | - | - | - | 1件: 226 226 💬 |
3140 | PD 0360324 | - | - | - | - | 2件: 46 46, 84 💬 |
3141 | PD patients H&Y=1.5-2 Medications OFF | - | - | - | - | 1件: 6 6 💬 |
3142 | PD patients H&Y=1.5-2 Medications ON | - | - | - | - | 1件: 6 6 💬 |
3143 | PD-0299685 | 1件: PD-0299685 PD-0299685 | - | - | - | 1件: 226 226 💬 |
3144 | PD-0325901 | 1件: Mirdametinib Mirdametinib | 1件: Mirdametinib
Mirdametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3145 | PDA001 (cenplacel-L) | - | - | - | - | 1件: 84 84 💬 |
3146 | PEA-LUT | - | - | - | - | 1件: 127 127 💬 |
3147 | PEG-liposomal Prednisolone Sodium Phosphate | 2件: Phosphate ion Phosphate ion, Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 97 💬 |
3148 | PEGINTERFERON BETA-1A | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3149 | Peginterferone beta 1a | - | - | - | - | 1件: 13 13 💬 |
3150 | PEGINTERFERONE BETA-1A | - | - | - | - | 1件: 13 13 💬 |
3151 | PEGINTERFERONE LAMBDA-1A | - | - | - | - | 1件: 13 13 💬 |
3152 | PEGylated Intereron Beta-1a | - | - | - | - | 1件: 13 13 💬 |
3153 | PEGylated Interferon Beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3154 | PEMINE - 150 MG CAPSULE RIGIDE 50 CAPSULE | - | - | - | - | 1件: 171 171 💬 |
3155 | Pentasa Compact 4g, granulate with prolonged release | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3156 | Pentasa Sachet 1 g | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 2件: 96 96, 97 💬 |
3157 | Pentasa Sachet 1 g prolonged release granules | 2件: Manganese citrate Manganese citrate, Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 96 96 💬 |
3158 | Pentasa Sachet 1g | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3159 | Pentosan polysulfate sodium 100 mg | 1件: Pentosan polysulfate Pentosan polysulfate | - | - | - | 1件: 226 226 💬 |
3160 | Pentoxifylline 400 MG | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬 | - | - | 1件: 97 97 💬 |
3161 | Perform blood cells and fibroblasts biochemical and immuno-labeled investigations | - | - | - | - | 1件: 265 265 💬 |
3162 | Peri-neural Dexamethasone 1 mg | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3163 | Persantin 100 mg | - | - | - | - | 1件: 46 46 💬 |
3164 | Persantin 100 mg and | - | - | - | - | 1件: 46 46 💬 |
3165 | PET with 11C-Flumazenil | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 13 13 💬 |
3166 | PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714 | - | - | - | - | 1件: 85 85 💬 |
3167 | PF 06687234 | - | - | - | - | 2件: 96 96, 97 💬 |
3168 | PF-00489791 | 1件: PF-00489791 PF-00489791 | - | - | - | 1件: 86 86 💬 |
3169 | PF-00547659 | - | - | - | - | 2件: 96 96, 97 💬 |
3170 | PF-00547659 SC injection | - | - | - | - | 2件: 96 96, 97 💬 |
3171 | PF-02545920 | - | - | - | - | 1件: 8 8 💬 |
3172 | PF-04171327 | - | - | - | - | 1件: 46 46 💬 |
3173 | PF-04171327 10 mg | - | - | - | - | 1件: 46 46 💬 |
3174 | PF-04171327 25 mg | - | - | - | - | 1件: 46 46 💬 |
3175 | PF-04236921 | - | - | - | - | 2件: 49 49, 96 💬 |
3176 | PF-04236921 SC injection | - | - | - | - | 1件: 96 96 💬 |
3177 | PF-04383119 | - | - | - | - | 1件: 226 226 💬 |
3178 | PF-05208763 | - | - | - | - | 1件: 67 67 💬 |
3179 | PF-05230917 | - | - | - | - | 1件: 97 97 💬 |
3180 | PF-05280586 | - | - | - | - | 1件: 46 46 💬 |
3181 | PF-05285401 | - | - | - | - | 1件: 97 97 💬 |
3182 | PF-06252616 | 1件: Domagrozumab Domagrozumab | 1件: Domagrozumab
Domagrozumab
💬 | 1件: MSTN MSTN 💬 | 1件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction 💬 | 1件: 113 113 💬 |
3183 | PF-06291826-83/Fx-1006A | 1件: Fx-1006A Fx-1006A | - | - | - | 1件: 28 28 💬 |
3184 | PF-06342674 0.25 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3185 | PF-06342674 1.5 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3186 | PF-06342674 6.0 mg/kg | - | - | - | - | 1件: 13 13 💬 |
3187 | PF-06410293 | - | - | - | - | 1件: 46 46 💬 |
3188 | PF-06412562 | - | - | - | - | 1件: 6 6 💬 |
3189 | PF-06438179 | - | - | - | - | 1件: 46 46 💬 |
3190 | PF-06462700 | - | - | - | - | 1件: 60 60 💬 |
3191 | PF-06480605 | - | - | - | - | 1件: 97 97 💬 |
3192 | PF-06480605 100 mg/ml | - | - | - | - | 1件: 97 97 💬 |
3193 | PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3194 | PF-06649751 - 15mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3195 | PF-06649751 - 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3196 | PF-06649751 - 5mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3197 | PF-06649751 high dose (15 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3198 | PF-06649751 low dose (1 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3199 | PF-06649751 middle dose 1 (3 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3200 | PF-06649751 middle dose 2 (7 mg QD) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3201 | PF-06650833 | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3202 | PF-06650833 100 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3203 | PF-06650833 20 mg | 1件: PF-06650833 PF-06650833 | - | - | - | 1件: 46 46 💬 |
3204 | PF-06651600 | 1件: PF-06651600 PF-06651600 | - | - | - | 3件: 46 46, 96, 97 💬 |
3205 | PF-06651600 10 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 97 97 💬 |
3206 | PF-06651600 50 mg | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
3207 | PF-06651600 50mg | 1件: PF-06651600 PF-06651600 | - | - | - | 1件: 96 96 💬 |
3208 | PF-06651600-15 | 1件: PF-06651600 PF-06651600 | - | - | - | 2件: 96 96, 97 💬 |
3209 | PF-06669571 | - | - | - | - | 1件: 6 6 💬 |
3210 | PF-06687234 | - | - | - | - | 1件: 97 97 💬 |
3211 | PF-06700841 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3212 | PF-06700841 15 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3213 | PF-06700841 25 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 2件: 96 96, 97 💬 |
3214 | PF-06700841 25mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3215 | PF-06700841 30 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3216 | PF-06700841 45 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3217 | PF-06700841 5 mg | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3218 | PF-06700841 5mg | 1件: PF-06700841 PF-06700841 | - | - | - | 1件: 49 49 💬 |
3219 | PF-06700841-15 | 1件: PF-06700841 PF-06700841 | - | - | - | 3件: 49 49, 96, 97 💬 |
3220 | PF-06730512 | - | - | - | - | 1件: 222 222 💬 |
3221 | PF-06755347 intravenous healthy participant | - | - | - | - | 1件: 63 63 💬 |
3222 | PF-06755347 subcutaneous healthy participant | - | - | - | - | 1件: 63 63 💬 |
3223 | PF-06755347 subcutaneous ITP | - | - | - | - | 1件: 63 63 💬 |
3224 | PF-06823859 | - | - | - | - | 1件: 50 50 💬 |
3225 | PF-06823859 high | - | - | - | - | 1件: 50 50 💬 |
3226 | PF-06823859 low | - | - | - | - | 1件: 50 50 💬 |
3227 | PF-06826647 | - | - | - | - | 1件: 97 97 💬 |
3228 | PF-06826647 100 mg QD | - | - | - | - | 1件: 97 97 💬 |
3229 | PF-06826647 300 mg QD | - | - | - | - | 1件: 97 97 💬 |
3230 | PF-06826647 600 mg QD | - | - | - | - | 1件: 97 97 💬 |
3231 | PF-06835375 | - | - | - | - | 3件: 46 46, 49, 63 💬 |
3232 | PF-06836922 | - | - | - | - | 1件: 78 78 💬 |
3233 | PF-06939926 | - | - | - | - | 1件: 113 113 💬 |
3234 | PF-07054894 | - | - | - | - | 1件: 97 97 💬 |
3235 | PF-07256472 | - | - | - | - | 1件: 276 276 💬 |
3236 | PF-6826647 400 mg QD | - | - | - | - | 1件: 97 97 💬 |
3237 | Pfefferminzblätter 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
3238 | PGT-1 gene lipid complex | - | - | - | - | 1件: 299 299 💬 |
3239 | Ph. Eur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
3240 | Ph. Eur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylprop acid | - | - | - | - | 1件: 6 6 💬 |
3241 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
3242 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
3243 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
3244 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
3245 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
3246 | PHA-794,428 | - | - | - | - | 1件: 78 78 💬 |
3247 | Phase 1, SQY51 | - | - | - | - | 1件: 113 113 💬 |
3248 | Phase 1: Conventiaonal DMARD | - | - | - | - | 1件: 46 46 💬 |
3249 | Phase 1: Etanercept | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3250 | Phase 1: Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
3251 | Phase 2a, SQY51 (cohort 1) | - | - | - | - | 1件: 113 113 💬 |
3252 | Phenylalanine-free protein substitute in tablet form (XPhe minis) | 1件: Phenylalanine Phenylalanine | 1件: Phenylalanine
Phenylalanine
💬 | - | - | 1件: 240 240 💬 |
3253 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND DUAL LSD1/MAO-B (LYSINE-SPECIFIC DEMETHYLASE 1 AND MONOAMINE OXIDASE-B) INHIBITOR | 1件: Lysine Lysine | 1件: Lysine
Lysine
💬 | - | - | 1件: 13 13 💬 |
3254 | PhEur.: (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid | 1件: Propanoic acid Propanoic acid | - | - | - | 1件: 6 6 💬 |
3255 | PhEur.: (2S)-3-(3,4-dihydroxyphenyl)-2hydrazino-2methylpropanoic acid | - | - | - | - | 1件: 6 6 💬 |
3256 | Phosphorodiamidate morpholino oligomer for exon 45 skipping | - | - | - | - | 1件: 113 113 💬 |
3257 | PI-0824 | 1件: PI-0824 PI-0824 | - | - | - | 1件: 35 35 💬 |
3258 | Pimavanserin (ACP-103) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
3259 | Pimavanserin tartrate (ACP-103) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 💬 |
3260 | Pimecrolimus 1% Cream | 1件: Pimecrolimus Pimecrolimus | 1件: Pimecrolimus
Pimecrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 160 160 💬 |
3261 | Pimozide 2mg/day (current) or 4 mg/day (study initiation) | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
3262 | Pimozide 4 mg per day | 1件: Pimozide Pimozide | 1件: Pimozide
Pimozide
💬 | 2件: ADRA2A ADRA2A, DRD2 💬 | 9件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 💬 |
3263 | Pioglitazone 15 mg | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 96 96 💬 |
3264 | Piperacilline/Tazobactam Fresenius Kabi 2 g/0,25 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
3265 | Piperacilline/Tazobactam Fresenius Kabi 4 g/0,5 g poeder voor oplossing voor infusie | 1件: Tazobactam Tazobactam | 1件: Tazobactam
Tazobactam
💬 | - | - | 1件: 299 299 💬 |
3266 | Pirepemat x fumarate | - | - | - | - | 1件: 6 6 💬 |
3267 | Pirepemat, 100 mg | - | - | - | - | 1件: 6 6 💬 |
3268 | Pittsburgh Compound B (C-11 PiB) | 1件: Pittsburgh Compound B Pittsburgh Compound B | - | - | - | 1件: 127 127 💬 |
3269 | PKU sphere liquid | - | - | - | - | 1件: 240 240 💬 |
3270 | PL 00095/5079R | - | - | - | - | 1件: 46 46 💬 |
3271 | PL 0010/0211 | - | - | - | - | 1件: 299 299 💬 |
3272 | PL 00512/0150 | - | - | - | - | 1件: 298 298 💬 |
3273 | PL 04515/0127 | - | - | - | - | 1件: 13 13 💬 |
3274 | PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | 1件: Water Water | 1件: Water
Water
💬 | - | - | 1件: 57 57 💬 |
3275 | PL 12762/0049 | - | - | - | - | 1件: 13 13 💬 |
3276 | PL 17901/0122 | - | - | - | - | 1件: 96 96 💬 |
3277 | PL 20532/0012 | - | - | - | - | 1件: 96 96 💬 |
3278 | Plasma Lyso-GB3 | - | - | - | - | 1件: 19 19 💬 |
3279 | Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI) | - | - | - | - | 1件: 96 96 💬 |
3280 | PLASMASAFE - SOLUZIONE PER INFUSIONE 1 SACCA DA 200 ML | - | - | - | - | 1件: 274 274 💬 |
3281 | Plegridy (peginterferon beta-1a), Biogen Idec Ltd | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3282 | PLEGRIDY - 125 MCG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - PENNA PRERIEMPITA - 0,5 ML - 6 PENNE PRERIEMPITE | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3283 | Plegridy 125 micrograms | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3284 | Pleneva TM BGC20-0134 | - | - | - | - | 1件: 13 13 💬 |
3285 | PLN-74809-000 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
3286 | PLN-74809-020 | 1件: PLN-74809 PLN-74809 | - | - | - | 1件: 85 85 💬 |
3287 | Plovamer acetate 0.5 milligram (mg) | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
3288 | Plovamer acetate 10 mg | 1件: Acetate Acetate | - | - | - | 1件: 13 13 💬 |
3289 | PMG1015 Dose 1 | - | - | - | - | 1件: 85 85 💬 |
3290 | PMG1015 Dose 4 | - | - | - | - | 1件: 85 85 💬 |
3291 | PN-101 | - | - | - | - | 1件: 50 50 💬 |
3292 | PN-10884A | - | - | - | - | 1件: 97 97 💬 |
3293 | PN-180307 | - | - | - | - | 1件: 78 78 💬 |
3294 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) | - | - | - | - | 2件: 13 13, 14 💬 |
3295 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE | 4件: Aluminium Aluminium, Aluminium phosphate, Corynebacterium diphtheriae CRM197 protein, Phosphate ion | - | - | - | 1件: 46 46 💬 |
3296 | Pneumococcal polysaccharide serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F | - | - | - | - | 1件: 46 46 💬 |
3297 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F | - | - | - | - | 1件: 46 46 💬 |
3298 | Pneumococcal polysaccharide serotype 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F | - | - | - | - | 1件: 222 222 💬 |
3299 | Pneumococcal polysaccharide serotype 11 2.2 µg | - | - | - | - | 1件: 222 222 💬 |
3300 | PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml | - | - | - | - | 2件: 62 62, 66 💬 |
3301 | POLY(OXY-1,2-ETHANEDIYL), A | - | - | - | - | 1件: 235 235 💬 |
3302 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2- | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
3303 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI | 1件: Diethyl ether Diethyl ether | 1件: Ether
Ether
💬 | - | - | 1件: 235 235 💬 |
3304 | POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1) | 2件: Diethyl ether Diethyl ether, Teriparatide | 2件: Ether
Ether
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3305 | Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes. | - | - | - | - | 1件: 13 13 💬 |
3306 | Pomalidomide (CC-4047 | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 85 85 💬 |
3307 | Pomalidomide (CC-4047) | 1件: Pomalidomide Pomalidomide | 1件: Pomalidomide
Pomalidomide
💬 | 2件: IL6 IL6, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 51 51 💬 |
3308 | Ponesimod 10 mg | 1件: Ponesimod Ponesimod | 1件: Ponesimod
Ponesimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3309 | Ponesimod 40 mg | 1件: Ponesimod Ponesimod | 1件: Ponesimod
Ponesimod
💬 | 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3310 | Posaconazole 100 MG [Noxafil] | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
3311 | Posaconazole 40 MG/ML | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 299 299 💬 |
3312 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
3313 | Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | - | - | - | - | 1件: 6 6 💬 |
3314 | PR-06410293 | - | - | - | - | 1件: 46 46 💬 |
3315 | Pramipexole 0.125 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3316 | Pramipexole 0.5 mg tablets | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3317 | Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3318 | Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride) | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3319 | Precedentemente denominato MEDI2070 e AMG 139 | - | - | - | - | 1件: 96 96 💬 |
3320 | PredniHEXAL® 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
3321 | PredniHEXAL® 5mg Tabletten, PredniHEXAL® 10mg Tabletten | - | - | - | - | 1件: 46 46 💬 |
3322 | Prednisolene tablets BP 1 mg | - | - | - | - | 1件: 46 46 💬 |
3323 | Prednisolon 1 mg JENAPHARM | - | - | - | - | 1件: 41 41 💬 |
3324 | Prednisolon 10 mg JENAPHARM | - | - | - | - | 1件: 41 41 💬 |
3325 | Prednisolone 1mg Tablets | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 81 81 💬 |
3326 | Prednisolone 40 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3327 | Prednisolone Labesfal | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3328 | Prednisolone Tablets BP 1 mg | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3329 | Prednison 10 mg GALEN | - | - | - | - | 1件: 35 35 💬 |
3330 | PREDNISON 5, 20 Léciva por. tablet nob | - | - | - | - | 1件: 50 50 💬 |
3331 | Prednison 5, 20 Léciva por. tablet nob. | - | - | - | - | 1件: 50 50 💬 |
3332 | Prednisone 0,5 mg/kg orally on alternate days | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
3333 | Prednisone 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3334 | Prednisone 15 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3335 | Prednisone 4 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
3336 | PREDNISONE DOC GENERICI - 5 MG COMPRESSE 10 COMPRESSE IN BLISTER PVC-PVDC/ALU | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 19 19 💬 |
3337 | PredniSONE Tablets USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 41 41, 46 💬 |
3338 | PredniSONE Tablets USP, 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3339 | PredniSONE Tablets USP, 1mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3340 | PredniSONE Tablets, USP 10 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3341 | PredniSONE Tablets, USP, 1 mg | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 💬 |
3342 | Prednisone, low dose rituximab | 2件: Prednisone Prednisone, Rituximab | 2件: Prednisone
Prednisone
,
Rituximab
💬 | 2件: MS4A1 MS4A1, NR3C1 💬 | 2件: Hematopoietic cell lineage Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬 | 1件: 61 61 💬 |
3343 | Prefilled liquid etanercept(Yisaipu) | 2件: Etanercept Etanercept, Yisaipu | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
3344 | PREFOLIC 15*30CPR GASTROR 15MG | - | - | - | - | 1件: 337 337 💬 |
3345 | PREFOLIC*30CPR GASTROR 15MG | - | - | - | - | 1件: 299 299 💬 |
3346 | Preladenant 10 mg tablet | 1件: Preladenant Preladenant | 1件: Preladenant
Preladenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3347 | Preparative regimen 4-6 weeks after Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
3348 | Prevenar 13 | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 5件: 13 13, 14, 46, 96, 222 💬 |
3349 | PREVENAR 13 - 0.5 ML SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - FLACONCINO MONODOSE (0,5 ML VETRO TIPO I) - 1 FLACONCINO MONODOSE | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
3350 | Prevenar 13 sospensione per iniezione | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 14 14 💬 |
3351 | Prevenar 13 suspension for injection | 12件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen, Streptococcus pneumoniae type 14 capsular polysaccharide antigen, Streptococcus pneumoniae type 18c capsular polysaccharide antigen, Streptococcus pneumoniae type 19a capsular polysaccharide antigen, Streptococcus pneumoniae type 19f capsular polysaccharide antigen, Streptococcus pneumoniae type 23f capsular polysaccharide antigen, Streptococcus pneumoniae type 3 capsular polysaccharide antigen, Streptococcus pneumoniae type 4 capsular polysaccharide antigen, Streptococcus pneumoniae type 5 capsular polysaccharide antigen, Streptococcus pneumoniae type 6b capsular polysaccharide antigen, Streptococcus pneumoniae type 7f capsular polysaccharide antigen, Streptococcus pneumoniae type 9v capsular polysaccharide antigen | - | - | - | 1件: 222 222 💬 |
3352 | Previously referred to as MEDI2070 and AMG 139 | - | - | - | - | 2件: 96 96, 97 💬 |
3353 | Previously referred to as MEDI2070 and AMG 139, AGN-151-598 | - | - | - | - | 1件: 96 96 💬 |
3354 | Previously termed sc.AAV9.CB.SMN and AVXS-101 | - | - | - | - | 1件: 3 3 💬 |
3355 | Pridia 10mg | - | - | - | - | 1件: 6 6 💬 |
3356 | Prior Donzepezil 10mg | - | - | - | - | 1件: 6 6 💬 |
3357 | PRIVIGEN - 100 MG/ML - SOLUZIONE PER INFUSIONE USO ENDOVENOSO FLACONCINO(VETRO) 1 FLACONCINO DA 100 ML | - | - | - | - | 1件: 51 51 💬 |
3358 | Privigen 100 mg/ml, solution pour perfusion | - | - | - | - | 1件: 53 53 💬 |
3359 | PRIVIGEN 100mg/ml | - | - | - | - | 1件: 85 85 💬 |
3360 | PRM-151 | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3361 | PRM-151 (Zinpentraxin Alfa) | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3362 | PRO045, 0.15 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3363 | PRO045, 1.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3364 | PRO045, 3.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3365 | PRO045, 6.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3366 | PRO045, 9.0 mg/kg/week | 1件: BMN-045 BMN-045 | - | - | - | 1件: 113 113 💬 |
3367 | Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 | 1件: Lactobacillus delbrueckii bulgaricus Lactobacillus delbrueckii bulgaricus | - | - | - | 1件: 46 46 💬 |
3368 | Probiotic-Lactobacillus plantarum PS128 | 1件: Lactobacillus plantarum Lactobacillus plantarum | - | - | - | 1件: 156 156 💬 |
3369 | PROCAPTAN - 10 MG COMPRESSE RIVESTITE CON FILM 60 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
3370 | PROCAPTAN - 5 MG COMPRESSE RIVESTITE CON FILM 10 COMPRESSE IN CONTENITORE PER COMPRESSE PP | - | - | - | - | 1件: 58 58 💬 |
3371 | PROCHYMAL (remestemcel-L) | 1件: Remestemcel-L Remestemcel-L | 1件: Remestemcel-L
Remestemcel-L
💬 | - | - | 1件: 96 96 💬 |
3372 | Prolastin-C, 120 mg/kg | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
3373 | Proleukin 18 MUI | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 2 2 💬 |
3374 | Prometic's Immune Globulin Intravenous 10% | - | - | - | - | 1件: 65 65 💬 |
3375 | Promixin 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
3376 | PROMIXIN*NEBUL 30MONOD 1MUI | - | - | - | - | 1件: 299 299 💬 |
3377 | Promixin, 1 million International Units (IU) Powder for Nebuliser Solution | - | - | - | - | 1件: 299 299 💬 |
3378 | Promixin,1 millón de Unidades Internacionales,polvo para solución para inhalación por nebulizador | - | - | - | - | 1件: 299 299 💬 |
3379 | PROPIONYL L-CARNITINE | 1件: Levocarnitine Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 97 97 💬 |
3380 | PROPIONYL L-CARNITINE HYDROCHLORIDE | 1件: Levocarnitine Levocarnitine | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 97 97 💬 |
3381 | Propionyl-L-Carnitine | 2件: Levocarnitine Levocarnitine, Levocarnitine propionate | 1件: Levocarnitine
Levocarnitine
💬 | - | - | 1件: 97 97 💬 |
3382 | Propofol-Lipuro | 1件: Propofol Propofol | 1件: Propofol
Propofol
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
3383 | Propranolol HCl CF 40 mg tablet | 1件: Propranolol Propranolol | 1件: Propranolol
Propranolol
💬 | 3件: ADRB1 ADRB1, ADRB2, ADRB3 💬 | 12件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
3384 | Proteína recombinante estimulante de la megacariopoyesis | - | - | - | - | 1件: 63 63 💬 |
3385 | Prototype capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
3386 | PROVIGIL - 100 MG COMPRESSE 30 COMPRESSE | 1件: Modafinil Modafinil | 1件: Modafinil
Modafinil
💬 | - | - | 1件: 113 113 💬 |
3387 | PRTX-100 | - | - | - | - | 1件: 46 46 💬 |
3388 | PRTX-100 (Staphylococcal protein A) | 1件: Bevifimod Bevifimod | - | - | - | 1件: 63 63 💬 |
3389 | PRTX-100 at 1.5 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3390 | PRTX-100 at 12.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3391 | PRTX-100 at 240 mcg | - | - | - | - | 1件: 46 46 💬 |
3392 | PRTX-100 at 3.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3393 | PRTX-100 at 420 mcg | - | - | - | - | 1件: 46 46 💬 |
3394 | PRTX-100 at 6.0 mcg/kg | - | - | - | - | 1件: 46 46 💬 |
3395 | PRV-6527 (JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
3396 | PRV-6527(JNJ-40346527) | 1件: JNJ-40346527 JNJ-40346527 | - | - | - | 1件: 96 96 💬 |
3397 | PRX-102 | - | - | - | - | 1件: 19 19 💬 |
3398 | PRX-102 (pegunigalsidase alfa) | 1件: Pegunigalsidase alfa Pegunigalsidase alfa | 1件: Pegunigalsidase alfa
Pegunigalsidase alfa
💬 | - | - | 1件: 19 19 💬 |
3399 | PRX-102 1 mg/kg every 2 weeks | - | - | - | - | 1件: 19 19 💬 |
3400 | PRX-102 2 mg/kg every 4 weeks | - | - | - | - | 1件: 19 19 💬 |
3401 | PRX-112 | - | - | - | - | 1件: 19 19 💬 |
3402 | Pseudoephedrine + 480 ml water | 2件: Pseudoephedrine Pseudoephedrine, Water | 2件: Water
Water
,
Pseudoephedrine
💬 | 9件: ADRA1A ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 | 14件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
3403 | PT320 2.0 mg | - | - | - | - | 1件: 6 6 💬 |
3404 | PTC-0161480 | - | - | - | - | 2件: 246 246, 299 💬 |
3405 | PTC-124 | - | - | - | - | 2件: 246 246, 299 💬 |
3406 | PTC0161480, PTC124 Compound 1a, RPS2505, PTC-C124, 291844 | - | - | - | - | 1件: 113 113 💬 |
3407 | PTG-100 | - | - | - | - | 1件: 97 97 💬 |
3408 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: Teriparatide
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 💬 |
3409 | PTI-428 | 1件: PTI-428 PTI-428 | - | - | - | 1件: 299 299 💬 |
3410 | PTR-01 | - | - | - | - | 1件: 36 36 💬 |
3411 | PTW-002 10 mg/g gel | - | - | - | - | 1件: 36 36 💬 |
3412 | Puerarin injection 400 mg | 1件: Puerarin Puerarin | - | - | - | 1件: 46 46 💬 |
3413 | PUR 0110 | - | - | - | - | 1件: 97 97 💬 |
3414 | PUR 0110 Rectal Enema | - | - | - | - | 1件: 97 97 💬 |
3415 | PUR 0110 Rectal Enema 1000 mg | - | - | - | - | 1件: 97 97 💬 |
3416 | PUR 0110 Rectal Enema 250 mg | - | - | - | - | 1件: 97 97 💬 |
3417 | PUR 0110 Rectal Enema 500 mg | - | - | - | - | 1件: 97 97 💬 |
3418 | Purified form of the lysosomal enzyme iduronate-2-sulfatase | - | - | - | - | 1件: 19 19 💬 |
3419 | PXT002331 - dose 1 | - | - | - | - | 1件: 6 6 💬 |
3420 | PXT3003 Dose 1 | - | - | - | - | 1件: 10 10 💬 |
3421 | PXT3003 Dose 2 (equivalent to twice Dose 1) | - | - | - | - | 1件: 10 10 💬 |
3422 | PXT3003 Low dose | - | - | - | - | 1件: 10 10 💬 |
3423 | Pyridoxine 10mg | 1件: Pyridoxine Pyridoxine | 1件: Pyridoxine
Pyridoxine
💬 | - | - | 1件: 93 93 💬 |
3424 | Pyridoxine 10mg BP | 1件: Pyridoxine Pyridoxine | 1件: Pyridoxine
Pyridoxine
💬 | - | - | 1件: 93 93 💬 |
3425 | Q4W GMA301 IV injections (1000 mg) | - | - | - | - | 1件: 86 86 💬 |
3426 | QBW276 1500mcg | - | - | - | - | 1件: 299 299 💬 |
3427 | QCC374 0.015 mg | - | - | - | - | 1件: 86 86 💬 |
3428 | QCC374 0.06 mg | - | - | - | - | 1件: 86 86 💬 |
3429 | Qing Re Huo Xue (QRHX) | - | - | - | - | 1件: 46 46 💬 |
3430 | Qingkailing injection 40 ml | - | - | - | - | 1件: 46 46 💬 |
3431 | QLS-101 ophthalmic solution, 2.0 % | - | - | - | - | 1件: 157 157 💬 |
3432 | QR-010 | - | - | - | - | 1件: 299 299 💬 |
3433 | QR-1123 | - | - | - | - | 1件: 90 90 💬 |
3434 | QR-421a | - | - | - | - | 2件: 90 90, 303 💬 |
3435 | QRL-201 - Dose 1 | - | - | - | - | 1件: 2 2 💬 |
3436 | QRL-201 - Dose 4 | - | - | - | - | 1件: 2 2 💬 |
3437 | QTXEW2-04-AF, EW2, GC-1, QRX-431 | - | - | - | - | 1件: 20 20 💬 |
3438 | Quality of life | - | - | - | - | 1件: 13 13 💬 |
3439 | R lipoic acid | 1件: Lipoic acid Lipoic acid | - | - | - | 1件: 13 13 💬 |
3440 | R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane hydrochloride | 1件: Benzofuran Benzofuran | - | - | - | 1件: 6 6 💬 |
3441 | R-021 | - | - | - | - | 1件: 222 222 💬 |
3442 | R-Gene 10 | 1件: Arginine Arginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 78 78 💬 |
3443 | R-hGH liquid (Saizen) | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
3444 | R-hIL-18BP | - | - | - | - | 1件: 65 65 💬 |
3445 | R788 sodium hexahydrate, RIG2-01, RIG-G | - | - | - | - | 1件: 46 46 💬 |
3446 | RAAV2/5-PBGD vector dosage 1 | - | - | - | - | 1件: 254 254 💬 |
3447 | RAAV2/5-PBGD vector dosage 4 | - | - | - | - | 1件: 254 254 💬 |
3448 | RAAV2/6 Left ZFN Vector | - | - | - | - | 1件: 19 19 💬 |
3449 | Rabbit ATG, Cyclosporine, Levamisole | 4件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Cyclosporine, Levamisole, Rabbit | 2件: Cyclosporine
Cyclosporine
,
Levamisole
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
3450 | RABBIT HUMAN T LYMPHOCYTE IMMUNOGLOBULIN | 1件: Rabbit Rabbit | - | - | - | 2件: 13 13, 60 💬 |
3451 | RAD001 1mg | - | - | - | - | 1件: 158 158 💬 |
3452 | RADAMTS-13 | - | - | - | - | 1件: 64 64 💬 |
3453 | RAG1 LV CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
3454 | Ranibizumab injection (0.5 mg) | 1件: Ranibizumab Ranibizumab | 1件: Ranibizumab
Ranibizumab
💬 | 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 2件: 166 166, 301 💬 |
3455 | Ranolazine 1000 MG | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 2 2 💬 |
3456 | Ranolazine 1000 mg PR tablets | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3457 | Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die | 1件: Ranolazine Ranolazine | 1件: Ranolazine
Ranolazine
💬 | - | - | 1件: 58 58 💬 |
3458 | Rapamicina tópica al 1% y excipiente | - | - | - | - | 1件: 157 157 💬 |
3459 | RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
3460 | RAPAMUNE 1 mg/ml oral solution | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3461 | Rapamune 1 mg/ml solución oral | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3462 | Rapamune 1mg tablets | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3463 | RAPAMUNE*100CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3464 | RAPAMUNE*30CPR RIV 1MG | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 67 67 💬 |
3465 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3466 | Raptiva 100 mg/ml powder and solvent for solution for injection | 1件: Efalizumab Efalizumab | 1件: Efalizumab
Efalizumab
💬 | 1件: ITGAL ITGAL 💬 | 12件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Neutrophil extracellular trap formation, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis 💬 | 7件: 11 11, 13, 46, 53, 61, 95, 96 💬 |
3467 | Rasagilina mesilato (12 weeks) | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3468 | Rasagiline 1 mg capsule | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3469 | Rasagiline 1mg tablet | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3470 | Rasagiline mesylate 1.0 mg | 1件: Rasagiline Rasagiline | 2件: Rasagiline
Rasagiline
,
Rasagiline tartrate
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3471 | Rasagiline mesylate with Levodopa | 2件: Levodopa Levodopa, Rasagiline | 3件: Levodopa
Levodopa
,
Rasagiline
,
Rasagiline tartrate
💬 | 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, MAOB 💬 | 20件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3472 | Ravicti low dose | 1件: Glycerol phenylbutyrate Glycerol phenylbutyrate | 1件: Glycerol phenylbutyrate
Glycerol phenylbutyrate
💬 | - | - | 1件: 299 299 💬 |
3473 | RAvPAL-PEG 0.001 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3474 | RAvPAL-PEG 0.003 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3475 | RAvPAL-PEG 0.01 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3476 | RAvPAL-PEG 0.03 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3477 | RAvPAL-PEG 0.1 mg/kg | 1件: Pegvaliase Pegvaliase | 1件: Pegvaliase
Pegvaliase
💬 | 1件: PAH PAH 💬 | 5件: Biosynthesis of amino acids Biosynthesis of amino acids, Folate biosynthesis, Metabolic pathways, Phenylalanine metabolism, Phenylalanine, tyrosine and tryptophan biosynthesis 💬 | 1件: 240 240 💬 |
3478 | RAXONE - 150 MG- COMPRESSE RIVESTITE CON FILM- USO ORALE- FLACONE (HDPE)- 180 COMPRESSE | 1件: Idebenone Idebenone | 1件: Idebenone
Idebenone
💬 | - | - | 1件: 113 113 💬 |
3479 | RC18 160 mg | - | - | - | - | 2件: 13 13, 53 💬 |
3480 | RC18 160 mg plus MTX | - | - | - | - | 1件: 46 46 💬 |
3481 | RC18 160 mg plus standard therapy | - | - | - | - | 1件: 49 49 💬 |
3482 | RC18 160mg | - | - | - | - | 3件: 11 11, 13, 66 💬 |
3483 | Rcombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3484 | RCTB-401 | - | - | - | - | 1件: 96 96 💬 |
3485 | RE-021 | - | - | - | - | 3件: 66 66, 218, 222 💬 |
3486 | RE-021 (Sparsentan) | 1件: Sparsentan Sparsentan | 1件: Sparsentan
Sparsentan
💬 | 2件: AGTR1 AGTR1, EDNRA 💬 | 17件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 💬 |
3487 | RE-024 | - | - | - | - | 1件: 120 120 💬 |
3488 | Rebif (IFN beta-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3489 | Rebif (IFN ß-1a subcutaneous three times per week) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3490 | Rebif (interferon beta 1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3491 | Rebif (Interferon beta-1a) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3492 | Rebif (interferon beta-1a), Merck Serono Europe Ltd | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3493 | REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3494 | Rebif 22 y 44 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3495 | Rebif 44 | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3496 | Rebif 44 microgrammi/0.5ml soluzione iniettabile in cartuccia | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3497 | REBIF 44 microgramos solución inyectable | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3498 | REBIF 44 microgramos solución inyectable en jeringa precargada | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3499 | Rebif 44 micrograms | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3500 | Rebif 44 micrograms solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3501 | Rebif 44 micrograms solution for injection in pre-filled syringe | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3502 | Rebif 44 µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3503 | Rebif 44® | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3504 | Rebif New Formulation 44mcg multidose cartridge | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3505 | REBIF SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3506 | REBIF SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3507 | REBIF*SC 12SIR 12000000UI44MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3508 | REBIF*SC 12SIR 6000000UI 22MCG | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3509 | Rebif® (clone 484-39) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3510 | Rebif® New Formulation (IFN-beta-1a, RNF) | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3511 | Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
3512 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 | - | - | - | - | 1件: 64 64 💬 |
3513 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs | - | - | - | - | 1件: 64 64 💬 |
3514 | Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13 | - | - | - | - | 1件: 64 64 💬 |
3515 | Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13) | - | - | - | - | 1件: 64 64 💬 |
3516 | RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR EXPRESSING THE HUMAN ALPHA-1-ANTITRYPSIN GENE | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 💬 |
3517 | Recombinant Adeno-Associated Viral vector, serotype 2 (rAAV2/2) containing the human wild-type mitochondrial NADH Dehydrogenase 4 gene (ND4) | 1件: NADH NADH | - | - | - | 1件: 302 302 💬 |
3518 | Recombinant coagulation FVIII Fc – von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3519 | Recombinant coagulation FVIII Fc –von Willebrand factor – XTEN fusion protein | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3520 | Recombinant Factor XIII | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 1件: 288 288 💬 |
3521 | Recombinant Factor XIII (rFXIII) | 1件: Factor XIII (human) Factor XIII (human) | - | - | - | 2件: 97 97, 288 💬 |
3522 | Recombinant human Arysulfatase B, recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
3523 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR - XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3524 | RECOMBINANT HUMAN COAGULATION FACTOR VIII FC - VON WILLEBRAND FACTOR -XTEN FUSION PROTEIN | 3件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3525 | RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1 | - | - | - | - | 1件: 166 166 💬 |
3526 | Recombinant human IGF-1 | - | - | - | - | 2件: 78 78, 299 💬 |
3527 | Recombinant Human Insulin Growth Factor 1 (rhIGF-1) | 1件: Insulin human Insulin human | 1件: Insulin human
Insulin human
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 156 156 💬 |
3528 | Recombinant human Insulin-like Growth Factor | 1件: Insulin human Insulin human | 1件: Insulin human
Insulin human
💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 96 96 💬 |
3529 | Recombinant human interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 26 26 💬 |
3530 | Recombinant Human Interleukin-11 (rhIL-11) | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 96 96 💬 |
3531 | Recombinant human lysosomal acid lipase | - | - | - | - | 1件: 19 19 💬 |
3532 | Recombinant human lysosomal acid lipase (rhLAL) | - | - | - | - | 1件: 19 19 💬 |
3533 | Recombinant human lysosomal acid lipase (rhLAL), esterase, cholesterol (human gene LIPA) | 1件: Cholesterol Cholesterol | 1件: Cholesterol
Cholesterol
💬 | - | - | 1件: 19 19 💬 |
3534 | Recombinant human lysosomal acid lipase (rhLAL), esterase, cholesterol (human gene LIPA), lysosomal acid lipase (human gene LIPA) | 1件: Cholesterol Cholesterol | 1件: Cholesterol
Cholesterol
💬 | - | - | 1件: 19 19 💬 |
3535 | Recombinant human lysosomal alpha-mannosidase | - | - | - | - | 1件: 19 19 💬 |
3536 | Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class | - | - | - | - | 3件: 106 106, 107, 108 💬 |
3537 | Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class | - | - | - | - | 1件: 271 271 💬 |
3538 | Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class | - | - | - | - | 1件: 46 46 💬 |
3539 | Recombinant human monoclonal antibody to interleukin-1beta of the IgG1-Kappa-class | - | - | - | - | 1件: 46 46 💬 |
3540 | Recombinant human N-acetylgalactosamine 4-sulfatase | - | - | - | - | 1件: 19 19 💬 |
3541 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 | - | - | - | - | 1件: 19 19 💬 |
3542 | Recombinant human N-acetylgalactosamine 6-sulfatase, BMN 110 drug substance | - | - | - | - | 1件: 19 19 💬 |
3543 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3544 | Recombinant human N-acetylgalactosamine-6-sulfatase, BMN 110 drug substance | 1件: Elosulfase alfa Elosulfase alfa | 1件: Elosulfase alfa
Elosulfase alfa
💬 | 1件: GALNS GALNS 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 💬 |
3545 | RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3546 | Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3547 | Recombinant human Pentraxin-2 (PRM-151) | 1件: PRM-151 PRM-151 | - | - | - | 1件: 85 85 💬 |
3548 | Recombinant human tripeptidyl peptidase-1 | - | - | - | - | 1件: 19 19 💬 |
3549 | RECOMBINANT HUMAN TRIPEPTIDYL PEPTIDASE-1 (RHTPP1) | - | - | - | - | 1件: 19 19 💬 |
3550 | Recombinant humanized anti-alpha 4 integrin antibody | - | - | - | - | 1件: 13 13 💬 |
3551 | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg | - | - | - | - | 1件: 331 331 💬 |
3552 | RECOMBINANT INTERFERON BETA-1B | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3553 | Recombinant interleukin-11 | 1件: Oprelvekin Oprelvekin | 1件: Oprelvekin
Oprelvekin
💬 | 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 💬 |
3554 | Recombinant LCAT | - | - | - | - | 1件: 259 259 💬 |
3555 | Recombinant microbial lipase | - | - | - | - | 1件: 298 298 💬 |
3556 | Recombinant Microbial Lipase SLV339 | - | - | - | - | 1件: 298 298 💬 |
3557 | Recombinant von Willebrand Factor 1300IU | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
3558 | Recombinant-methionyl human glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 💬 |
3559 | Reduced Glutathione 100mg | 1件: Glutathione Glutathione | 2件: Glutathione
Glutathione
,
Oxiglutatione
💬 | - | - | 1件: 6 6 💬 |
3560 | REF CRUZADA PEI Nº 12-088 | - | - | - | - | 1件: 274 274 💬 |
3561 | Reference capsule GDC-0134 | 1件: GDC-0134 GDC-0134 | - | - | - | 1件: 2 2 💬 |
3562 | Regimen Selection Phase Group 1 (COMPLETED) | - | - | - | - | 1件: 113 113 💬 |
3563 | REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | - | - | - | - | 1件: 79 79 💬 |
3564 | Reldesemtiv 150 mg | 1件: Reldesemtiv Reldesemtiv | 1件: Reldesemtiv
Reldesemtiv
💬 | 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 3 3 💬 |
3565 | Reldesemtiv 450 mg | 1件: Reldesemtiv Reldesemtiv | 1件: Reldesemtiv
Reldesemtiv
💬 | 1件: TNNC2 TNNC2 💬 | 1件: Calcium signaling pathway Calcium signaling pathway 💬 | 1件: 3 3 💬 |
3566 | Remestemcel-L | 1件: Remestemcel-L Remestemcel-L | 1件: Remestemcel-L
Remestemcel-L
💬 | - | - | 2件: 96 96, 97 💬 |
3567 | REMICADE - 100 MG POLVERE PER CONCENTRATO PER INFUSIONE ENDOVENOSA 1 FLACONE VETRO 20 ML USO EV | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3568 | Remicade 100 mg | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 56 56, 96 💬 |
3569 | Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
3570 | REMICADE 100 mg polvo para concentrado para solución para perfusión | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 💬 |
3571 | Remicade 100 mg powder for concentrate for solution for infusion. | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬 |
3572 | Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3573 | Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning. | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3574 | REMICADE*EV F 100MG+F 2ML | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3575 | Remodulin 10mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
3576 | Remodulin 1mg/ml 20ml | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 88 88 💬 |
3577 | Remodulin® (treprostinil) 1 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3578 | Remodulin® (treprostinil) 10 mg/ml solution for infusion | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
3579 | REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3580 | Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 💬 |
3581 | Repatha 140 mg Solution for Injection in Pre-filled Pen | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3582 | Repatha 140 mg soluzione per iniezione in penna preriempita. | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3583 | Repatha 420 mg solution for injection in cartridge | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3584 | Repatha 420 mg soluzione per iniezione in cartuccia | 1件: Evolocumab Evolocumab | 1件: Evolocumab
Evolocumab
💬 | 1件: PCSK9 PCSK9 💬 | 1件: Cholesterol metabolism Cholesterol metabolism 💬 | 1件: 79 79 💬 |
3585 | REQUIP 21 CPR 0,25 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3586 | REQUIP 21 CPR 0,5 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3587 | REQUIP 21 CPR 1 MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3588 | Requip Modutab, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3589 | Requip XL prolonged-release | 2件: Manganese citrate Manganese citrate, Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3590 | REQUIP*21CPR 0,25MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3591 | REQUIP*21CPR 0,5MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3592 | REQUIP*21CPR 1MG | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3593 | REQUIP-LP | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3594 | REQUIP-MODUTAB , 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3595 | REQUIP-MODUTAB, 4mg | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3596 | REVATIO - 0.8 MG/ML - SOLUZIONE INIETTABILE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO DA 20 ML | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
3597 | Revatio 0.8mg/ml solution for injection | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 294 294 💬 |
3598 | Revatio 10 mg/ml powder for oral suspension | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3599 | Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir | 3件: Abacavir Abacavir, Lamivudine, Zidovudine | 3件: Lamivudine
Lamivudine
,
Zidovudine
,
Abacavir
💬 | - | - | 1件: 325 325 💬 |
3600 | Rexlemestrocel-L | - | - | - | - | 2件: 210 210, 211 💬 |
3601 | REYATAZ 150MG 60 CPS BL | 1件: Atazanavir Atazanavir | 1件: Atazanavir
Atazanavir
💬 | - | - | 1件: 265 265 💬 |
3602 | RG-012 | - | - | - | - | 1件: 218 218 💬 |
3603 | RG6042, formerly ISIS 443139, IONIS-HTTRx | - | - | - | - | 1件: 8 8 💬 |
3604 | RGB-03 | - | - | - | - | 1件: 46 46 💬 |
3605 | RGX-111 | - | - | - | - | 1件: 19 19 💬 |
3606 | RGX-121 | - | - | - | - | 1件: 19 19 💬 |
3607 | RhASA - Dose Level 1 | - | - | - | - | 1件: 19 19 💬 |
3608 | RhASA - Dose Level 2 | - | - | - | - | 1件: 19 19 💬 |
3609 | RhASA - Dose Level 3 | - | - | - | - | 1件: 19 19 💬 |
3610 | RHB-104 | - | - | - | - | 2件: 13 13, 96 💬 |
3611 | RhHNS-10 mg | - | - | - | - | 1件: 19 19 💬 |
3612 | RhHNS-45 mg | - | - | - | - | 1件: 19 19 💬 |
3613 | RhIDU (recombinant human-Alpha-L-Iduronidase) | - | - | - | - | 1件: 19 19 💬 |
3614 | RhIFN beta-1b | - | - | - | - | 1件: 13 13 💬 |
3615 | RhIGF-1 | - | - | - | - | 1件: 156 156 💬 |
3616 | RhIGF-1 (CEP-151) | - | - | - | - | 1件: 13 13 💬 |
3617 | RhIGF-1/rhIGFBP-3 | 1件: rhIGFBP-3 rhIGFBP-3 | - | - | - | 1件: 195 195 💬 |
3618 | RhIL-11 | - | - | - | - | 1件: 97 97 💬 |
3619 | RhNGF 180 µg/ml eye drops solution | 1件: Cenegermin Cenegermin | 1件: Cenegermin
Cenegermin
💬 | 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 90 90 💬 |
3620 | RhPTH (1-34) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
3621 | RhPTH (1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3622 | RhPTH(1-84) | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
3623 | RhuDex 100 mg (127 mg RhuDex choline salt) granules | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 93 93 💬 |
3624 | RhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 4件: 13 13, 46, 56, 96 💬 |
3625 | RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 1件: 96 96 💬 |
3626 | RhumAb to IL-17A igG1-k-class | - | - | - | - | 1件: 13 13 💬 |
3627 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
3628 | Rifampin 300mg BID + istradefylline 40mg Day 8 only | 2件: Istradefylline Istradefylline, Rifampicin | 2件: Rifampin
Rifampin
,
Istradefylline
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3629 | Rifaximin 550 MG Oral Tablet [XIFAXAN] | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 299 299 💬 |
3630 | Rifaximin delayed release 400 mg film coated tablet | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 1件: 96 96 💬 |
3631 | RIL-1RA | - | - | - | - | 1件: 107 107 💬 |
3632 | Rilonacept (IL-1 Trap) | 1件: Rilonacept Rilonacept | 1件: Rilonacept
Rilonacept
💬 | 2件: IL1A IL1A, IL1B 💬 | 45件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 107 107 💬 |
3633 | Rilonacept 160 mg | 1件: Rilonacept Rilonacept | 1件: Rilonacept
Rilonacept
💬 | 2件: IL1A IL1A, IL1B 💬 | 45件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 106 106 💬 |
3634 | Rilpivirine - Injectable Suspension (RPV LA) | 1件: Rilpivirine Rilpivirine | 1件: Rilpivirine
Rilpivirine
💬 | - | - | 1件: 256 256 💬 |
3635 | Riluzole (100 mg) | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
3636 | Riluzole 100mg/day | 1件: Riluzole Riluzole | 1件: Riluzole
Riluzole
💬 | 14件: GRIA1 GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 | 23件: Alcoholism Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬 | 1件: 2 2 💬 |
3637 | Ringer lactate | - | - | - | - | 1件: 51 51 💬 |
3638 | Riociguat coated tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3639 | Riociguat coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3640 | Riociguat coated tablet 1.5 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3641 | Riociguat coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 51 51 💬 |
3642 | Riociguat granules 0.3% for oral application | 1件: Riociguat Riociguat | 1件: Riociguat
Riociguat
💬 | 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3643 | Risankizumab 10 mg/ml | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3644 | Risankizumab 180 mg SC | 1件: Risankizumab Risankizumab | 1件: Risankizumab
Risankizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 💬 |
3645 | Risperidone 1Mg Tab | 1件: Risperidone Risperidone | 1件: Risperidone
Risperidone
💬 | 2件: DRD2 DRD2, HTR2A 💬 | 11件: Alcoholism Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway 💬 | 1件: 8 8 💬 |
3646 | Ritalin LA 20mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
3647 | Ritalin LA 30mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
3648 | Ritalin LA 40mg capsules | 1件: Methylphenidate Methylphenidate | 1件: Methylphenidate
Methylphenidate
💬 | 2件: SLC6A2 SLC6A2, SLC6A3 💬 | 7件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
3649 | Ritlecitinib 10 mg | - | - | - | - | 1件: 97 97 💬 |
3650 | Rituximab 1g IV | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 162 162 💬 |
3651 | Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 💬 |
3652 | Rituximab-EU+ Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
3653 | Rituximab-Pfizer (PF-05280586) x 3 courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
3654 | Rituximab-US + Rituximab-Pfizer x 2 Courses | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
3655 | RIV-TDS 13.3 mg/24 h | - | - | - | - | 1件: 6 6 💬 |
3656 | Rivastigmin Luye Transdermal Patches - 4.6mg/24h | - | - | - | - | 1件: 6 6 💬 |
3657 | Rivastigmine Luye Transdermal Patch- 9.5mg/24h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
3658 | Rivastigmine transdermal system 13.3 mg/24 h | 1件: Rivastigmine Rivastigmine | 1件: Rivastigmine
Rivastigmine
💬 | 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 1件: 6 6 💬 |
3659 | RM-131 | - | - | - | - | 1件: 6 6 💬 |
3660 | RM-493 | - | - | - | - | 2件: 193 193, 202 💬 |
3661 | RNS60 125 ml | - | - | - | - | 1件: 13 13 💬 |
3662 | Ro 001-9265 | - | - | - | - | 1件: 41 41 💬 |
3663 | Ro 001-9265/F02 | - | - | - | - | 1件: 41 41 💬 |
3664 | RO 001-9265/F02-01 | - | - | - | - | 1件: 46 46 💬 |
3665 | Ro 001-9265/F03 | - | - | - | - | 1件: 41 41 💬 |
3666 | Ro 001-9265/F04 | - | - | - | - | 1件: 41 41 💬 |
3667 | Ro 002-9893/F02 | - | - | - | - | 1件: 46 46 💬 |
3668 | Ro 106-1443 | - | - | - | - | 1件: 49 49 💬 |
3669 | Ro 45-2294 | - | - | - | - | 1件: 46 46 💬 |
3670 | Ro 47-0203 | - | - | - | - | 4件: 51 51, 85, 86, 88 💬 |
3671 | Ro 47-0203 / ACT-050088 | - | - | - | - | 1件: 86 86 💬 |
3672 | Ro 48-77533 | - | - | - | - | 1件: 46 46 💬 |
3673 | Ro 487-533/F01 | - | - | - | - | 1件: 271 271 💬 |
3674 | Ro 487-5733/F01 | - | - | - | - | 1件: 271 271 💬 |
3675 | RO 487-7533 | - | - | - | - | 1件: 46 46 💬 |
3676 | Ro 487-7533/F01 | - | - | - | - | 3件: 46 46, 107, 271 💬 |
3677 | Ro 487-7533/F10 | - | - | - | - | 2件: 46 46, 107 💬 |
3678 | Ro 487-7533/F10-02 | - | - | - | - | 1件: 46 46 💬 |
3679 | Ro 487-7533/F10-04 | - | - | - | - | 4件: 41 41, 46, 51, 107 💬 |
3680 | Ro 491-7523/F18 | - | - | - | - | 1件: 206 206 💬 |
3681 | Ro 491-7523/F19 | - | - | - | - | 1件: 206 206 💬 |
3682 | RO 496-4913 | - | - | - | - | 2件: 46 46, 49 💬 |
3683 | Ro 496-4913/F03 | - | - | - | - | 2件: 13 13, 46 💬 |
3684 | Ro 496-4913/F07 | - | - | - | - | 1件: 13 13 💬 |
3685 | Ro 533-3787/F01- 06 | - | - | - | - | 1件: 13 13 💬 |
3686 | Ro 533-3787/F01-06 | - | - | - | - | 1件: 11 11 💬 |
3687 | Ro 549-0261/F04 | - | - | - | - | 1件: 97 97 💬 |
3688 | Ro 549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
3689 | Ro 549-0261/F08-02 | - | - | - | - | 1件: 96 96 💬 |
3690 | Ro 723-4292/F02 | - | - | - | - | 1件: 8 8 💬 |
3691 | Ro-47-0203 | - | - | - | - | 1件: 86 86 💬 |
3692 | Ro-47-0203/029 | - | - | - | - | 1件: 86 86 💬 |
3693 | RO-496-4913 | - | - | - | - | 1件: 46 46 💬 |
3694 | Ro106-1443 | - | - | - | - | 1件: 43 43 💬 |
3695 | Ro47-0203 | - | - | - | - | 1件: 86 86 💬 |
3696 | Ro47-0203 / ACT-050088 | - | - | - | - | 2件: 51 51, 86 💬 |
3697 | RO487-7533/F10-04 | - | - | - | - | 2件: 46 46, 51 💬 |
3698 | RO4917523 0.5 mg | - | - | - | - | 1件: 206 206 💬 |
3699 | RO4917523 1.5 mg | - | - | - | - | 1件: 206 206 💬 |
3700 | RO496-4913 | - | - | - | - | 1件: 46 46 💬 |
3701 | RO4964913/F07-01 | - | - | - | - | 1件: 13 13 💬 |
3702 | Ro549-0261/F04-02 | - | - | - | - | 1件: 96 96 💬 |
3703 | RO5490255/F01-02 | - | - | - | - | 1件: 85 85 💬 |
3704 | RO5490261/F04-02 | - | - | - | - | 1件: 97 97 💬 |
3705 | RO7112689/F03-01 | - | - | - | - | 2件: 62 62, 109 💬 |
3706 | RO7112689/F03-10 | - | - | - | - | 2件: 62 62, 109 💬 |
3707 | RO7123520/F03-01 | - | - | - | - | 1件: 46 46 💬 |
3708 | RO7204239/F01-01 | - | - | - | - | 1件: 3 3 💬 |
3709 | RO7239361 Injections, 15 mg/Syringe (21.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3710 | RO7239361 Injections, 50 mg/Syringe (71.4 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3711 | RO7239361 Injections, 7.5 mg/Syringe (10.7 mg/mL) | - | - | - | - | 1件: 113 113 💬 |
3712 | RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
3713 | RO7248824/F03-01 (Diluent for RO7248824/F02-01 | - | - | - | - | 1件: 201 201 💬 |
3714 | RO7490677 160 mg/8 ml | - | - | - | - | 1件: 85 85 💬 |
3715 | RO7490677 160 mg/8mL | - | - | - | - | 1件: 85 85 💬 |
3716 | RO7490677 160mg/8mL | - | - | - | - | 1件: 85 85 💬 |
3717 | RO7490677 320 mg/16 ml (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
3718 | RO7490677 320mg/16mL (1st generation) | - | - | - | - | 1件: 85 85 💬 |
3719 | RO7490677 320mg/16mL (2nd generation) | - | - | - | - | 1件: 85 85 💬 |
3720 | RO7490677/ F01-02 | - | - | - | - | 1件: 85 85 💬 |
3721 | RO7490677/F01-01 | - | - | - | - | 1件: 85 85 💬 |
3722 | RO7490677/F01-02 | - | - | - | - | 1件: 85 85 💬 |
3723 | RO7490677/F01-03 | - | - | - | - | 1件: 85 85 💬 |
3724 | ROACTEMRA - 162 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA 0,9ML (VETRO) - 4 SIRINGHE PRERIEMPITE | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
3725 | ROACTEMRA - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 4ML 1 FLACONCINO | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3726 | RoActemra 162 mg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 51 💬 |
3727 | RoActemra 162 mg solution for injection in pre-filled syringe | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
3728 | RoActemra 162 mg solution injectable en seringue préremplie | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3729 | RoActemra 162 mg soluzione iniettabile in siringa preriempita | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 50 50 💬 |
3730 | Rob 803 (capsules 12.5 mg) | - | - | - | - | 1件: 46 46 💬 |
3731 | Rob 803 (capsules 15 mg) | - | - | - | - | 1件: 46 46 💬 |
3732 | Rob 803 12.5mg capsule | - | - | - | - | 1件: 46 46 💬 |
3733 | Rob 803 15mg capsule | - | - | - | - | 1件: 46 46 💬 |
3734 | Roferon-A, 4.5miu | 1件: Interferon alfa-2a Interferon alfa-2a | 1件: Interferon alfa-2a
Interferon alfa-2a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 56 56 💬 |
3735 | Rokan (r) Novo 120 mg | - | - | - | - | 1件: 18 18 💬 |
3736 | ROP+L-Dopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3737 | Ropinirole PR/XR | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3738 | Ropinirole PR/XR Tablets | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3739 | Ropinirole prolonged release/extended release(PR/XR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3740 | Ropinirole XL | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3741 | Ropinirole XL (formerly CR) | 1件: Ropinirole Ropinirole | 1件: Ropinirole
Ropinirole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3742 | Ropinirole/L-dopa | 2件: Levodopa Levodopa, Ropinirole | 2件: Levodopa
Levodopa
,
Ropinirole
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3743 | Rosiglitazone XR | 1件: Rosiglitazone Rosiglitazone | 1件: Rosiglitazone
Rosiglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
3744 | Rosuvastatin 10 mg | 1件: Rosuvastatin Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 96 96 💬 |
3745 | Rosuvastatin 10mg | 1件: Rosuvastatin Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 97 97 💬 |
3746 | Rosuvastatin calcium 40mg | 2件: Calcium Calcium, Rosuvastatin | 1件: Rosuvastatin
Rosuvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 56 56 💬 |
3747 | Rotigotine (Reference product PR 2.1.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3748 | Rotigotine (Test product PR 2.3.1) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3749 | Rotigotine transdermal patch 2mg/24h(10cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3750 | Rotigotine transdermal patch 4mg/24h (20cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3751 | Rotigotine transdermal patch 8mg/24h (40cm2) | 1件: Rotigotine Rotigotine | 1件: Rotigotine
Rotigotine
💬 | 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3752 | RP 103 | - | - | - | - | 2件: 8 8, 19 💬 |
3753 | RP-L102 | - | - | - | - | 1件: 285 285 💬 |
3754 | RP-L201 | - | - | - | - | 1件: 65 65 💬 |
3755 | RPC-1063 | - | - | - | - | 1件: 13 13 💬 |
3756 | RPH-104 | - | - | - | - | 1件: 266 266 💬 |
3757 | RQ-00000010 | - | - | - | - | 1件: 6 6 💬 |
3758 | RSLV-132 | - | - | - | - | 2件: 49 49, 53 💬 |
3759 | RST-001 | - | - | - | - | 1件: 90 90 💬 |
3760 | RTA 402 | - | - | - | - | 3件: 67 67, 86, 218 💬 |
3761 | RTL1000 (recombinant T cell receptor ligand) | - | - | - | - | 1件: 13 13 💬 |
3762 | RTX-134 | - | - | - | - | 1件: 240 240 💬 |
3763 | RVG 03820 | - | - | - | - | 1件: 3 3 💬 |
3764 | RVG 05565 | - | - | - | - | 1件: 96 96 💬 |
3765 | RVG 07151 | - | - | - | - | 1件: 96 96 💬 |
3766 | RVG 08740 | - | - | - | - | 1件: 6 6 💬 |
3767 | RVG 08938 | - | - | - | - | 1件: 75 75 💬 |
3768 | RVG 101614 | - | - | - | - | 1件: 60 60 💬 |
3769 | RVG 104433 | - | - | - | - | 1件: 107 107 💬 |
3770 | RVG 105155 | - | - | - | - | 1件: 60 60 💬 |
3771 | RVG 114681 | - | - | - | - | 1件: 96 96 💬 |
3772 | RVG 116648 | - | - | - | - | 1件: 96 96 💬 |
3773 | RVG 13760 | - | - | - | - | 1件: 298 298 💬 |
3774 | RVG 15375 | - | - | - | - | 1件: 75 75 💬 |
3775 | RVG 15790 or RVG 25480 | - | - | - | - | 1件: 78 78 💬 |
3776 | RVG 18236 | - | - | - | - | 2件: 75 75, 227 💬 |
3777 | RVG 18388 | - | - | - | - | 1件: 160 160 💬 |
3778 | RVT-101 35 mg | - | - | - | - | 1件: 6 6 💬 |
3779 | RVT-1201 | - | - | - | - | 1件: 86 86 💬 |
3780 | RVT-1401 | - | - | - | - | 2件: 11 11, 61 💬 |
3781 | RVT-1601 | - | - | - | - | 1件: 85 85 💬 |
3782 | RVT-1601 (formerly, PA101B) | - | - | - | - | 1件: 85 85 💬 |
3783 | RVT-1601 (in precedenza PA101B) | - | - | - | - | 1件: 85 85 💬 |
3784 | RWJ-445380 100 mg | - | - | - | - | 1件: 46 46 💬 |
3785 | RWJ-445380 200 mg | - | - | - | - | 1件: 46 46 💬 |
3786 | RWJ-445380 300 mg | - | - | - | - | 1件: 46 46 💬 |
3787 | RWJ-445380 capsule 100 mg | - | - | - | - | 1件: 46 46 💬 |
3788 | RWJ-445380 capsules 150 mg | - | - | - | - | 1件: 46 46 💬 |
3789 | RWJ-445380 Capsules 50 mg | - | - | - | - | 1件: 46 46 💬 |
3790 | RWJ-445380-002 | - | - | - | - | 1件: 46 46 💬 |
3791 | Rytary 145 mg | - | - | - | - | 1件: 6 6 💬 |
3792 | Rytary 195 mg | - | - | - | - | 1件: 6 6 💬 |
3793 | S(-)-3-[3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl]-N,4-dimethylbenzamide | - | - | - | - | 1件: 46 46 💬 |
3794 | S-1226 | - | - | - | - | 1件: 299 299 💬 |
3795 | S-adenosyl-L-methionine | 1件: Methionine Methionine | 1件: Methionine
Methionine
💬 | - | - | 1件: 93 93 💬 |
3796 | SA-001 | - | - | - | - | 1件: 298 298 💬 |
3797 | SA001 Low dose | - | - | - | - | 1件: 53 53 💬 |
3798 | Saffron 100 | - | - | - | - | 1件: 97 97 💬 |
3799 | Safinamide + Levodopa | 2件: Levodopa Levodopa, Safinamide | 2件: Levodopa
Levodopa
,
Safinamide
💬 | 6件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5, MAOB 💬 | 20件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Gap junction, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3800 | Safinamide metansolfonato (12 weeks) | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3801 | Safinamide Methanesulfonate 100mg | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3802 | Safinamide Methanesulfonate 150mg | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3803 | Safinimide 50-100 mg/day | - | - | - | - | 1件: 6 6 💬 |
3804 | Sage leaf | 1件: Sage Sage | - | - | - | 1件: 6 6 💬 |
3805 | SAIZEN - 1 FLACONCINO POLV. 8 MG + 1 CARTUCCIA. SOLV. INSERITI IN UN DISPOSITIVO PER LA RICOSTITUZIONE | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
3806 | Salbutamol 4Mg Tablet | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
3807 | Salbutamol WZF 4 mg | 1件: Salbutamol Salbutamol | 1件: Albuterol
Albuterol
💬 | 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 11 11 💬 |
3808 | Saline 0.9% inhalation solution | - | - | - | - | 1件: 299 299 💬 |
3809 | Saline 0.9% NaCl | - | - | - | - | 1件: 235 235 💬 |
3810 | Salofalk 1000mg Granu-Stix | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3811 | Salofalk 1000mg Granu-Stix® | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3812 | Salofalk 4g/60ml Klysma | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3813 | Salofalk® 1000mg Granu-Stix® | 1件: Mesalazine Mesalazine | 1件: Mesalamine
Mesalamine
💬 | - | - | 1件: 97 97 💬 |
3814 | Samsca 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
3815 | SAMSCA*10CPR 15MG | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 💬 |
3816 | SAN-300 0.5 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3817 | SAN-300 1.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3818 | SAN-300 2.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
3819 | SAN-300 4.0 mg/kg QOW | - | - | - | - | 1件: 46 46 💬 |
3820 | SAN-300 4.0 mg/kg QW | - | - | - | - | 1件: 46 46 💬 |
3821 | SANDIMMUN NEORAL - 10 MG CAPSULE MOLLI 50 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
3822 | SANDIMMUN NEORAL - 100 MG CAPSULE MOLLI 30 CAPSULE | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 60 60 💬 |
3823 | SANDIMMUN NEORAL*30CPS 100MG | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 46 46 💬 |
3824 | Sandostatin LAR | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 4件: 67 67, 84, 193, 227 💬 |
3825 | Sandostatin LAR 20 mg | 1件: Octreotide Octreotide | 1件: Octreotide
Octreotide
💬 | 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 💬 |
3826 | SANDOSTATINA - LAR 20 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI | - | - | - | - | 1件: 67 67 💬 |
3827 | SANDOSTATINA LAR | - | - | - | - | 1件: 67 67 💬 |
3828 | Sandostatina Lar IM Fl 20mg +2F | - | - | - | - | 1件: 67 67 💬 |
3829 | Sargramostim (Leukine) | 1件: Sargramostim Sargramostim | 1件: Sargramostim
Sargramostim
💬 | 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 96 96 💬 |
3830 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | 1件: Sarilumab Sarilumab | 1件: Sarilumab
Sarilumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
3831 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 | 1件: Sarilumab Sarilumab | 1件: Sarilumab
Sarilumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 84 84 💬 |
3832 | Saroglitazar Magnesium 1 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 💬 |
3833 | Saroglitazar magnesium 4 mg | 2件: Magnesium Magnesium, Saroglitazar | - | - | - | 1件: 93 93 💬 |
3834 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3835 | Satralizumab (120 mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3836 | Satralizumab (120mg/vial) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3837 | Satralizumab 120 mg | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
3838 | SB-47171 | - | - | - | - | 1件: 19 19 💬 |
3839 | SB-47898 | - | - | - | - | 1件: 19 19 💬 |
3840 | SB-497115 | - | - | - | - | 1件: 63 63 💬 |
3841 | SB-497115-GR | - | - | - | - | 1件: 63 63 💬 |
3842 | SB-497115-GR 12.5mg | - | - | - | - | 1件: 63 63 💬 |
3843 | SB-497115-GR 25mg | - | - | - | - | 1件: 63 63 💬 |
3844 | SB-497115-GR 50 mg | - | - | - | - | 1件: 63 63 💬 |
3845 | SBC-102 | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3846 | SBC-102, recombinant human lysosomal acid lipase | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3847 | SBC-103 | - | - | - | - | 1件: 19 19 💬 |
3848 | SBI-087 | - | - | - | - | 2件: 46 46, 49 💬 |
3849 | SBT-020 | - | - | - | - | 1件: 8 8 💬 |
3850 | SC interferon beta-1a | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3851 | SC interferon beta-1b | 2件: Human interferon beta Human interferon beta, Interferon beta-1b | 1件: Interferon beta-1b
Interferon beta-1b
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3852 | SC Peginterferon beta-1a | 1件: Peginterferon beta-1a Peginterferon beta-1a | 1件: Peginterferon beta-1a
Peginterferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
3853 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
3854 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
3855 | SC0062 low dose | - | - | - | - | 1件: 66 66 💬 |
3856 | SC12267 (4SC-101) | 1件: SC12267 SC12267 | - | - | - | 3件: 46 46, 96, 97 💬 |
3857 | SCH 420814 | - | - | - | - | 1件: 6 6 💬 |
3858 | SCH 420814 10 mg | - | - | - | - | 1件: 6 6 💬 |
3859 | SCH 420814 100 mg | - | - | - | - | 1件: 6 6 💬 |
3860 | SCIO-469 | - | - | - | - | 1件: 46 46 💬 |
3861 | SCM-010 | - | - | - | - | 1件: 13 13 💬 |
3862 | SD-101 | - | - | - | - | 1件: 36 36 💬 |
3863 | SD-101 dermal cream (3%) | - | - | - | - | 1件: 36 36 💬 |
3864 | SD-101 Dermal Cream (6%) | - | - | - | - | 1件: 36 36 💬 |
3865 | SD-101-6.0 cream | - | - | - | - | 1件: 36 36 💬 |
3866 | Search for exocrine pancreatic insufficiency at week 0 and 12 | - | - | - | - | 1件: 96 96 💬 |
3867 | Sebelipase alfa (SBC-102) | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3868 | Sebelipase alfa 0.35 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3869 | Sebelipase alfa 1 mg/kg | 1件: Sebelipase alfa Sebelipase alfa | 1件: Sebelipase alfa
Sebelipase alfa
💬 | 1件: LIPA LIPA 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Steroid biosynthesis 💬 | 1件: 19 19 💬 |
3870 | Secukinumab (150 mg) | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3871 | Secukinumab (AIN457) 150 mg s.c. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3872 | Secukinumab 150 mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 41 41 💬 |
3873 | Secukinumab 150 mg (2 injections per dose | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 269 269 💬 |
3874 | Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3875 | Secukinumab 150 mg/1 mL Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 2件: 37 37, 271 💬 |
3876 | Secukinumab 150 mg/ml | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3877 | Secukinumab 150 milligram [Cosentyx] | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3878 | Secukinumab 150mg | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 37 37 💬 |
3879 | Secukinumab 75 mg/0.5 ml Solution for injection | 1件: Secukinumab Secukinumab | 1件: Secukinumab
Secukinumab
💬 | 1件: IL17A IL17A 💬 | 6件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 271 271 💬 |
3880 | Seladelpar 10 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3881 | Seladelpar 10 mg Capsule | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3882 | Seladelpar 10 mg or less | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3883 | Seladelpar 5-10 mg | 1件: Seladelpar Seladelpar | 1件: Seladelpar
Seladelpar
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 93 93 💬 |
3884 | Selumetinib 10mg capsule | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3885 | Selumetinib capsules 10mg | 1件: Selumetinib Selumetinib | 1件: Selumetinib
Selumetinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
3886 | Semi continuous intra-oral administration of LD/CD | - | - | - | - | 1件: 6 6 💬 |
3887 | SEN0014196 (Low Dose) | - | - | - | - | 1件: 8 8 💬 |
3888 | Serum physiologique 0.9 % | - | - | - | - | 1件: 96 96 💬 |
3889 | Sezione * D.3.6.2.1 - valore: 400mg alla settimana 0, in seguito 200mg ogni due settimane | - | - | - | - | 1件: 96 96 💬 |
3890 | SGT-001 | - | - | - | - | 1件: 113 113 💬 |
3891 | SHR-1209 | - | - | - | - | 1件: 79 79 💬 |
3892 | SHR-1314 | - | - | - | - | 1件: 271 271 💬 |
3893 | SHR-1906 | - | - | - | - | 1件: 85 85 💬 |
3894 | Sifalimumab 1,200 mg | 1件: Sifalimumab Sifalimumab | 1件: Sifalimumab
Sifalimumab
💬 | 13件: IFNA1 IFNA1, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA2, IFNA21, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8 💬 | 25件: Alcoholic liver disease Alcoholic liver disease, Autoimmune thyroid disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, PI3K-Akt signaling pathway, Pathways in cancer, RIG-I-like receptor signaling pathway, Toll-like receptor signaling pathway, Tuberculosis 💬 | 1件: 49 49 💬 |
3895 | Sifrol 0,088 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3896 | Sifrol 0,18 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3897 | Sifrol 0,35 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3898 | Sifrol 0,7 | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3899 | Sifrol, 0,35 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3900 | Sifrol, 0,70 mg Tablette | 1件: Pramipexole Pramipexole | 1件: Pramipexole
Pramipexole
💬 | 3件: DRD2 DRD2, DRD3, DRD4 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3901 | Sildenafil (Acute-1 hour) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
3902 | Sildenafil (Subchronic-4 weeks) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
3903 | Sildenafil 40mg oral capsule | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 299 299 💬 |
3904 | Sildenafil and Losartan | 2件: Losartan Losartan, Sildenafil | 2件: Losartan
Losartan
,
Sildenafil
💬 | 2件: AGTR1 AGTR1, PDE5A 💬 | 18件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Purine metabolism, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 85 85 💬 |
3905 | Sildenafil citrate (UK-92,480) | 1件: Sildenafil Sildenafil | 1件: Sildenafil
Sildenafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
3906 | SIMPONI - 50 MG-SOLUZIONE PER INIEZIONE IN PENNA PRERIEMPITA-USO SOTTOCUTANEO-PENNA PRERIEMPITA(VETRO) -0.5 ML 3 (3X1) PENNE PRERIEMPITE | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
3907 | SimvaHEXAL® 40 mg Filmtabletten | - | - | - | - | 1件: 13 13 💬 |
3908 | Simvastatin 40 mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
3909 | Simvastatin 40 mg film-coated tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
3910 | Simvastatin 40 mg tablets | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 86 86 💬 |
3911 | Simvastatin 40mg | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 94 94 💬 |
3912 | Simvastatina Sandoz 40 mg comprimidos recubiertos con película EFG | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
3913 | Simvastatine Sandoz 40 mg filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
3914 | Simvastatine Sandoz 40mg deelbare filmomhulde tabletten | 1件: Simvastatin Simvastatin | 1件: Simvastatin
Simvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
3915 | SIN LV Mediated ex vivo transduced autologous fibroblasts expressing codon-optimised COL7A1 | - | - | - | - | 1件: 36 36 💬 |
3916 | Sinemet (carbidopa/levodopa) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3917 | Sinemet (levodopa/carbidopa) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3918 | SINEMET - 100 MG + 25 MG COMPRESSE 50 COMPRESSE DIVISIBILI | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3919 | SINEMET 10-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3920 | SINEMET 100 mg + 25 mg compresse | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3921 | SINEMET 100 mg + 25 mg tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3922 | SINEMET 125 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3923 | Sinemet 125 mg | - | - | - | - | 1件: 6 6 💬 |
3924 | SINEMET 25-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3925 | Sinemet 25-100 Oral Tablet | 1件: Carbidopa Carbidopa | 1件: Carbidopa
Carbidopa
💬 | 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
3926 | SINEMET 25/100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3927 | Sinemet CR 25Mg-100Mg Extended-Release Tablet | 3件: Carbidopa Carbidopa, Levodopa, Manganese citrate | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3928 | Sinemet plus (levodopa/carbidopa) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3929 | SINEMET*50CPR 100MG+25MG | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3930 | Sinemet® 100/25 | - | - | - | - | 1件: 6 6 💬 |
3931 | Sinemet® 100/25 mg | - | - | - | - | 1件: 6 6 💬 |
3932 | Sinemet® controlled release (Carbidopa/levodopa) | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3933 | Sinemet® CR 100/25 | - | - | - | - | 1件: 6 6 💬 |
3934 | SINEMET® Plus 25 mg/100 mg Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3935 | Sinemet®25-100 | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3936 | Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) | - | - | - | - | 1件: 28 28 💬 |
3937 | Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy | - | - | - | - | 1件: 79 79 💬 |
3938 | Sinvastatina Sandoz 40 mg comprimidos revestidos por película | - | - | - | - | 1件: 13 13 💬 |
3939 | Siponimod 0,25 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3940 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3941 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3942 | Siponimod 1 mg | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 💬 |
3943 | Siponimod 1 mg tablet | 1件: Siponimod Siponimod | 1件: Siponimod
Siponimod
💬 | 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 💬 |
3944 | SIRIO*30CPR EFF 25MG+100MG | - | - | - | - | 1件: 6 6 💬 |
3945 | Sirolimus 0,1% crème | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
3946 | Sirolimus 0.2% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3947 | Sirolimus 0.4% | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
3948 | Sirolimus 1mg/mL | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 2件: 278 278, 280 💬 |
3949 | Sirolimus and Hydroxychloroquine 400 mg | 2件: Hydroxychloroquine Hydroxychloroquine, Sirolimus | 2件: Sirolimus
Sirolimus
,
Hydroxychloroquine
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 89 89 💬 |
3950 | Sirolimus Oral Liquid Product 1mg/mL | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
3951 | Sirukumab 100 mg | 1件: Sirukumab Sirukumab | 1件: Sirukumab
Sirukumab
💬 | 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 💬 |
3952 | Sivatin 40 mg film-coated tablets | - | - | - | - | 1件: 13 13 💬 |
3953 | SKF-101468A | - | - | - | - | 1件: 6 6 💬 |
3954 | SLS-005 | - | - | - | - | 1件: 2 2 💬 |
3955 | SLS-005 Trehalose | 1件: Trehalose Trehalose | - | - | - | 1件: 2 2 💬 |
3956 | SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML | 2件: Medium-chain triglycerides Medium-chain triglycerides, Sodium glycerophosphate | 1件: Sodium glycerophosphate
Sodium glycerophosphate
💬 | - | - | 1件: 66 66 💬 |
3957 | SMP-114 | - | - | - | - | 1件: 46 46 💬 |
3958 | Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca | - | - | - | - | 1件: 299 299 💬 |
3959 | Sodium (S)-3-(4-hydroxyphenyl)-2-(2-((S)-1-((S)-1-palmitoylpyrrolidine-2-carbonyl)pyrrolidine-2-carboxamido)acetamido)propanoate | 1件: Pyrrolidine Pyrrolidine | - | - | - | 1件: 97 97 💬 |
3960 | Sodium 4-Phenylbutyrate | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
3961 | Sodium 4-Phenylbutyrate (4PBA) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 299 299 💬 |
3962 | Sodium acetate (1-13C) | 2件: Acetate Acetate, Sodium acetate | 1件: Sodium acetate
Sodium acetate
💬 | - | - | 1件: 251 251 💬 |
3963 | Sodium chloride 0,9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
3964 | Sodium Chloride 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 2件: 14 14, 227 💬 |
3965 | SODIUM CHLORIDE SOLUTION 0.9% | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 4件: 51 51, 60, 288, 299 💬 |
3966 | Sodium Ethanoate (1- 13 C) | 1件: Acetic acid Acetic acid | 1件: Acetic acid, glacial
Acetic acid, glacial
💬 | - | - | 1件: 251 251 💬 |
3967 | Sodium Ethanoate (1-13C) | 1件: Acetic acid Acetic acid | 1件: Acetic acid, glacial
Acetic acid, glacial
💬 | - | - | 1件: 251 251 💬 |
3968 | Sodium fluoride 18F | 1件: Sodium fluoride Sodium fluoride | 1件: Sodium fluoride
Sodium fluoride
💬 | - | - | 1件: 51 51 💬 |
3969 | Sodium Picosulfate/Magnesium Citrate Laxative | 4件: Magnesium Magnesium, Magnesium citrate, Picosulfuric acid, Polyethylene glycol | 2件: Magnesium citrate
Magnesium citrate
,
Polyethylene glycol 3350
💬 | - | - | 1件: 97 97 💬 |
3970 | Sodium Pyruvate in 0.9% Sodium Chloride Solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: Sodium chloride
Sodium chloride
💬 | - | - | 1件: 299 299 💬 |
3971 | Sodium Thiosulfate 10% | - | - | - | - | 2件: 50 50, 51 💬 |
3972 | Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
3973 | Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
3974 | SOL-116 | - | - | - | - | 1件: 46 46 💬 |
3975 | SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML) | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 13 13, 62, 109 💬 |
3976 | SOLU MEDROL - 125 MG/2 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 125 MG/2 ML | - | - | - | - | 3件: 13 13, 14, 53 💬 |
3977 | SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML | - | - | - | - | 1件: 56 56 💬 |
3978 | SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML | - | - | - | - | 1件: 56 56 💬 |
3979 | Solu-Cortef 100 MG Injection | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
,
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 83 83 💬 |
3980 | Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial' | 3件: Hydrocortisone Hydrocortisone, Hydrocortisone cypionate, Hydrocortisone succinate | 3件: Hydrocortisone
Hydrocortisone
,
Hydrocortisone cypionate
,
Hydrocortisone succinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
3981 | Solu-medrol inj. PSO LQF 40mg | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 50 50 💬 |
3982 | Solu-Medrone 125mg | - | - | - | - | 1件: 46 46 💬 |
3983 | SOLU-MODERIN 1 g | - | - | - | - | 1件: 13 13 💬 |
3984 | Solumedrol IM 125mg/2ml | - | - | - | - | 1件: 13 13 💬 |
3985 | Soluzione di levodopa/carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3986 | SOM230 LAR | - | - | - | - | 1件: 75 75 💬 |
3987 | SOM230 LAR 10 mg | - | - | - | - | 1件: 75 75 💬 |
3988 | SOM230 LAR 30 mg | - | - | - | - | 1件: 75 75 💬 |
3989 | SOM230 LAR, 20 mg | - | - | - | - | 1件: 75 75 💬 |
3990 | SOM3355 100mg BID | - | - | - | - | 1件: 8 8 💬 |
3991 | Somapacitan 10 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
3992 | Somapacitan 10 mg/1.5ml PDS290S | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
3993 | Somapacitan 15 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
3994 | Somapacitan 15 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
3995 | Somapacitan 5 mg/1.5 mL PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 195 195 💬 |
3996 | Somapacitan 5 mg/1.5ml PDS290 | 1件: Somapacitan Somapacitan | 1件: Somapacitan
Somapacitan
💬 | 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 💬 |
3997 | Somatic gene-therapy by X-CGD | - | - | - | - | 1件: 65 65 💬 |
3998 | Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate | 5件: Arginine Arginine, Clonidine, Estradiol, Estradiol valerate, Somatotropin | 4件: Estradiol
Estradiol
,
Clonidine
,
Estradiol valerate
,
Arginine
💬 | 5件: ADRA2A ADRA2A, ADRA2B, ADRA2C, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Neuroactive ligand-receptor interaction, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
3999 | Sortis 10 mg | - | - | - | - | 1件: 93 93 💬 |
4000 | Sotatercept - 45 mg/vial | 1件: Sotatercept Sotatercept | 1件: Sotatercept
Sotatercept
💬 | 1件: ACVR2A ACVR2A 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway 💬 | 1件: 86 86 💬 |
4001 | SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM | 1件: Ioflupane I-123 Ioflupane I-123 | - | - | - | 1件: 2 2 💬 |
4002 | SPI-1005 Ebselen 200mg Capsule x1 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4003 | SPI-1005 Ebselen 200mg Capsule x2 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4004 | SPI-1005 Ebselen 200mg Capsule x3 | 1件: Ebselen Ebselen | - | - | - | 1件: 299 299 💬 |
4005 | SPI-62 dose 4 | - | - | - | - | 1件: 75 75 💬 |
4006 | Sporanox 10 mg/ml Oral Solution | 1件: Itraconazole Itraconazole | 1件: Itraconazole
Itraconazole
💬 | - | - | 1件: 299 299 💬 |
4007 | SPP-004 | - | - | - | - | 1件: 21 21 💬 |
4008 | SPX-101 | - | - | - | - | 1件: 299 299 💬 |
4009 | SRK-015 | - | - | - | - | 1件: 3 3 💬 |
4010 | SRP-4045 | - | - | - | - | 1件: 113 113 💬 |
4011 | SRP-4053 | - | - | - | - | 1件: 113 113 💬 |
4012 | SS-1 | - | - | - | - | 1件: 53 53 💬 |
4013 | SSP-004184 100 mg | - | - | - | - | 1件: 284 284 💬 |
4014 | SSP-004184 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4015 | SSP-004184 250 mg | - | - | - | - | 1件: 284 284 💬 |
4016 | SSP-004184 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4017 | SSP-004184 375 mg | - | - | - | - | 1件: 284 284 💬 |
4018 | SSP-004184 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4019 | SSP-004184 50 mg | - | - | - | - | 1件: 284 284 💬 |
4020 | SSP-004184 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4021 | SSP-004184 500 mg | - | - | - | - | 1件: 284 284 💬 |
4022 | SSP-004184 500 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4023 | SSP-004184AQ 100 mg | - | - | - | - | 1件: 284 284 💬 |
4024 | SSP-004184AQ 100 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4025 | SSP-004184AQ 200 mg | - | - | - | - | 1件: 284 284 💬 |
4026 | SSP-004184AQ 200 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4027 | SSP-004184AQ 250 mg | - | - | - | - | 1件: 284 284 💬 |
4028 | SSP-004184AQ 250 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4029 | SSP-004184AQ 375 mg | - | - | - | - | 1件: 284 284 💬 |
4030 | SSP-004184AQ 375 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4031 | SSP-004184AQ 50 mg | - | - | - | - | 1件: 284 284 💬 |
4032 | SSP-004184AQ 50 mg Capsule | - | - | - | - | 1件: 284 284 💬 |
4033 | ST-0529 | - | - | - | - | 1件: 97 97 💬 |
4034 | ST10-021 | - | - | - | - | 2件: 96 96, 97 💬 |
4035 | Stalevo (levodopa/ carbidopa/ entacapone) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4036 | Stalevo (levodopa/carbidopa/entacapona) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4037 | Stalevo (levodopa/carbidopa/entacapone) | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4038 | Stalevo 100 | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4039 | Stalevo 100 mg/ 25 mg/ 200 mg Filmtabletten | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4040 | Stalevo 100 mg/25 mg / 200 mg | - | - | - | - | 1件: 6 6 💬 |
4041 | Stalevo 100/25/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4042 | Stalevo 150 | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4043 | Stalevo 150/37.5/200 mg | 3件: Carbidopa Carbidopa, Entacapone, Levodopa | 3件: Levodopa
Levodopa
,
Carbidopa
,
Entacapone
💬 | 7件: COMT COMT, DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 17件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Steroid hormone biosynthesis, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4044 | STALEVO*100CPR 100/25/200MG | 2件: Entacapone Entacapone, Levodopa | 2件: Levodopa
Levodopa
,
Entacapone
💬 | 6件: COMT COMT, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Steroid hormone biosynthesis, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4045 | STALEVO*100CPR 50/12,5/200MG | 2件: Entacapone Entacapone, Levodopa | 2件: Levodopa
Levodopa
,
Entacapone
💬 | 6件: COMT COMT, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Steroid hormone biosynthesis, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4046 | Standard Dose YPT-01 | - | - | - | - | 1件: 299 299 💬 |
4047 | Standard LD/CD | - | - | - | - | 1件: 6 6 💬 |
4048 | Standard-dose vitamin D (400IU per day) | 1件: Vitamin D Vitamin D | - | - | - | 1件: 274 274 💬 |
4049 | STELARA - 45 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 0.5 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4050 | STELARA - 90 MG - SOLUZIONE INIETTABILE IN SIRINGHE PRERIEMPITE - USO SOTTOCUTANEO - SIRINGA PRERIEMPITA(VETRO) 1 ML(90MG/ML) 1 SIRINGA PRERIEMPITA DA 1 ML | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4051 | STELARA - 90 MG SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) 1.0 ML (90 MG/ML) 1 FLACONCINO | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 2件: 96 96, 97 💬 |
4052 | STELARA 130 mg concentrate for solution for infusion | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4053 | Stelara 130mg / 26mL concentrate for solution for | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4054 | Stelara 130mg / 26mL concentrate for solution for infusion | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4055 | Stelara 90mg/1ml solution for injecti | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4056 | Stelara 90mg/1ml solution for injection in pre-filled syringe (PFS) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4057 | Sterile Normal Saline (0.9% NaCl) | - | - | - | - | 2件: 62 62, 254 💬 |
4058 | STERILE PYROGEN-FREE ISOTONIC NACL SOLUTE (0.9% W / V) | - | - | - | - | 1件: 299 299 💬 |
4059 | STG-001 | 1件: STG-001 STG-001 | - | - | - | 1件: 301 301 💬 |
4060 | STK-001 | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4061 | STK-001 - Multiple Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4062 | STK-001 - Single Ascending Doses | 1件: Zorevunersen Zorevunersen | - | - | - | 1件: 140 140 💬 |
4063 | STNM01 1.84 mg | - | - | - | - | 1件: 97 97 💬 |
4064 | Subcutaneous hydrocortisone 10mg | 1件: Hydrocortisone Hydrocortisone | 1件: Hydrocortisone
Hydrocortisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 💬 |
4065 | Subcutaneous tocilizumab 162mg/biweekly | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4066 | Subjects will undergo the 123-I IBVM imaging visit | - | - | - | - | 1件: 6 6 💬 |
4067 | Sublingual tizanidine 12 mg | 1件: Tizanidine Tizanidine | 1件: Tizanidine
Tizanidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 13 13 💬 |
4068 | Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] | 1件: Sulfur hexafluoride Sulfur hexafluoride | 1件: Sulfur hexafluoride
Sulfur hexafluoride
💬 | - | - | 1件: 215 215 💬 |
4069 | Sulindac (HLX-0201), dose strength 1 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
4070 | Sulindac (HLX-0201), dose strength 2 | 1件: Sulindac Sulindac | 1件: Sulindac
Sulindac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 206 206 💬 |
4071 | Suspension containing 250 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4072 | Suspension containing 250 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4073 | Suspension containing 2500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4074 | Suspension containing 2500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4075 | SUSPENSION CONTAINING 7500 EMBRYONATED VIABLE TRICHURIS SUIS OVA/15ML | - | - | - | - | 1件: 97 97 💬 |
4076 | Suspension containing 7500 embryonated, viable Trichuris suis ova (TSO)/15ml | - | - | - | - | 1件: 96 96 💬 |
4077 | Suspension of 7500 embryonated, viable TSO/15ml | - | - | - | - | 1件: 96 96 💬 |
4078 | Suspension of human autologous MSC 3P in 1,5 ml | - | - | - | - | 1件: 2 2 💬 |
4079 | Suspension of human autologous MSC 3P in 1.5 ml | - | - | - | - | 1件: 2 2 💬 |
4080 | Symkevi 100mg/150mg Film-coated tablets | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4081 | Synacthen Depot 1mg | 1件: Tetracosactide Tetracosactide | 1件: Cosyntropin
Cosyntropin
💬 | 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 222 222 💬 |
4082 | Synbiotic (Synergy I / B.longum) | - | - | - | - | 1件: 96 96 💬 |
4083 | Synergy-1 | - | - | - | - | 1件: 97 97 💬 |
4084 | Synthetic 15-amino-acid macrocyclic peptide | - | - | - | - | 1件: 62 62 💬 |
4085 | Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 | - | - | - | - | 1件: 62 62 💬 |
4086 | Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol24 palmitoylated linker | - | - | - | - | 1件: 62 62 💬 |
4087 | Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker | - | - | - | - | 1件: 62 62 💬 |
4088 | Synthetic Human Parathyroid Hormone 1-34 | 1件: Parathyroid hormone Parathyroid hormone | 1件: Parathyroid hormone
Parathyroid hormone
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
4089 | Syntocinon 40 IU/ml nasal spray | 1件: Oxytocin Oxytocin | 1件: Oxytocin
Oxytocin
💬 | 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4090 | Sübetaholzwurzel 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
4091 | Süßholzwurzel 1ml/10ml | - | - | - | - | 1件: 97 97 💬 |
4092 | T 100 PARI | - | - | - | - | 1件: 299 299 💬 |
4093 | T Cell-Depleted Donor Lymphocyte Infusion | - | - | - | - | 1件: 60 60 💬 |
4094 | TA-46 | - | - | - | - | 1件: 276 276 💬 |
4095 | TA-650 10 mg/kg | - | - | - | - | 1件: 46 46 💬 |
4096 | TACHIPIRINA - 1000 MG COMPRESSE 8 COMPRESSE | - | - | - | - | 1件: 14 14 💬 |
4097 | Tacrolimus capsule (low-dose) | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
4098 | Tadalafil 40 mg | 1件: Tadalafil Tadalafil | 1件: Tadalafil
Tadalafil
💬 | 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
4099 | TAK-018 | - | - | - | - | 1件: 96 96 💬 |
4100 | TAK-071 | - | - | - | - | 1件: 6 6 💬 |
4101 | TAK-079 | - | - | - | - | 3件: 11 11, 49, 63 💬 |
4102 | TAK-079, TSF-021, TSF79 | - | - | - | - | 1件: 11 11 💬 |
4103 | TAK-475 | 1件: TAK-475 TAK-475 | - | - | - | 1件: 79 79 💬 |
4104 | Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication) | 3件: Amoxicillin Amoxicillin, Clarithromycin, Metronidazole | 4件: Amoxicillin
Amoxicillin
,
Clarithromycin
,
Metronidazole
,
Amoxicillin
💬 | - | - | 1件: 63 63 💬 |
4105 | Tamoxifen 40 mg daily for one year | 1件: Tamoxifen Tamoxifen | 1件: Tamoxifen
Tamoxifen
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 2 2 💬 |
4106 | TAP-144-SR(3M) | - | - | - | - | 1件: 1 1 💬 |
4107 | Targinact 10 mg/5 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 2件: 6 6, 226 💬 |
4108 | Targinact 20 mg/10 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 6 6 💬 |
4109 | Targinact 20mg/10 mg prolonged-release tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 226 226 💬 |
4110 | TAS5315 low dose | - | - | - | - | 1件: 46 46 💬 |
4111 | Tasigna 150mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 💬 |
4112 | Tasigna® 150 mg | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 💬 |
4113 | Tau (18-F-AV-1451) | - | - | - | - | 1件: 127 127 💬 |
4114 | Tavapadon 0.25 mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4115 | Tavapadon 0.25mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4116 | Tavapadon 1mg | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4117 | TAVT-18 (sirolimus) | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
4118 | TBX-1400 | - | - | - | - | 1件: 65 65 💬 |
4119 | TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt) | 1件: Hydrogen Hydrogen | - | - | - | 1件: 6 6 💬 |
4120 | TCM (Gan-Lu-Yin)GLY | - | - | - | - | 1件: 53 53 💬 |
4121 | TD-1058 | - | - | - | - | 1件: 85 85 💬 |
4122 | TD-1473 | - | - | - | - | 2件: 96 96, 97 💬 |
4123 | TD-1473 Dose A | - | - | - | - | 1件: 97 97 💬 |
4124 | TD-1473 Dose B | - | - | - | - | 1件: 97 97 💬 |
4125 | TD-1473 Dose C | - | - | - | - | 1件: 97 97 💬 |
4126 | Tea leaf | 1件: Tea leaf Tea leaf | - | - | - | 1件: 17 17 💬 |
4127 | Tecfidera® 120 mg | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
4128 | Tecfidera® 120mg magensaftresistente Hartkapseln | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: Dimethyl fumarate
Dimethyl fumarate
💬 | 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 💬 |
4129 | Teduglutide (ALX-0600) | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4130 | Teduglutide 0.05 | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4131 | Teduglutide 0.05 dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4132 | Teduglutide 0.1 mg dose | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4133 | Teduglutide 0.2 mg | 1件: Teduglutide Teduglutide | 1件: Teduglutide
Teduglutide
💬 | 1件: GLP2R GLP2R 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 96 96 💬 |
4134 | Telitacicept 160 mg | - | - | - | - | 1件: 53 53 💬 |
4135 | Telitacicept 160mg | - | - | - | - | 1件: 66 66 💬 |
4136 | Terguride 0,5mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
4137 | Terguride 0.5 mg tablet | 1件: Terguride Terguride | 1件: Terguride
Terguride
💬 | 2件: DRD2 DRD2, PRL 💬 | 12件: Alcoholism Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 86 86 💬 |
4138 | Teriflunomide 14 MG | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
4139 | Teriflunomide 14 MG Oral Tablet [Aubagio] | 1件: Teriflunomide Teriflunomide | 1件: Teriflunomide
Teriflunomide
💬 | 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 💬 |
4140 | Teriparatide [rDNA origin] contains recombinant human parathyroid hormone (1-34) | 2件: Parathyroid hormone Parathyroid hormone, Teriparatide | 2件: Parathyroid hormone
Parathyroid hormone
,
Teriparatide
💬 | 2件: PTH1R PTH1R, PTH2R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 70 70 💬 |
4141 | Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker | 2件: Polyethylene glycol Polyethylene glycol, Teriparatide | 2件: Polyethylene glycol 3350
Polyethylene glycol 3350
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
4142 | TETA 4HCL | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
4143 | TETA.4HCI | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
4144 | TETA.4HCl | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 💬 |
4145 | TETRACT-HIB - 1 SIRINGA PRECARICATA 0.5 ML | - | - | - | - | 1件: 222 222 💬 |
4146 | Tetrahydro-6,6,9-tri methyl-3-penthyl-6 H-dibenzo[ b,d ]pyran-1-ol | - | - | - | - | 1件: 298 298 💬 |
4147 | TEV-48574 | - | - | - | - | 2件: 96 96, 97 💬 |
4148 | TEV-48574 Dose Regimen A | - | - | - | - | 2件: 96 96, 97 💬 |
4149 | TEV-48574 Dose Regiment B | - | - | - | - | 2件: 96 96, 97 💬 |
4150 | Tezacaftor/Ivacaftor 100mg/150mg | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4151 | Tezacaftor/Ivacaftor/100mg/150mg | 2件: Ivacaftor Ivacaftor, Tezacaftor | 2件: Ivacaftor
Ivacaftor
,
Tezacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4152 | TG-1101 | - | - | - | - | 1件: 13 13 💬 |
4153 | Thalidomide 100mg | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
4154 | Thalidomide 150mg | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 💬 |
4155 | The 0.5 mL dose of vaccine contains 25 micrograms of each of the following 23 pneumococcal polysaccharide | - | - | - | - | 1件: 222 222 💬 |
4156 | The effectiveness of Xeljanz in rheumatoid arthritis patients | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4157 | The investigational medicinal product (IMP) may be labelled as either PF-04236921 106 mg/vial, Clonal SC lyophilized form” or PF-04236921 Powder for Injection, 106 mg/vial”. Supplies labelled with either nomenclature are equivalent. | - | - | - | - | 1件: 96 96 💬 |
4158 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
4159 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
4160 | The lung mycobiota and microbiota profile | - | - | - | - | 1件: 299 299 💬 |
4161 | Therapeutic Allogeneic Lymphocytes | - | - | - | - | 3件: 60 60, 65, 285 💬 |
4162 | THRX-139060 | - | - | - | - | 2件: 96 96, 97 💬 |
4163 | THRX-199687 hydrochloride | - | - | - | - | 1件: 99 99 💬 |
4164 | Thymosin alpha 1 | - | - | - | - | 1件: 299 299 💬 |
4165 | Thymosin Beta 4 | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 2件: 36 36, 53 💬 |
4166 | Thymosin Beta 4 eye drops | 1件: Thymosin beta-4 Thymosin beta-4 | - | - | - | 1件: 53 53 💬 |
4167 | Tibulizumab (LY3090106) | 1件: Tibulizumab Tibulizumab | 1件: Tibulizumab
Tibulizumab
💬 | 2件: IL17A IL17A, TNFSF13B 💬 | 8件: Alcoholic liver disease Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis, Th17 cell differentiation 💬 | 1件: 53 53 💬 |
4168 | Tildrakizumab 100 mg/ml | 1件: Tildrakizumab Tildrakizumab | 1件: Tildrakizumab
Tildrakizumab
💬 | 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 271 271 💬 |
4169 | Timolol Alcon 0.5% collyre | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
4170 | Tiotropium bromide low | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4171 | Tiotropium bromide-low dose-2.5mcg | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4172 | Tiotropium Respimat 1.25 microgram solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4173 | Tiotropium Respimat 1.25 microgram, solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4174 | Tiotropium Respimat 1.25 micrograms solution for inhalation | 1件: Tiotropium Tiotropium | - | - | - | 1件: 299 299 💬 |
4175 | TLL-018 | - | - | - | - | 1件: 46 46 💬 |
4176 | TLR7/8 Antagonist (10mg) | - | - | - | - | 1件: 49 49 💬 |
4177 | TMI-005 | - | - | - | - | 1件: 46 46 💬 |
4178 | TMI-005 (WAY-177005) | - | - | - | - | 1件: 46 46 💬 |
4179 | TMI-005 WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
4180 | TNR-001 | - | - | - | - | 2件: 46 46, 271 💬 |
4181 | TNR-001, TNFR:FC | - | - | - | - | 1件: 271 271 💬 |
4182 | TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | - | - | - | - | 1件: 85 85 💬 |
4183 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4184 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4185 | TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4186 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4187 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4188 | TOBI™ Podhaler™ 112 mg inhaled twice daily | - | - | - | - | 1件: 299 299 💬 |
4189 | Tobramycin 100 PARI | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4190 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4191 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
4192 | Tocilizumab 162 mg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4193 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
4194 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4195 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4196 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4197 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4198 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
4199 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
4200 | Tocovid Suprabio (HOV-12020) | - | - | - | - | 1件: 6 6 💬 |
4201 | Tofacitinib (Xeljanz) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4202 | Tofacitinib (Xeljanz®) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4203 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4204 | Tofacitinib 10 mg | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 💬 |
4205 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
4206 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 💬 |
4207 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
4208 | Tofacitinib XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 271 💬 |
4209 | Tolebrutinib 120mg | - | - | - | - | 1件: 13 13 💬 |
4210 | Tolerogenic Dendritic cells loaded with myelin peptides | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
4211 | TOLVAPTAN (OPC-41061) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4212 | TOLVAPTAN 15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4213 | Tolvaptan 15 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4214 | Tolvaptan 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4215 | Tolvaptan 15mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4216 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
4217 | Tominersen 100 mg | - | - | - | - | 1件: 8 8 💬 |
4218 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
4219 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
4220 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
4221 | TORVAST*10CPR 10MG | - | - | - | - | 1件: 13 13 💬 |
4222 | Total Body Irradiation (TBI) (Plan 1) | - | - | - | - | 2件: 60 60, 285 💬 |
4223 | TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML | - | - | - | - | 1件: 299 299 💬 |
4224 | Tozadenant (SYN115) 120 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4225 | Tozadenant (SYN115) 180 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4226 | TPN-101 | - | - | - | - | 3件: 2 2, 127, 325 💬 |
4227 | TPN-101, 400 mg/day | - | - | - | - | 2件: 2 2, 127 💬 |
4228 | TRACLEER 125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 88 88 💬 |
4229 | TRACLEER*125MG 56CPR RIV. | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 51 51, 86 💬 |
4230 | TRACLEER*56CPR RIV 125MG | 1件: Bosentan Bosentan | 2件: Bosentan
Bosentan
,
Bosentan
💬 | 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 88 💬 |
4231 | Trade Name Xarelto | 1件: Rivaroxaban Rivaroxaban | 1件: Rivaroxaban
Rivaroxaban
💬 | 1件: F10 F10 💬 | 1件: Complement and coagulation cascades Complement and coagulation cascades 💬 | 1件: 49 49 💬 |
4232 | Tralokinumab cohort 1 | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬 | 1件: IL13 IL13 💬 | 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬 |
4233 | Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor | 1件: Tralokinumab Tralokinumab | 1件: Tralokinumab
Tralokinumab
💬 | 1件: IL13 IL13 💬 | 8件: Asthma Asthma, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation 💬 | 1件: 85 85 💬 |
4234 | Trametinib (0.5 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
4235 | Trametinib (1 mg) | 1件: Trametinib Trametinib | 1件: Trametinib
Trametinib
💬 | 2件: MAP2K1 MAP2K1, MAP2K2 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, B cell receptor signaling pathway, Bladder cancer, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, VEGF signaling pathway, Vascular smooth muscle contraction, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 2 2 💬 |
4236 | TransCon hGH (ACP-011) | - | - | - | - | 1件: 78 78 💬 |
4237 | TransCon hGH (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
4238 | TransCon hGH (ACP-011) - 12.1mg | - | - | - | - | 1件: 78 78 💬 |
4239 | TransCon hGH (ACP-011) - 24.2mg | - | - | - | - | 1件: 78 78 💬 |
4240 | TransCon hGH CT-301 (ACP-011) - 12,1mg | - | - | - | - | 1件: 78 78 💬 |
4241 | TransCon PTH low-dose pen | - | - | - | - | 1件: 235 235 💬 |
4242 | Transdermal flumazenil (Added 4/2020) | 1件: Flumazenil Flumazenil | 1件: Flumazenil
Flumazenil
💬 | 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 💬 |
4243 | Transduced Lymphocytes | - | - | - | - | 1件: 65 65 💬 |
4244 | Translarna 1000 mg granules for oral suspension | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
4245 | Translarna 125 mg granules for oral suspension | 1件: Ataluren Ataluren | 1件: Ataluren
Ataluren
💬 | - | - | 1件: 113 113 💬 |
4246 | Transvamix (100mg/mL THC, 50mg/mL CBD) | - | - | - | - | 1件: 36 36 💬 |
4247 | Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms | 1件: Lansoprazole Lansoprazole | 1件: Lansoprazole
Lansoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 98 98 💬 |
4248 | Treatment Phase Group 4 | - | - | - | - | 1件: 113 113 💬 |
4249 | Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor | 4件: Elexacaftor Elexacaftor, Ivacaftor, Lumacaftor, Tezacaftor | 4件: Ivacaftor
Ivacaftor
,
Lumacaftor
,
Tezacaftor
,
Elexacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4250 | Treatment with polyethylene glycol (Macrogol 4000) | 1件: Polyethylene glycol Polyethylene glycol | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 299 299 💬 |
4251 | TREPROSTINIL SODIUM, UT-15 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4252 | Treprostinil, UT-15, LRX-15, 15AU81, BW A15AU, U-62, 840 | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4253 | Triam 40 mg Lichtenstein | - | - | - | - | 1件: 46 46 💬 |
4254 | Triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
4255 | Triamcinolone hexacetonid (Lederspan) | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
4256 | Triamcinolone hexacetonide (Lederspan) | 1件: Triamcinolone Triamcinolone | 1件: Triamcinolone
Triamcinolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 💬 |
4257 | Triheptanoin 1g/kg/day | 1件: Triheptanoin Triheptanoin | 1件: Triheptanoin
Triheptanoin
💬 | - | - | 1件: 8 8 💬 |
4258 | TRIMETON - 10 MG/1 ML SOLUZIONE INIETTABILE 5 FIALE 1 ML | - | - | - | - | 1件: 14 14 💬 |
4259 | Triptorelin pamoate 15mg | 1件: Triptorelin Triptorelin | 1件: Triptorelin
Triptorelin
💬 | 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 76 76 💬 |
4260 | Triptorlin or Leuprorelin | 1件: Leuprolide Leuprolide | - | - | - | 1件: 76 76 💬 |
4261 | TRK-100STP | - | - | - | - | 1件: 86 86 💬 |
4262 | TRK-170 | - | - | - | - | 1件: 96 96 💬 |
4263 | TRU-015 | 1件: TRU-015 TRU-015 | - | - | - | 3件: 46 46, 49, 222 💬 |
4264 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
4265 | Trulicity 0,75 mg injekcný roztok naplnený v injekcnom pere. | 1件: Dulaglutide Dulaglutide | 1件: Dulaglutide
Dulaglutide
💬 | 1件: GLP1R GLP1R 💬 | 3件: Insulin secretion Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 13 13 💬 |
4266 | TS-152 | - | - | - | - | 1件: 46 46 💬 |
4267 | TSHA-101 | - | - | - | - | 1件: 19 19 💬 |
4268 | TSHA-102 | - | - | - | - | 1件: 156 156 💬 |
4269 | TTI-101 | - | - | - | - | 1件: 85 85 💬 |
4270 | TTI-1612 | - | - | - | - | 1件: 226 226 💬 |
4271 | TU-100 | 1件: TU-100 TU-100 | - | - | - | 1件: 96 96 💬 |
4272 | TV-1106 | - | - | - | - | 1件: 78 78 💬 |
4273 | TV-4710 | - | - | - | - | 1件: 49 49 💬 |
4274 | TVP-1012 | - | - | - | - | 1件: 6 6 💬 |
4275 | TVP-1012 (1 mg/day) with levodopa | 1件: Levodopa Levodopa | 1件: Levodopa
Levodopa
💬 | 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4276 | TVP-1012 0.5mg | - | - | - | - | 1件: 6 6 💬 |
4277 | TVP-1012 1mg | - | - | - | - | 1件: 6 6 💬 |
4278 | Twice-daily dosage with 0.5% cyclosporine-A eyedrops | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 90 90 💬 |
4279 | TY-0305 | - | - | - | - | 1件: 58 58 💬 |
4280 | TYSABRI*IV 1FL 300MG 15ML | 1件: Natalizumab Natalizumab | 1件: Natalizumab
Natalizumab
💬 | 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 💬 |
4281 | Téralithe LP | - | - | - | - | 1件: 2 2 💬 |
4282 | Ucb L059 | - | - | - | - | 1件: 13 13 💬 |
4283 | UF-021 | - | - | - | - | 1件: 90 90 💬 |
4284 | UF-021 (isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
4285 | UF-021(isopropyl unoprostone) | 1件: Unoprostone Unoprostone | 1件: Unoprostone
Unoprostone
💬 | 1件: PTGFR PTGFR 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway 💬 | 1件: 90 90 💬 |
4286 | UK 092480 | - | - | - | - | 1件: 86 86 💬 |
4287 | UK-427,857 | - | - | - | - | 1件: 46 46 💬 |
4288 | UK-92,480 | - | - | - | - | 1件: 86 86 💬 |
4289 | UK-92,480-10 | - | - | - | - | 1件: 86 86 💬 |
4290 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
4291 | Ultomiris 1,100 mg/11 mL | 1件: Ravulizumab Ravulizumab | 1件: Ravulizumab
Ravulizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 11 11 💬 |
4292 | Umbilical Cord Lining Stem Cells | - | - | - | - | 1件: 50 50 💬 |
4293 | UN-ALPHA-R 0.25µg | - | - | - | - | 1件: 235 235 💬 |
4294 | Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein) | 1件: Genistein Genistein | 1件: Genistein
Genistein
💬 | - | - | 1件: 299 299 💬 |
4295 | Upadacitinib (ABT-494) | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
4296 | Upadacitinib 12mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4297 | Upadacitinib 15mg | 1件: Upadacitinib Upadacitinib | 1件: Upadacitinib
Upadacitinib
💬 | 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4298 | Updacitinib (ABT-494) | - | - | - | - | 1件: 97 97 💬 |
4299 | UR-12746-S | - | - | - | - | 1件: 97 97 💬 |
4300 | Urbason 40 mg | - | - | - | - | 1件: 13 13 💬 |
4301 | URBASON 40 mg comprimidos | - | - | - | - | 1件: 13 13 💬 |
4302 | Urbason solubile forte 1000mg | - | - | - | - | 1件: 13 13 💬 |
4303 | URBASON*IM EV 1F 250MG+1F 5ML | - | - | - | - | 1件: 222 222 💬 |
4304 | Urbason® solubile forte 1000 mg | - | - | - | - | 1件: 13 13 💬 |
4305 | Urinary levels of PIIINP as a marker of changes in renal function | - | - | - | - | 1件: 299 299 💬 |
4306 | Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
4307 | Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone) | 2件: Methylprednisolone Methylprednisolone, Ursodeoxycholic acid | 2件: Methylprednisolone
Methylprednisolone
,
Ursodiol
💬 | 2件: NR1H4 NR1H4, NR3C1 💬 | 2件: Bile secretion Bile secretion, Neuroactive ligand-receptor interaction 💬 | 1件: 93 93 💬 |
4308 | US-licensed Humira® | - | - | - | - | 1件: 46 46 💬 |
4309 | Use of lipid-lowering drugs. | - | - | - | - | 1件: 265 265 💬 |
4310 | Ustekinumab 130 mg IV | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4311 | Ustekinumab 180 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 93 93 💬 |
4312 | Ustekinumab 1mg/kg (IP) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4313 | Ustekinumab 4.5 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4314 | Ustekinumab 45 mg | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 93 93 💬 |
4315 | Ustekinumab 90 mg (SC) Group 1 | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 💬 |
4316 | Ustekinumab liquid in prefilled syringe | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 84 84 💬 |
4317 | UT-15 SR | - | - | - | - | 1件: 51 51 💬 |
4318 | UT-15C | - | - | - | - | 1件: 86 86 💬 |
4319 | UT-15C (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4320 | UT-15C 0.25 mg | - | - | - | - | 1件: 86 86 💬 |
4321 | UT-15C 1 mg | - | - | - | - | 1件: 86 86 💬 |
4322 | UT-15C 5 mg | - | - | - | - | 1件: 86 86 💬 |
4323 | UT-15C LP | - | - | - | - | 1件: 86 86 💬 |
4324 | UT-15C SR | - | - | - | - | 2件: 51 51, 86 💬 |
4325 | UT-15C SR (treprostinil diethanolamine) | 1件: Treprostinil Treprostinil | 1件: Treprostinil
Treprostinil
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4326 | UT-15C-SR | - | - | - | - | 2件: 51 51, 86 💬 |
4327 | UVADEX and UVAR XTS Photopheresis System | 1件: Methoxsalen Methoxsalen | 1件: Methoxsalen
Methoxsalen
💬 | - | - | 1件: 96 96 💬 |
4328 | UVEDOSE 100 000 UI | - | - | - | - | 1件: 13 13 💬 |
4329 | UVEDOSE 100 000 UI, solution buvable en ampoule | - | - | - | - | 1件: 13 13 💬 |
4330 | UX701 (1.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4331 | UX701 (2.0 × 10^13 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4332 | UX701 (5.0 × 10^12 genome copies/kg) | - | - | - | - | 1件: 171 171 💬 |
4333 | VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135) | - | - | - | - | 3件: 61 61, 62, 66 💬 |
4334 | VAL-1221 | - | - | - | - | 1件: 256 256 💬 |
4335 | Valproate, Levocarnitine | 2件: Levocarnitine Levocarnitine, Valproic acid | 2件: Valproic acid
Valproic acid
,
Levocarnitine
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 💬 |
4336 | Valproic Acid and Levocarnitine | 2件: Levocarnitine Levocarnitine, Valproic acid | 2件: Valproic acid
Valproic acid
,
Levocarnitine
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 1件: 3 3 💬 |
4337 | Vamorolone 0.25 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4338 | Vamorolone 0.25 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4339 | Vamorolone 0.75 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4340 | Vamorolone 0.75 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4341 | Vamorolone 2.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4342 | Vamorolone 2.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4343 | Vamorolone 4% suspension for oral dosing | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
4344 | Vamorolone 6.0 mg/day/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4345 | Vamorolone 6.0 mg/kg/day | 1件: Vamorolone Vamorolone | 1件: Vamorolone
Vamorolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 💬 |
4346 | Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S | 1件: AstraZeneca COVID-19 Vaccine AstraZeneca COVID-19 Vaccine | - | - | - | 1件: 299 299 💬 |
4347 | VAY736 lower dose | - | - | - | - | 1件: 53 53 💬 |
4348 | VB-201 160mg | 1件: VB-201 VB-201 | - | - | - | 1件: 97 97 💬 |
4349 | Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana | - | - | - | - | 1件: 19 19 💬 |
4350 | Vedolizumab 108 mg SC | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬 |
4351 | Vedolizumab SC 108 mg | 1件: Vedolizumab Vedolizumab | 1件: Vedolizumab
Vedolizumab
💬 | 2件: ITGA4 ITGA4, ITGB7 💬 | 15件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬 |
4352 | Vehicle (SD-101 0%) | - | - | - | - | 1件: 36 36 💬 |
4353 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 💬 |
4354 | VELCADE*1FL 3,5MG | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
4355 | VELCADE*EV 1FL 3,5MG 1MG/ML | 2件: Bortezomib Bortezomib, Bortezomib D-mannitol | 1件: Bortezomib
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 💬 |
4356 | Velmanase Alfa (e.g. Lamazym) | 1件: Velmanase alfa Velmanase alfa | 1件: Velmanase alfa
Velmanase alfa
💬 | 1件: MAN2B1 MAN2B1 💬 | 2件: Lysosome Lysosome, Other glycan degradation 💬 | 1件: 19 19 💬 |
4357 | Venetoclax Oral Tablet, 400 mg | 1件: Venetoclax Venetoclax | 1件: Venetoclax
Venetoclax
💬 | 1件: BCL2 BCL2 💬 | 43件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Autophagy - animal, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Epstein-Barr virus infection, Estrogen signaling pathway, Fluid shear stress and atherosclerosis, Focal adhesion, Gastric cancer, HIF-1 signaling pathway, Hedgehog signaling pathway, Hepatitis B, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, JAK-STAT signaling pathway, Lipid and atherosclerosis, Measles, MicroRNAs in cancer, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prostate cancer, Protein processing in endoplasmic reticulum, Salmonella infection, Shigellosis, Small cell lung cancer, Sphingolipid signaling pathway, Toxoplasmosis, Tuberculosis, p53 signaling pathway 💬 | 1件: 28 28 💬 |
4358 | Ventavis 10 | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
4359 | Ventoline oral solution 0,4mg/ml | - | - | - | - | 1件: 111 111 💬 |
4360 | VESIcare 10Mg Tablet | - | - | - | - | 1件: 13 13 💬 |
4361 | Vett Lentiviral con gene ABCA4 | - | - | - | - | 1件: 301 301 💬 |
4362 | VEYVONDI 1300 IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4363 | VEYVONDI 1300I IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4364 | VEYVONDI 1300IU powder and solvent for solution for injection | 1件: Vonicog alfa Vonicog alfa | 1件: Vonicog alfa
Vonicog alfa
💬 | - | - | 1件: 288 288 💬 |
4365 | VFEND 40 mg/ml powder for oral suspension | 1件: Voriconazole Voriconazole | 1件: Voriconazole
Voriconazole
💬 | - | - | 1件: 299 299 💬 |
4366 | Vibrox 100mg Capsules | - | - | - | - | 1件: 167 167 💬 |
4367 | VigantOL oil plus interferon beta-1a (Rebif) | 2件: Human interferon beta Human interferon beta, Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
4368 | Vigantol® Öl 20.000 I.E./ml | - | - | - | - | 1件: 13 13 💬 |
4369 | VIOKASE 16 | - | - | - | - | 1件: 298 298 💬 |
4370 | Viokase 16 (pancrelipase) + Nexium | 2件: Esomeprazole Esomeprazole, Pancrelipase | 2件: Pancrelipase
Pancrelipase
,
Esomeprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 298 298 💬 |
4371 | Viokase® 16 | - | - | - | - | 1件: 298 298 💬 |
4372 | Viral load driven treatment interruption | - | - | - | - | 1件: 265 265 💬 |
4373 | Vitamin AD sig: 1 tablet/tid | - | - | - | - | 1件: 90 90 💬 |
4374 | Vitamin B sig: 10mg/tid | - | - | - | - | 1件: 90 90 💬 |
4375 | Vitamin D 100ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
4376 | Vitamin D 10ug | 1件: Vitamin D Vitamin D | - | - | - | 1件: 298 298 💬 |
4377 | Vitamin D3 400 IU | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 49 49 💬 |
4378 | Vitamin D3 4000 UI daily | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
4379 | Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 96 96 💬 |
4380 | Vitamin K supplementation, dose #1 | 1件: Phylloquinone Phylloquinone | - | - | - | 1件: 299 299 💬 |
4381 | Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1 | 1件: Choline Choline | 1件: Choline
Choline
💬 | - | - | 1件: 299 299 💬 |
4382 | Vizamyl (flutemetamol(F-18)) | 2件: Flutemetamol Flutemetamol, Flutemetamol (18F) | - | - | - | 3件: 5 5, 7, 127 💬 |
4383 | VOLIBRIS 10 mg comprimidos recubiertos con película | 1件: Ambrisentan Ambrisentan | 1件: Ambrisentan
Ambrisentan
💬 | 1件: EDNRA EDNRA 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 💬 |
4384 | Volixibat (formely SHP626, LUM002 or SAR548304B) | 1件: Volixibat Volixibat | 1件: Volixibat
Volixibat
💬 | - | - | 1件: 94 94 💬 |
4385 | VOLMAX*30CPR 4MG R.P. | - | - | - | - | 1件: 3 3 💬 |
4386 | VPRIV - 400 U - POLVERE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
4387 | VPRIV 400 Units powder for solution of infusion | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: Velaglucerase alfa
Velaglucerase alfa
💬 | 1件: GBA1 GBA1 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
4388 | VRT-893661 VRT-0893661 | - | - | - | - | 1件: 299 299 💬 |
4389 | VSN16R 100mg | - | - | - | - | 1件: 13 13 💬 |
4390 | VT-001 | - | - | - | - | 1件: 66 66 💬 |
4391 | VX-121 | - | - | - | - | 1件: 299 299 💬 |
4392 | VX-121/TEZ/D-IVA | - | - | - | - | 1件: 299 299 💬 |
4393 | VX-121/tezacaftor/deutivacaftor | 2件: Deutivacaftor Deutivacaftor, Tezacaftor | 2件: Tezacaftor
Tezacaftor
,
Deutivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4394 | VX-147 | - | - | - | - | 1件: 222 222 💬 |
4395 | VX-152 | - | - | - | - | 1件: 299 299 💬 |
4396 | VX-440 | - | - | - | - | 1件: 299 299 💬 |
4397 | VX-445 | - | - | - | - | 1件: 299 299 💬 |
4398 | VX-445 / TEZ / IVA | - | - | - | - | 1件: 299 299 💬 |
4399 | VX-445 / TEZ / IVA FDC | - | - | - | - | 1件: 299 299 💬 |
4400 | VX-445 /TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
4401 | VX-445/TEZ/IVA | - | - | - | - | 1件: 299 299 💬 |
4402 | VX-661/ivacaftor (VX-770) 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4403 | VX-661/ivacaftor 100 mg/ 150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4404 | VX-661/ivacaftor 100mg/150 mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4405 | VX-661/ivacaftor 100mg/150mg | 1件: Ivacaftor Ivacaftor | 1件: Ivacaftor
Ivacaftor
💬 | 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 💬 |
4406 | VYNT-0126 | - | - | - | - | 1件: 156 156 💬 |
4407 | WAY-130799 | - | - | - | - | 1件: 13 13 💬 |
4408 | WAY-177005 | - | - | - | - | 1件: 46 46 💬 |
4409 | WD-1603 | - | - | - | - | 1件: 6 6 💬 |
4410 | WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4411 | WD-1603 Carbidopa-Levodopa Extended-Release Tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4412 | WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS | 2件: Carbidopa Carbidopa, Levodopa | 2件: Levodopa
Levodopa
,
Carbidopa
💬 | 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4413 | White chocolate (0% cocoa) | 1件: Cocoa Cocoa | - | - | - | 1件: 6 6 💬 |
4414 | Wilate 1000 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4415 | WILATE 1000 I.U. | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4416 | WILATE 450 | 2件: Antihemophilic factor human Antihemophilic factor human, Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4417 | WILATE® 450 | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 288 288 💬 |
4418 | WIN-1001X | - | - | - | - | 1件: 6 6 💬 |
4419 | WVE-003 | - | - | - | - | 1件: 8 8 💬 |
4420 | WVE-004 | - | - | - | - | 2件: 2 2, 127 💬 |
4421 | WVE-120101 | - | - | - | - | 1件: 8 8 💬 |
4422 | WVE-120102 | - | - | - | - | 1件: 8 8 💬 |
4423 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
4424 | XADAGO - 100 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- BLISTER (PVC/PVDC/ALLUMINIO)- 30 COMPRESSE | 1件: Safinamide Safinamide | 1件: Safinamide
Safinamide
💬 | 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
4425 | Xeljanz XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4426 | Xeljanz® 11mg Prolonged Release Tablet | 2件: Manganese citrate Manganese citrate, Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
4427 | Xenon-129 | 1件: Xenon Xenon | 2件: Xenon
Xenon
,
Xenon Xe 133
💬 | - | - | 1件: 299 299 💬 |
4428 | XGEVA - 120 MG - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 1.7 ML 4 FLACONCINI | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
4429 | XmAb5871_1.0MG | - | - | - | - | 1件: 46 46 💬 |
4430 | XmAb5871_10.0MG | - | - | - | - | 1件: 46 46 💬 |
4431 | XmAb5871_3.0MG | - | - | - | - | 1件: 46 46 💬 |
4432 | Xolair 150 mg Pulver und Injektionslösung zur Herstellung einer Injektionslösung | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 299 299 💬 |
4433 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 💬 |
4434 | Yarrowia lipolytica lipase | - | - | - | - | 1件: 298 298 💬 |
4435 | Yellow Fever vaccine (17D) | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: Yellow fever vaccine
Yellow fever vaccine
💬 | - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 💬 |
4436 | YONDELIS 0,25 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4437 | Yondelis 0.25 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4438 | YONDELIS 1 mg polvo para concentrado para solución para perfusión | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4439 | Yondelis 1 mg powder for concentrate for solution for infusion. | 1件: Trabectedin Trabectedin | 1件: Trabectedin
Trabectedin
💬 | - | - | 1件: 159 159 💬 |
4440 | YRA-1909 high dose | - | - | - | - | 1件: 46 46 💬 |
4441 | YRA-1909 low dose | - | - | - | - | 1件: 46 46 💬 |
4442 | YRA-1909 mid dose | - | - | - | - | 1件: 46 46 💬 |
4443 | ZAVESCA 84CPS 100MG | 1件: Miglustat Miglustat | 1件: Miglustat
Miglustat
💬 | 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 💬 |
4444 | ZD 4522 | - | - | - | - | 1件: 46 46 💬 |
4445 | Zestoretic 10,20 | 1件: Lisinopril Lisinopril | 2件: Lisinopril
Lisinopril
,
Lisinopril
💬 | 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 19 19 💬 |
4446 | ZGN-440 | - | - | - | - | 1件: 193 193 💬 |
4447 | ZGN-440 for Injectable Suspension | - | - | - | - | 1件: 193 193 💬 |
4448 | ZGN-440 sterile diluent | - | - | - | - | 1件: 193 193 💬 |
4449 | Zidovudine/lamivudine | 2件: Lamivudine Lamivudine, Zidovudine | 2件: Lamivudine
Lamivudine
,
Zidovudine
💬 | - | - | 1件: 26 26 💬 |
4450 | ZITHOMAX 40 mg/ml ENFANTS | - | - | - | - | 1件: 299 299 💬 |
4451 | ZK 157046 | - | - | - | - | 1件: 13 13 💬 |
4452 | Zoenasa-1:4 | - | - | - | - | 1件: 97 97 💬 |
4453 | Zoledronic Acid 5Mg/Bag 100Ml Inj | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 3件: 5 5, 6, 17 💬 |
4454 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4455 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion, generic medicinal product. | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4456 | Zoledronic Acid Kern Pharma 4 mg/100 mL solution for infusion,generic medicinal product | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 274 274 💬 |
4457 | Zolgensma 2 x 1013 vector genomes/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
4458 | Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: Onasemnogene abeparvovec
Onasemnogene abeparvovec
💬 | 1件: SMN1 SMN1 💬 | - | 1件: 3 3 💬 |
4459 | Zomacton 10 mg/ml | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 💬 |
4460 | ZSP1603 12.5 mg | - | - | - | - | 1件: 85 85 💬 |
4461 | ZX008 - 0.2 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
4462 | ZX008 - 0.8 mg/kg/day | - | - | - | - | 1件: 140 140 💬 |
4463 | ZX008 0.2 or 0.8 mg/kg/day | - | - | - | - | 1件: 144 144 💬 |
4464 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |
4465 | ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE | 1件: Abiraterone Abiraterone | - | - | - | 1件: 75 75 💬 |
4466 | LNP023 HYDROCHLORIDE SALT | - | - | - | - | 5件: 61 61, 62, 66, 109, 222 💬 |